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ABSTRACT
Japanese encephalitis virus (JEV) is the most important cause of epidemic 
encephalitis worldwide but its origin is unknown. Epidemics of encephalitis suggestive of 
Japanese encephalitis (JE) were described in Japan from the 1870s onwards. Four genotypes 
of JEV have been characterised and representatives of each genotype have been fully 
sequenced. Based on limited information, a single isolate from Malaysia, the Muar strain, is 
thought to represent a putative fifth genotype. I have determined the complete nucleotide and 
amino acid sequence of the Muar stmin and compared it with other fully sequenced JEV 
genomes. Muar was the least similar’, with nucleotide divergence ranging from 20.2 to 21.2% 
and amino acid divergence ranging from 8.5 to 9.9%. Phylogenetic analysis of the Muar 
strain revealed that it does represent a distinct fifth genotype of JEV. I elucidated the Muar 
signature amino acids in the envelope (E) protein, including E327 Glutamine on the exposed 
lateral surface of the putative receptor binding domain of the E protein, which distinguishes 
the Muar strain from the other four genotypes. Evolutionary analysis of full-length JEV 
genomes revealed that the mean (range) evolutionary rate is 4.35 x 10'4 (3.4906 x 10"4 to 
5.303 x 10 4) nucleotides substitutions per site per year* and suggests JEV originated from its 
ancestral virus in the mid 1500s. It is postulated to have originated in the Indonesia-Malaysia 
region and evolved there into different genotypes, which then spread across Asia. No strong 
evidence for positive selection was found between JEV strains of the five genotypes and the 
E gene has generally been subjected to strong purifying selection. The ability of intravenous 
immunoglobulins (IVIGs) which sometimes are used as supportive treatment for JEV 
infection to protect against stmins of JEV representing the five major genotypes was 
assessed. Neutralization assays showed IVIGs appeal* cross-reactive across the five JEV 
genotypes with effective but lower titers for the Muar strain as well as representatives from 
genotype IV. Whether there are other strains from genotype V, and what happened to them 
remains unknown.
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CHAPTER 1: INTRODUCTION
1.1 General Introduction to Japanese Encephalitis Virus (JEV)
Flavivimses are important human pathogens; they include a number of emerging and re- 
emerging pathogens such as Japanese encephalitis virus (JEV), West Nile vims (WNV), St. 
Louis encephalitis virus (SLEV), Kunjin virus (KUNV), Murray Valley encephalitis virus 
(MVEV), yellow fever virus (YFV) and dengue vimses (DENV) causing a variety of diseases 
ranging from mild febrile illness to severe encephalitis and hemorrhagic fever (Mishra and 
Basu, 2008).
The most important cause of epidemic encephalitis worldwide is JEV, with an estimated 
35,000 to 50,000 cases and 10,000 deaths annually (Tsai, 2000). The magnitude of the 
problem is even more alanning since a high proportion of survivors have serious and 
permanent neuropsychiatric sequelae, especially in children (Kaur and Vrati, 2003).
JEV belongs to the Japanese encephalitis (JE) serogroup of the genus Flavivirus, 
family Flaviviridae and is transmitted in nature by mosquitoes between vertebrate hosts 
including birds and pigs (Yun et al,, 2003). The risk of JE increases as the number of vector 
mosquitoes increases. Because the rice paddy-breeding Culex mosquitoes are unavoidable, 
the majority of the population in rural Asia has been infected with the virus by early 
adulthood. Humans become infected during the bite of an infected mosquito. The expansion 
of the JE-endemic area depends on increasing inigated rice field and pig farming. These 
environments that are suitable for the infectious cycle of JEV exist widely in Asia 
(Dutta et al., 2011; Oya and Kurane, 2007).
Following infection with JEV, the ratio of symptomatic to asymptomatic disease is estimated 
to be 1:50-1:300 (Libraty et al., 2002a). JEV targets the CNS causing encephalitis as well as 
meningitis (Hosokawa et al., 2007) clinically manifesting with fever, headache, vomiting, 
signs of meningeal irritation and altered consciousness (Kumar* et al., 1991). Clinical 
variables reported to be associated with a poor outcome include depth of coma, extremes of 
age, hyporeflexia, decerebrate posturing and apnoea attacks, increased febrile response, and 
elevated cerebrospinal fluid (CSF) pleocytosis, seizures or a polio-like flaccid paralysis 
(Dapeng, 1995; Hoke et al., 1992; Huy et al,, 1994; Kumar et al., 1990; Misra et al, 1998; 
Schneider et al., 1974; Solomon et al., 2002; Solomon et al., 1998).
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JEV was first isolated in Japan in 1935 (Lewis et aL, 1947). Subsequently, JEV has been 
found throughout most of Asia and the vims was most recently isolated in Papua New 
Guinea and the Torres Straits of Australia, indicating that this virus could become a 
worldwide public health threat (Hanna et ah, 1999; Hanna et aL, 1996; Mackenzie et ah, 
1994).
the origins of the vims are uncertain, but phylogenetic comparisons with other flavivimses 
suggest it evolved from an African ancestral vims, perhaps as recently as a few centuries ago 
(Gould, 2002).
Two distinct epidemiological patterns of JEV transmission have been observed. In northern 
temperate regions of Asia JE occurs in summer epidemics, whereas in southern tropical areas 
the disease is endemic and occurs year-round (Vaughn and Hoke, 1992).
Genetic Studies Reveal Different JEV Genotypes
Based on genetic studies, JEV consists of four genotypes (GI, II, III and IV) (Chen et aL, 
1992; Chen et aL, 1990). Genotype I includes isolates from Northern Thailand, Cambodia, 
Korea, China, Japan, Vietnam, Taiwan, and Australia from 1967 and the present, Genotype II 
includes isolates from southern Thailand, Malaysia, Indonesia, Papua New Guinea and 
Northern Australia before 1951 to 1999, Genotype III includes isolates from mostly 
temperate regions of Asia, including Japan, China, Taiwan, the Philippines, and the Asian 
subcontinent from 1935 to the present, and Genotype IV includes isolates from Indonesia 
between 1980 and 1981 only (Schuh et aL, 2010). A representative of each of these four 
genotypes has been frilly sequenced (Solomon et aL, 2003b). In addition, a strain of JEV, 
Muar strain, isolated in Singapore in 1952 from a brain of a patient who originated in Muar, 
Malaysia (Hale et aL, 1952) may represent a fifth genotype as determined by monoclonal 
antibodies (MAbs) reactivities (Hasegawa et aL, 1995; Kobayashi et aL, 1984) and limited 
phylogenetic analysis depending on E gene sequence (Hasegawa et aL, 1994; Solomon et aL, 
2003b; Uchil and Satchidanandam, 2001).
Therapy for JE is supportive and no clearly effective specific antiviral agents exist 
(Mishra and Basu, 2008). There have been only two placebo-controlled trials in JE which 
showed no benefit associated with the administration of corticosteroids (dexamethasone) or
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interferon alpha (IFN-a) (Hoke et al., 1992; Solomon et al., 2003a). However, there have 
been case reports of intravenous immune globulin (IVIG), which has been shown to be of 
benefit when administered with symptomatic treatment for this disease. In the case report, 
clinical improvement was rapid and the patient made an almost complete recovery 
(Caramello et al., 2006). Vaccination remains the most promising tool to reduce this deadly 
infection (Tsai, 2000).
1.2 History of JE
Encephalitis due to JEV was described as early as 1870 in Japan but the first described large 
epidemic occurred in 1924 (Pond and Smadel, 1954). JEV was first isolated in 1934 from the 
brain of a fatal case of encephalitis and was characterized as the prototype (Nakayama) 
strain of JEV (Mitamura et al., 1936; Monath, 1988).
Observations of JE epidemics suggested that it was spread by a mosquito vector and had a 
seasonal disease occurrence. JEV was first isolated from Culex tritaeniorhynchus 
mosquitoes in 1938 (Mitamura et al., 1938). It was over 20 years later that the transmission 
cycle of JEV between viremic swine and birds to man, an incidental dead-end host, by the 
mosquito vector Culex tritaeniorhynchus was described (Buescher et al., 1959; Scherer, 
1959).
1.3 Epidemiology of JEV
1.3.1 Geographic Distribution and Seasonal Occurrence
JEV has been found throughout most of Asia with reported cases of JE in Thailand, India, 
Nepal, Bangladesh, Sir Lanka, Vietnam, Burma, Laos, Cambodia, Malaysia, Singapore, 
Taiwan, Philippines, Indonesia, China, Siberia, Korea, and Japan (Tsai and Yu, 2000).
JEV could become a worldwide public health threat as it was most recently isolated in Papua 
New Guinea and the Torres Straits of Australia (Hanna et al., 1999; Hanna et al., 1996; 
Mackenzie et al., 1994). Figure 1-1 shows the current geographical distribution of JEV.
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Figure 1-1. Approximate geographic distribution of Japanese encephalitis virus. Yellow 
indicates areas current or previous epidemics. Taken from Centers for Disease Control and 
Prevention (CDC). http://www.cdc.gov/ncidod/dvbid/iencephalitis/map.htm
JE incidence in humans is seasonal and varies by country. This is probably due to irrigation 
practices, ambient temperature and the migration pattern of susceptible birds. For example, in 
the temperate climates of Korea and Japan, JE occurs from May to September while it occurs 
from April to October in the tropical countries of Southeast Asia such as Thailand, Cambodia 
and Vietnam, and from September to December in Nepal and Northern India (Endy and 
Nisalak, 2002).
1.3.2 Transmission Cycle
JEV is a mosquito-borne flavivirus. It is transmitted between vertebrate hosts by mosquitoes, 
principally by Culex species and in particular Culex tritaeniorhynchus (Yun et al., 2003).
JEV is maintained in nature mainly between vector mosquitoes and animal vertebrate hosts 
such as pigs and water birds such as egrets and herons.
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The primary cycle of transmission and environmental maintenance of JEV depends on a 
cycle of mosquito infection and vertical transmission to its offspring, infection in water birds 
and pigs, and further infection in uninfected mosquitoes (van den Hurk et al., 2009).
Swine and water birds develop high levels of viremia upon JE infection, which serves as a 
viral amplification stage and enhances transmission to mosquitoes that results in further 
perpetuation of this enzootic cycle. Humans and horses may develop asymptomatic infection 
or severe encephalitis when infected by JEV following mosquito bite. Humans and horses are 
considered dead-end hosts as the level of viremia is insufficient for further infection of the 
mosquito vector and transmission to other susceptible hosts (Endy and Nisalak, 2002). The 
transmission cycle of JEV is illustrated in Figure 1-2.
Other vertebrate hosts can be naturally infected with JE and include the domestic vertebrates 
donkeys, chickens, ducks, water buffalos, cattle, and sheep as well as vertebrates in nature to 
include mice, bats, snakes and frogs (Shortridge et al., 1977). It is not known what role these 
hosts play in maintaining JEV in nature.
Mosquito vectors
(Culex tritaeniorhynchus)
Birds Pi9s
Children
Incidental
Infections
Horses
Figure 1-2. Transmission cycle of Japanese encephalitis virus. Adapted from (Misra and 
Kalita, 2010).
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1.3.3 Vectors
In field studies, it has been demonstrated that JEV can infect and be transmitted by wide 
range of mosquito species including Cx. tritaeniorhynchuS;, Cx. gelidus, Mansonia spp., 
Aedes curtipes, and mixed Anopheles spp. (Simpson et ah, 1970a; Simpson et ah, 1974; 
Simpson et ah, 1970b; Simpson et ah, 1976).
In addition to Cx. tritaeniorhynchus, JEV has been isolated from other mosquito species such 
as Ae. subpictus, and Cx. whitmorei in southern India; Anopheles hyrcanus group and An. 
barbirostris in Pakistan; Ae. albopictus, and Armigeres obturans in China; Cx. fuscocephala, 
and Mansonia uniformis in Sri Lanka (Gajanana et al., 1997; George et ah, 1987a; Huang, 
1982; Okuno et ah, 1973; Peiris et ah, 1992).
In laboratory studies, it has been demonstrated that JEV can infect and be transmitted by a 
wide range of mosquito species which are considered to be the most competent vectors in 
transmitting JEV (Jeong et ah, 2011). Certain mosquito species are competent in JE 
transmission but with lower efficiency including Cx. pipiens pallens, Cx. p. quinquefasciatus, 
Cx. pseudovishnui, and Anopheles tessalatus (Burke and Leake, 1988; Grosser et ah, 1958; 
Mourya et ah, 1991). Under laboratory condition, Aedes spp. are considered to be the least 
efficient in JEV transmission (Endy and Nisalak, 2002).
Vector competence studies showed the importance of Cx. tritaeniorhynchus in JEV 
transmission. One hundred percent infection rates of laboratory-raised Cx. tritaeniorhynchus 
are observed (Hill, 1970; Soman et ah, 1977; Takahashi, 1976).
JEV replicates rapidly in Cx. tritaeniorhynchus mosquitoes and viral kinetics, viral load, and 
transmission are dependent on the ambient temperature (Weng et ah, 2005). For example, 
Maximal titers of vims are reached within 5 days in mosquitoes kept at 28 °C (Takahashi, 
1976).
JEV is maintained in mosquitoes through four important mechanisms: overwintering, 
transovarial infection, infection at oviposition, and sexual transmission (Makiya et ah, 1985). 
Overwintering of JEV has been demonstrated in Cx. tritaeniorhynchus (Hayashi et ah, 1975; 
Lee, 1971; Ura, 1976). Transovarial transmission of JEV can occur in Cx. tritaeniorhynchus,
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(Rosen et al., 1989; Rosen et al., 1978; Soman and Mourya, 1985). Infection at oviposition 
has been demonstrated to occur in Cx. pipiens, Ae. alcasidi, and Ae. flavus (Rosen et al., 
1989). Furthermore, JEV was sexually transmitted from male to female Cx. tritaeniorhynchus 
(Mourya and Soman, 1999; Rosen et al., 1989).
Determinants in JEV epidemiology of human infection include the behavioural 
characteristics of the primary mosquito vector such as host preference, time of day of 
feeding, feeding behaviour1, and ideal environmental conditions for breeding (Gould et ah, 
1974).
1.3.4 Vertebrate Hosts 
Domestic Pigs
Pigs play an important role in the JEV transmission cycle. Most domestic pigs can develop 
viremia capable of infecting mosquitoes (Chen and Beaty, 1982). Field studies showed that 
when JE naive swine are placed into a JE endemic area, they will develop infection within 
one week (Unni et al., 2011). Swine develop a viremia lasting for four- days (Komada et al., 
1968; Maedaetal., 1978; Scherer, 1959).
Domestic pigs have been used as sentinel population to monitor and estimate the 
environmental burden of JE due to the susceptibility of pigs for JEV infection and its 
preference as a blood meal for the mosquito vector. For example, In India, 18.5% of sentinel 
pigs the Kolar district, Karnataka, demonstrated seroconversion to JE with isolation of JEV 
from several sentinel pigs and hemagglutination inhibition (HI) antibodies persisted for 3 
years in these pigs (Geevarghese et al., 1987; Geevarghese et al., 1991).
In JE endemic areas free of human epidemic JE, pigs have been used to measure the intensity 
of environmental transmission of JE (Burke et al., 1985d). In a 5-year survey of JE antibody 
in swine located in the Natori District of Miyagi Prefecture, Japan, a 100% infection rate of 
swine was observed even in the absence of human cases (Yamamoto et al., 1970). The 
appearance of rising antibody and the duration of high-titered antibody were associated with 
the intensity of JE transmission from mosquitoes and correlated with a higher incidence of 
human disease (Endy and Nisalak, 2002).
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It is not known, how JEV changes at a molecular level during swine infection and within the 
enzootic cycle of JEV between birds and pigs and its transmission to humans. Also, the 
effects of interspecies transmission of JE from an avian host to swine and back again on 
mutation rates and recombination events are not known. However, it is known for other 
viruses that have an avian-swine transmission, such as the influenza virus, that swine play an 
important role in the recombination events of this virus and its ability to infect humans (Stech 
et ah, 1999). Transmission from avian to swine hosts may induce an increase in mutation 
rates (Stech et al., 1999). Pigs are susceptible to infection with avian influenza due to a 
receptor similar to that found in birds. Following infection, swine act as a mixing vessel that 
allows recombination events to occur'. Swine influenza viral replication then allows 
reassortment and adaptation of the influenza virus and emergence of a dominant strain that is 
able to infect humans (Webby et al., 2000), There is no doubt that for JEV reassortment is not 
possible, because flaviviruses have just a single piece of nucleic acid.
Swine are a major source of food and income in most of Asia (http://www.pigprogress.net). 
Swine production and the production of newborn and susceptible litters produce a steady 
supply of susceptible hosts for JEV infection. JE will remain a pail of the environment in 
these countries and as pig production increases, the environmental burden of JE will increase 
as well as its potential to infect humans (Endy and Nisalak, 2002).
Swine are the preferred hosts for Cx. tritaeniorhynchus, followed by birds and then humans 
(Scherer, 1959). Pigs play an important role in the transmission and maintenance of JEV in 
the environment as well as for human infection.
Avian Vertebrates
The role birds play in JEV transmission has been demonstrated. High levels of viremia can be 
produced in large water birds such as the Black-crowned night heron (Nycticorax 
nycticorax), egrets (Ardea spp.) as well as Pond herons {Ardeola grayii) (Scherer, 1959).
Night herons. Plumed egret and domestic chickens have a high seroprevalance for JE 
antibody and they are considered sources of JE transmission (Ogata et al., 1970).
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Horses
Horses can be infected with JEV and develop CNS infections, and at times precede human 
clinical cases (Paterson et ah, 1952). The clinical signs of JE in horses are similar to human 
disease (Paterson et ah, 1952). Viremia in horses develops from 1 to 4 days after infection, 
lasting 2-6 days. However, horses, like humans, represent a dead-end host for JE 
transmission (Gould et al., 1964).
In Japan, JE incidence declined in horses from the initial 0.3 per 100,000 in 1960 to 0.03 per 
100,000 in 1967 (Nakamura, 1972). This decline was attributed to the increase in numbers of 
vaccinated horses with an inactivated JE vaccine (Endy and Nisalak, 2002).
Other Vertebrates
Other vertebrate-hosts could play a role in the JEV transmission cycle. The highest antibody 
seroprevalence observed was in swine (88.1%), followed by buffalo (45%), cattle (42%), 
sheep (17.9%), and goats (13.8%) (Oda et al., 1996).
Domestic livestock other than swine appeal' to have the ability to be infected by JE with low 
levels of viremia and do not contribute to JE transmission cycle in nature and are considered 
to represent dead-end hosts (Gibbs, 1976).
Significant antibody titres to JEV have been found in cattle and goats and have been 
correlated to the occurrence of human diseases (Peiris et al., 1993). Cattle can be infected by 
JEV with the development of JE antibody, but demonstrate no evidence of viremia (Ilkal et 
al., 1988). In Japan, 63.6% of new-born calves had maternally derived JE antibody 
(Horimoto and Sakai, 1990; Horimoto et al., 1987).
Overwintering of JEV has been reported to occur in snakes, frogs, and bats (Oh et al., 1974). 
For example, insectivorous bats, microchiroptera, can be infected under laboratory conditions 
with JEV and have demonstrated persistence of viral infection under low environmental 
temperatures (Sulkin et al., 1970; Sulkin et al., 1966a; Sulkin et al., 1966b). Sera from 626 
bats of seven different species in Karnataka State, India were tested for JE antibody 
(Baneijee et ah, 1988). Five species of bats tested positive for JE antibody (7.3%
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seroprevalence). This was similar to rates observed in Japan (Mima et aL, 1970). However, 
the role of reptiles, amphibians, and bats in the overwintering of JEV and their contribution 
to its environmental maintenance is not known.
Rodents are tolerant to JEV infection and in ecologic studies have had no antibodies against 
JE (Scherer, 1959; Williams and Imlarp, 1972).
1.3.5 Environmental Factors 
Climate and Weather
Climate and weather are important detenninants in the environmental maintenance and 
transmission of JEV to humans. Ambient temperature is the important factor in mosquito 
vector infectivity and maintenance (Mogi, 1983).
It has been observed that large epidemics occurred during unseasonably dry, hot summers 
while, wet, cool summers were associated with little human infection (Endy and Nisalak, 
2002).
Mosquitoes are extremely sensitive to the climate. For example, meteorological conditions 
have effect on vector reproduction, mortality rates, blood feeding frequency of the vector and 
extrinsic incubation period of the viral pathogen (Hay et al., 2000; Kuno, 1997; Lindsay and 
Birley, 1996).
To demonstrate the climate effect on one mosquito species, a survey of Cx. tritaeniorhynchus 
population from 38 geographical sites throughout Asia was conducted (Reisen et al., 1976). 
Cx. tritaeniorhynchus peaked from June to September in Pakistan following the annual 
planting of rice fields. In India, Cx. tritaeniorhynchus breeding continued throughout the year 
and peaked during September to December. In Thailand, population trends paralleled the 
seasonal rainfall pattern with peaks occurring during breeding throughout the year with a 
peak during October and November. Okinawa, Japan, and Korea all had similar* population 
dynamics with peaks occurring during June to August (Endy and Nisalak, 2002).
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1.4 Molecular Epidemiology of JEV 
1.4.1 The JE Serocomplex
Depending on cross-neutralization tests, the Flavivirus genus of the family Flaviviridae has 
been divided into eight serocomplexes, including TBE serocomplex, the DEN serocomplex, 
and the JE serocomplex, with some viruses, including the prototype virus, YFV, not falling 
into any of these serocomplexes (Calisher et al., 1989; De Madrid and Porterfield, 1974).
The JE serocomplex includes members from across the world, such as MVEV, WNV, KUNV 
and SLEV (Chamberlain, 1980; Kimura-Kuroda and Yasui, 1986; Porterfield, 1980). JEV is 
found primarily in Asia whereas WNV is found in Africa and north into Europe, and more 
recently in North America. SLEV is endemic to North America whereas MVEV and KUNV 
are found in Australia.
JE serocomplex viruses were classified based on examination of the serological differences 
among vimses isolated from various regions throughout Asia (Gould, 2002). Strain variation 
among JEV isolates was first reported by Hale and Lee in 1954 who compared six Malaysian 
isolates of JEV ‘types’ (Hale and Lee, 1954). Antigenic variation among JEV isolates based 
on biological tests using polyclonal antisera, such as HI and neutralization (NT), have been 
described by others (Banerjee, 1986; Huang, 1982).
Two major immunotypes have been differentiated (Okmio et ah, 1968). Using polyclonal 
antiserum, four- ‘subtypes’ of JEV from northern Thailand were identified on the basis of HI 
and NT tests (Ali and Igarashi, 1997; Ali et ah, 1995).
Polyclonal antisera are clearly able to distinguish separate JEV immunotypes. However, 
using MAbs allowed a more precise delineation of JEV strains, and several studies have used 
MAbs generated against one strain of JEV to examine cross-reactivity with other strains.
It has been demonstrated by two laboratories that at least five antigenic subgroups of JEV 
have circulated in Asia since isolation of the original Nakayama vims in 1935 (Hasegawa et 
ah, 1994; Kedamath et al., 1986; Kobayashi et ah, 1984; Kobayashi et ah, 1985). One of 
these subgroups includes only the Nakayama-derived strains, whereas the majority of the
more recent isolates are within a subgroup containing the Kamiyama strain isolated in 1966 
(Kobayashi et al.3 1985). In addition, two serological subgroups are quite distinct, the 691004 
(isolated in Sri Lanka in 1969) and Muar (isolated in Singapore in 1952) subgroups, each 
containing only the prototype virus for the respective subgroup (Kobayashi et ah, 1985).
Examination of 11 geographically diverse JEV strains suggests at least five epitopes 
associated with HI activity (Kobayashi et ah, 1985) whereas examination of a combination of 
HI, NT, and enzyme-linked immunosorbent assay (ELISA) data suggests up to eight distinct 
epitopes (Ghosh et ah, 1989; Kimura-Kuroda and Yasui, 1983, 1986). JE-specific HI and NT 
epitopes appear to be distinct from each other (Kimura-Kuroda and Yasui, 1983) 
demonstrating the structural separation of specific activities on the viral E protein.
1.4.2 Oligonucleotide Mapping of JEV Isolates
RNA fingerprinting was used to examine the genetic makeup of JEV isolates. Some studies 
suggested that geographic boundaries limited migration of JEV and viruses isolated at 
approximately the same time were quite similar (Hori, 1986; Hori et al,, 1986).
A panel of JEV strains were sepamted into six groups based on geographic and temporal 
boundaries. One of these groups contained the isolate Muar from Singapore, which had 
previously been shown to be serologically distinct from other JEV isolates (Kobayashi et al., 
1984; Kobayashi et al., 1985).
1.4.3 JEV Strain Variation at the Amino Acid Level
Examination of nucleotide sequences is an excellent way for describing the genetic variation 
of viruses within particular geographical areas. However, sometimes the genetic variation 
seen between vims strains is not translated to the protein level and mutations are silent and in 
this case the structure of the virus is not affected. Therefore, examination of virus strain 
variation at the amino acid level is important to understand the true variation within a virus 
population (Holbrook and Barrett, 2002).
Analysis of the amino acid sequence of the E protein of 35 strains of JEV demonstrated that 
while the genotypes were conserved among the strains examined, some of the viruses that
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were closely related genetically were less well related at the amino acid level (Mangada and 
Takegami, 1999). For example, antigenic examination of 12 Thai strains from genotype I and 
comparison with two Japanese and a single Chinese strain (GUI) demonstrated that the Thai 
strains have a definite antigenic difference compared to Nakayama and JaGArOl strains (Ali 
and Igamshi, 1997).
The maximum genetic difference between JEV genotypes was found to be 10% and the 
maximum within genotypes was 6%, demonstrating that the JEV strains examined are closely 
related with the exception of the Muar vims (Chen et ah, 1992; Chen et ah, 1990; Williams et 
ah, 2000). Therefore, based on the nucleotide and amino acid sequences of the E protein, it 
has been suggested that JEV isolates exist as a single serotype (Tsarev et al., 2000) .
However, cross-referencing genetic and antigenic data for JEV isolates is difficult as many of 
the older isolates have never been sequenced and many of the recent isolates have not been 
examined serologically.
1.5 Molecular Virology of JEV 
1.5.1 Viron
JEV belongs to the JE serogroup of genus Flavivirus, family Flaviviridae. It is a small- 
enveloped virus with a single-stranded, positive-sense RNA genome (Zhang et al., 2009).
JEV has a genome structure, which is similar to that of other flaviviruses. The genome 
contains a single long ORF flanked by 5' and 3' nontranslated regions (NTRs) that are 
important for viral replication (Sumiyoshi et al., 1987).
The RNA genome lacks a poly (A) tail at its 3' (Sun et al., 2009). The ORF is translated into 
a large polyprotein that is co- or posttranslationally processed into three structural and seven 
NS proteins whose genes are arranged in the genome as follows: C- prM- E- NS1- NS2A- 
NS2B- NS3-NS4A- NS4B- NS5 (Chambers et al., 1990; Lindenbach, 2001;
Venugopal, 1994). Schematic of JEV genome is shown in Figure 1-3.
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Figure 1-3. Schematic of Japanese encephalitis virus genome. Adapted from 
(http://expasy.org/viralzone/all by protein/24.htmO.
1.5.2 JEV Non Coding Regions (NCR)
The JEV genome contains 5’ and 3’ NCRs located at the extreme 5’ and 3’ ends of the virus 
genome (Markoff, 2003). The 5’ and 3’ NCR form secondary structures that are essential for 
replication and translation.
The 5’ NCR is not conserved among members of the family Flaviviridae (Brinton and 
Dispoto, 1988; Pestovaet al., 1998).
Mutations or deletions in the 3’ NCR have been shown to reduce RNA replication 
(Elghonemy et al., 2005; Hanley et al., 2004; Khromykh et al., 2003; Lo et al., 2003). A 
DENY vaccine candidate has been proposed based on a mutant virus containing a 30 
nucleotide deletion within the 3’NCR, which shows reduced replication in monkeys whilst 
still inducing a protective immune response (Hanley et al., 2004).
1.5.3 JEV Structural Proteins
JEV contains three structural proteins including the C, prM/M and E proteins. They are 
involved in various steps of the replication cycle and comprise the virus.
C Protein
The C protein is a small basic protein about 12 KD in size that binds viral RNA and is not 
highly conserved among flavivimses (Khromykh and Westaway, 1996; Patkar et ah, 2007).
vrM/M Protein
The larger prM protein is the precursor to the small M protein (Amberg et ah, 1994).
The role of the M protein has been demonstrated. A single mutation at M5 for JEY increased 
plaque size and infectivity in cell culture, but did not affect virulence in mice. Since this 
mutation was shown to inactivate the vims at low pH, it has been hypothesized that the M 
protein may function to stabilize the E protein in dimers at neutral pH from forming trimers 
(Maier et ah, 2007).
The prM protein is associated with immature virus particles and is likely to protect the E 
protein from inactivation by the low pH during transport through the intracellular- vesicles 
(Heinz and Allison, 2000). The prM protein also elicits a chaperone-like function preventing 
conformational changes in the E protein within the low pH secretory pathway (Guirakhoo et 
ah, 1992). The prM protein is cleaved by furin or a furin-like protease after the virus leaves 
the trans-Golgi network, but before the release of the virus, to reveal the mature form of the 
virus (Murray et aL, 1993; Stadler et al., 1997).
E Protein
The E protein is the major surface viral protein involved in tissue tropism, cell fusion, 
infection and immunogenicity as it elicits neutralizing antibodies (Zhang et ah, 2011). 
Neutmlizing antibodies against E protein are important for protective immunity and are 
involved in the clearance of viral infection.
The E protein lies parallel to the virion surface and forms an antiparallel dimer at 
physiological pH with a shift to a trimeric form at acidic pH (Heinz and Allison, 2000).
The X-ray crystallographic structure of the E protein for TBE, DEN-2 and WN viruses 
revealed some similarities including three domains; domain I, elongated dimerization, 
domain II containing the fusion peptide and an immunoglobulin-like domain III (Modis et al., 
2003; Nybakken et al., 2006; Rey et al., 1995b; Zhang et al., 2004). The putative receptor 
binding domain III for mosquito-borne flaviviruses, including JE, YF and WN viruses, 
contain an RGD/RGE integrin binding recognition motif (van der Most et al., 1999). Figure 
1-4 shows the X-ray crystallographic structure of the TBEV E protein.
Figure 1-4. X-ray crystallographic structure of tick borne encephalitis virus envelope protein. 
The E protein is comprised of three domains: domain I is the central domain with 128 
residues, domain II is the dimerisation domain with 171 residues and domain III is the 
contiguous stretch with 100 resides. Taken from (Kolaskar & Kulkami-Kale, 1999).
Several regions of structural disparity are found between the TBEV structure and the JEV 
model. These regions of structural variation map to all three domains of the E protein, but the 
majority of differences are found in domains I and III (Rey et al., 1995).
A study of Korean isolates of JEV identified three amino acid changes among five isolates on 
the top surface of the domain III barrel, though none were predicted to have a significant 
effect on the antigenicity (Chung et al., 1996). However, the local conformation of a protein 
can be affected by changes in the amino acid architecture in other regions of the protein.
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Comparison of JEV strains isolated in China, Japan, and India demonstrated that the viruses 
had a number of amino acid substitutions within the viral E protein when compared to the 
structure-based antigenic determinant predictions (Mangada and Takegami, 1999; Ni and 
Barrett, 1996; Vrati et ah, 1999). However, few substitutions fell within predicted antigenic 
regions.
1.5.4 JEV NS Proteins
JEV synthesizes seven NS proteins inside virus-infected cells, including NS1, NS2A, NS2B, 
NS3, NS4A, NS5B and NS5. These proteins are necessary for vims replication.
NS1 Protein
NS1 protein is highly conserved among flaviviruses. It has extensive identity and homology 
between different flaviviruses (Lindenbach and Rice, 1999). The NS1 protein interacts with 
other proteins necessary for replication, including the NS2A and NS4A proteins (Kummerer 
and Rice, 2002; Lindenbach and Rice, 1999).
Although the function of this protein has yet to be identified, the NS1 protein has been 
identified as essential for replication (Lindenbach and Rice, 1997).
The NS1 protein has been suggested to possess immunomodulatory capabilities. High levels 
of circulating NS1 protein has been linked to serious DEN infection, which may lead to 
potentially lethal infection (Alcon et al., 2002; Avirutnan et al., 2006; Libraty et al., 2002b; 
Macdonald et al., 2005; Young et al., 2000).
The role of secreted NS1 protein is unclear, but it is thought to be involved in the immune 
complex formation (Young et al., 2000), induction of autoreactive antibodies against 
extracellular matrix proteins (Chang et al., 2002), and enhanced viral production (Alcon- 
LePoder et al., 2005).
Antibodies against NS 1 have no neutralizing activity in vitro but do induce protective 
immunity, probably by antibody dependent cellular cytotoxicity and elicit passive protection 
in mouse and monkey models (Gibson et al., 1988).
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Intersetingly, the NS1 protein for WNV has been shown to inhibit complement activation, 
which may prevent complement-dependent lysis of infected cells (Chung et ah, 2006). This is 
contrary to studies with DENY where NS1 appears to activate complement (Avirutnan et ah, 
2006), suggesting a novel function for WNV NS1.
NS2A Protein
The NS2A is a hydrophobic and small protein about 22 KD in size (Kummerer and Rice,
2002).
The NS2A protein is required for viral assembly and has been shown to contribute to the 
virulence of the virus in mice (Liu et ah, 2003; Liu et ah, 2006).
NS2B Protein
The NS2B protein is a hydrophobic protein that contains a 40 residue central region that is a 
cofactor of the NS 3 serine protease and is necessary for the activation of the protease 
(Chambers et al., 1993; Leimg et al., 2001; Mastrangelo et al, 2007).
Cleavage of the NS2B/NS3 complex is necessary for replication (Chambers et al., 1995).
The NS2B protein also may be involved in the cleavage of the C protein (Amberg and Rice, 
1999).
NS3 Protein
NS3 protein contains an N-terminal serine protease and C-temhnal helicase, with nucleotide 
5'-triphosphatase (NTPase) and 5'-terminal RNA triphosphatase (RTPase) activities 
(Mastrangelo et al., 2007). It is thought that the NTPase may be required for the helicase to 
unwind viral RNA and RTPase may be involved in the formation of the 5’ cap (Brinton, 
2002). The protease is responsible for the proteolytic cleavage of the N-terminal/C-terminal 
regions of the C protein, NS2A/NS2B, NS2B/NS3, NS3/NS4A, NS4A/NS4B and 
/NS4B/NS5 junctions (Nowak et al., 1989). Figure 1-5 illustrates X-ray crystallographic 
structure of DENY NS 3 protein.
It has been demonstrated that NS3 protein is also involved in host cell apoptosis through the 
recruitment of caspase-8 (Ramanathan et al., 2006).
NS3 protein
Figure 1-5. X-ray crystallographic structure of flaviviruses NS3 protein. NS3 protein is 
trifunctional, containing domains for protease, helicase and RNA triphosphatase. Taken from 
(Luo et al., 2008).
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NS4A Protein
The NS4A protein is a small hydrophobic protein, approximately 16 KD in size. It is 
involved in the replication complex.
Cleavage of NS4A protein may be regulated since two precursors, NS3/NS4A and 
NS4A/NS4B, are found within the cell (Chambers et al., 1990; Preugschat et al., 1990).
The NS4A interacts with the NS1 protein in an undetermined fashion possibly essential for 
replication (Lindenbach and Rice, 1999).
NS4B Protein
The NS4B is a small hydrophobic protein of approximately 27 KD, which may participate in 
the replication cycle and immune evasion.
The NS4B protein shows only 35% amino acid identity between DEN, WN and YF viruses 
(Umareddy et al., 2006), however, members of the family Flaviviridae share common ER, 
cytoplasmic regions and transmembrane domains (Miller et al, 2006) that may indicate 
similarities in the function of this protein between viruses.
Mutations within the central hydrophobic region of the NS4B protein have been identified in 
several attenuated and passage-adapted flavivirus strains, including: chimeric WN/DEN-4 
and DEN-2/DEN-4 viruses, passage adapted DEN-4 virus, JE vaccine strain, YF vaccine 
strain and hamster passage adapted YFV strain, and a WNV mouse attenuated strain (Blaney 
et al., 2003; Halm et al., 1987; McArthur- et al., 2003; Ni et al., 1995; Pletnev et al., 2002; 
Wang et al, 2003; Wicker et al, 2006).
NS5 Protein
The NS5 protein is approximately 100 KD in size and the largest flaviviral protein. It is 
highly conserved among flaviviruses, containing a ethyltransferase activity in the N-terminus, 
which is utilized in 5’ capping, and a 3’ viral RNA-dependent RNA polymerase (RdRp) 
required for replication (Khromykh et al, 1999). The X-ray crystallographic structure of 
flavivims NS 5 protein is shown in Figure 1-6.
The NS5 protein has been shown to elicit immunomodulatory capabilities, specifically in 
interferon inhibition (Best et al, 2005; Lin et al., 2006).
NS5 protein
Figure 1-6. X-ray crystallographic structure of flavivirus NS5 protein. NS5 protein is RNA 
dependant RNA Polymerase and It is conserved among flaviviruses (10 conserved Cys 
residues). It contains a putative methyltransferase domain. Taken from (Zhou et al., 2007).
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1.6 Molecular Evolution of JEV
JEV is one of the major encephalitic flaviviruses of public health importance. It belongs to 
the genus Flavivirus.
The Flavivirus genus in the family Flaviviridae comprises approximately 70 antigenically 
related members. Most members are arboviruses, transmitted by arthropod vectors, either 
ticks or mosquitoes, and usually replicate alternately in susceptible vertebrate and arthropod 
hosts. A few viruses have no known vectors. The most recent classification, as listed in the 
7th Report of the International Committee on Taxonomy of Viruses (ICTY), has assigned 
members of the genus into species, with some members demoted to strains or serotypes. Thus 
there are now 27 mosquito-bome species, 12 tick-borne species, and 14 species with no 
known vector. The major criteria for determining the groupings of species, strains and 
serotypes within the genus are association and geographic incidence. The interpretation of the 
criteria for assigning a species level, and the definition of what constitutes a “strain” or 
“serotype” may be controversial in some instances, and indeed changes may be necessary as 
more information becomes available. Perhaps a more useful indication of relationships 
between flaviviruses can be obtained from phylogenetic studies which tend to agree with 
antigenic and vector/host relationships (Gould et ah, 2001; Zanotto et ah, 1996).
Molecular genetic classification of flavivurses has been attempted before. In all previous 
studies, fewer than one-third of the members, primarily mosquito-borne and tick-bome 
viruses, were used to create phylogenetic trees, which showed evolution of mosquito-borne 
and tick-bome viruses from the presumed ancestor (Zanotto et al., 1996).
1.6.1 Phylogenetic Relationships
The availability of complete or partial genome sequences for an increasing number of 
flaviviruses has provided the means for estimating phylogenetic relationships and the basis 
for hypotheses regarding their evolution (Drummond et al., 2003).
Phylogenetic analyses have been based on complete (Billoir et al, 2000; Cook and Holmes, 
2006) or partial genome nucleotide sequences or predicted amino acid sequences of vims 
proteins. Most recent phylogenetic trees have been based on sequences of the NS3 and/or
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NS5 genes (Billoir et al., 2000; Cook and Holmes, 2006; Gaunt et al., 2001). The basic 
segregation of tickbome viruses from mosquitoborne viruses was demonstrated in a 
dendrogram. Subsequently, phylograms confirmed this to be a primary evolutionary division 
and suggested that flaviviruses have evolved by divergent mutational change (Blok et al., 
1992). Phylogenetic studies on E gene sequences revealed a difference in the rate of 
mutation with the mosquitoborne group having nearly twice that of the tickbome group 
(Zanotto et al., 1995).
1.6.1.1 Building Phylogenetic Trees
A phylogenetic tree is a simple way to show evolutionary relationships between taxa which 
may be unrooted or rooted. Rooted trees include the position of the last common ancestor of 
each tree member.
Principles of phylogenetic tree building were discussed in detail by (Felsenstein, 1988, 2001; 
Goldman, 1993; Jukes, 1969; Lanave et al., 1984; Posada and Crandall, 1998) and are briefly 
mentioned here.
There are two types of tables that show the relation between taxa at either the percentage of 
matches (similarity table) or percentage of differences (distance table). The table will be 
converted into a matrix to be used to construct a phylogenetic tree.
There are several software packages for phylogenetic analysis such as PAUP (phylogenetic 
analysis using parsimony) and PHYLIP (phylogenetic inference package). There are different 
methods of phylogenetic analysis including distance matrix, maximum parsimony (MP) and 
maximum likelihood (ML).
However, there are some limitations of phylogenetic algorithms such as incorrect sequence 
alignment, failure to account for variation of evolution rates at different sites within a 
sequence, and failure to account for sequences evolving at different rates in different taxa 
which will generate incorrect trees. Therefore, the problems can be addressed in several 
ways. The first is to make sure that sequence alignments are robust. Caution should be 
exercised in particular if a newly built tree disagrees with others generated through the 
analysis of different genes or proteins.
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Reliability of the phylogenetic trees could be determined through bootstrapping in which data 
are randomly sampled from any position within a multiple sequence alignment, and are built 
into new artificial alignments, which are then tested by tree building. The trees built by 
bootstrapping should always match the original tree, and this would be defined as “100% 
bootstrap support”.
1.6.2 Evolutionary Relationships
Theories of the evolution of flaviviruses must fit constraints imposed by (a) their observable 
genetic relatedness, (b) the ecology of the individual virus species in nature (e.g., vector and 
vertebrate hosts), and (c) the geographic distribution.
The conclusion that vectorbome flaviviruses arose in Africa is supported by the observation 
that all the tick- and mosquitobome viruses that diverge at the lower nodes of the flavivirus 
tree are predominantly Old World viruses (Gaunt et ah, 2001).
The hypothesis that mosquitobome viruses arose from tickbome viruses or that the two 
clusters share a common ancestor is supported by the findings that viruses which are usually 
associated with mosquitoes, Koutango, Saboya, WN, and YF viruses, have been repeatedly 
isolated from ticks too (Billoir et ah, 2000).
Differences in the speed of evolution between tick- and mosquitobome viruses are mirrored 
at the amino acid sequence level. Adaptive substitution mutations in tickborne vims proteins 
are typically conservative, whereas those observed in mosquitobome virus proteins are more 
likely nonconservative (Lobigs et ah, 1990). The rate of mutation at the amino acid level 
between tick- and mosquitobome vimses supports the concept of a slower evolutionary rate 
in the tickbome vimses (Zanotto et ah, 1996).
JEV is believed to be one of the most recently diverged members of the family Flaviviridae, 
and most JEV isolates are estimated to have evolved over the last 130 years (Zanotto et ah, 
1996).
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1.6.2.1 Evolutionary Analysis
There is no doubt that evolution and statistics are two common subjects that pervade the 
modern analysis of molecular sequence variation. Questions related to molecular' sequences 
are statistical in nature and should be trained in terms of parameter estimation and hypothesis 
testing.
Bayesian evolutionary analysis by sampling trees (BEAST) software package is an ambitious 
attempt providing a general framework for both parameter estimation and hypothesis testing 
of evolutionary models from molecular' sequence data (Drummond & Rambaut 2007). It uses 
a Bayesian statistical framework and thus provides a role for prior knowledge in combination 
with the information provided by data,
BEAST is a cross-platform program for bayesian mar'kov chain Monte Carlo (MCMC) 
analysis of molecular sequences. It is oriented towards rooted, time-measured phylogenies 
inferred using strict or relaxed molecular' clock models. It is intended both as a method of 
reconstructing phylogenies and as a framework for testing evolutionary hypotheses without 
conditioning on a single tree topology.
BEAST is a powerful and flexible evolutionary analysis package for molecular' sequence 
variation as it provides considerable flexibility in the specification of an evolutionay model.
Substitution models describe the process of one nucleotide or amino acid being substituted 
for another. Transitions are interchanges of purines (A ++ G) or pyrimidines (C 4-f T). 
While, fransversions are interchanges of purine for pyrimidine bases. Figure 1-7 illustrates 
the possibility of fransitions and transversions. However, some sites such as initiation codons 
may not be free to vary at all (Akmaev et al., 2000).
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Figure 1-7. The possibility of transitions (red arrows) and transversions (blue arrows).
1.7 JE Infection and Disease in Humans
1.7.1 Incidence of JEV Infection and Disease Association
The incidence of JEV infection and encephalitis varies by country due to many factors, 
including the amount of virus circulating, people’s exposure to the virus, the country’s policy 
for vaccination against JE and underreporting of the disease. In endemic countries, JE is an 
illness of children under 10 years of age (Thisyakom and Nimmannitya, 1985;
Thongcharoen, 1985, 1989).
There is not much disease in infants; this is a reflection of maternal transfer of antibody that 
lasts between 8 and 12 months of age and host exposure to the vector. Adult immune naives 
are represented by travellers, tourists and military soldiers, are at significant risk of JEV 
infection and encephalitis when travelling to JE endemic areas (Ketel and Ognibene, 1971; 
Tsai, 2000).
1.7.2 Risk Factors for JEV Infection and Disease
Human JEV infection could be asymptomatic with antibody seroconversion, could induce a 
subclinical or febrile illness, or it could target the centeral nervous system (CNS) causing 
encephalitis as well as meningitis (Hosokawa et al., 2007).
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People living in endemic rural areas of Asia are exposed to JEV during childhood, but only 1 
in 300 develops disease (Vaughn and Hoke, 1992). Generally, the ratio of symptomatic to a 
symptomatic disease is estimated to be 1:50 - 1:300 (Libraty et ah, 2002a).
The factors determining which of all the infected humans with JEV develops disease could 
include viral factors such as strain differences, site of entry, and inoculating dose, as well as 
host factors such as living in endemic areas for JE, age, genetic make-up, general health and 
pre-existing immunity, lack of JE-specific antibody from natural infection or vaccine, and 
behaviour' that increases exposure to the mosquito vector such as night exposure or lack of 
bed nets and mosquito repellents.
Exposure to Infected Mosquito Vector
Human behaviour that affects exposure to infected mosquitoes may play an important role in 
getting JEV infection. Humans become infected during the bite of an infected mosquito. 
Incidence of JE in young children (<3 year's old) is less than in older children because they 
play outside less after dusk (Hoke et al., 1992; Huang, 1982).
The risk of JE increases as the number of vector mosquitoes increases. Because the rice 
paddy-breeding Culex mosquitoes are unavoidable, the majority of the population in rural 
Asia has been infected with the vims by early adulthood. The expansion of JEV-endemic 
area depends on irrigated rice field and pig farming. These environments that are suitable for 
the infectious cycle of JEV exist widely in Asia (Oya and Kurane, 2007).
Virus Strain Differences
It has been suggested that strain-specific differences in neurovirulence may determine the 
clinical presentation as it has been observed that JEV isolates from northern Thailand, where 
the disease is epidemic, are of a different genotype than isolates from southern Thailand, 
where the disease is endemic (Chen et al., 1990). However, in Vietnam, both epidemic and 
endemic patterns are caused by a single genotype (Huong et al., 1993).
Wild-type isolates of JEV with differing phenotypes in terms of neurovirulence and 
neuroinvasiveness in mice do occur* (Hasegawa et al., 1992; Huang and Wong, 1963; Ni and
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Barrett, 1996). It is unknown whether the same could be true for humans (McMimi, 1997). 
Though, more subtle strain differences may be important as the reported genotyping is based 
on a limited portion of the genome (Solomon and Vaughn, 2002).
Protective Effect of Anti-flavivirus Antibodies
The most important risk factor for developing severe encephalitis is the lack of flavivims 
antibody prior to JE infection (Burke et ah, 1985a; Edelman et ah, 1975; Sather and 
Hammon, 1970). Children with pre-existing flavivims antibody (most often presumed to be 
DENY in Southeast Asia) have milder JE disease which may be due either to the cross- 
protective property of flavivims antibody that modifles disease severity, or to a marker that 
results in cross-protective T-cell responses.
Some JE endemic areas are also endemic for other flaviviruses, such as DENY. However, 
prior anti-flavivirus antibodies do not entirely protect against JEV infection but they may 
make infections less severe (Grossman et al, 1973).
It has been observed that children younger than 10 years of age are more likely to die or to 
have severe sequelae than older children and young adults (Schneider et al., 1974). Older 
patients with JE have a secondary anti-flavivirus antibody response suggesting that previous 
infection with a different flavivims may give some protection (Endy and Nisalak, 2002).
The reason by which older patients are protected is thought to be due to cross-protective 
immunity from prior DENY infection (Edelman et al., 1975; Grossman et al., 1973; Libraty 
et al, 2000).
Crossing the Blood-Brain Barrier (BBS)
Humans get JEV infection during the bite of an infected mosquito. Following inoculation, 
JEV is thought to replicate in the skin before being transported by Langerhans’ dendritic cells 
to local lymph nodes as has been observed in the experimental intradermal (i.d.) infection of 
BALB/c mice with WNV and in volunteers receiving candidate live-attenuated DENY 
vaccines (Johnston et al., 2000; Wu et al., 2000).
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It is not well known how neurotropic flaviviruses enter the CNS. The two postulated routes 
are through the olfactory mucosa where there is no BBB, or via hematogenous spread 
(Rapoport, 1976).
Intranasal inoculation (in.) is an effective means of experimentally inoculating rhesus 
monkeys with JEV and vims replication was widespread in the CNS and not always 
identified in the olfactory bulb suggesting hematogenous spread (Myint et al., 1999; 
Raengsakulrach et ah, 1999).
However, i.d. inoculation in mice, showed that JEV establishes infection in the regional 
lymph nodes, then spreads via the blood to other organs such as liver, heart, and kidney, 
before crossing into the brain. A close relationship was shown between vims multiplication 
in the periphery and cerebral involvement (Huang and Wong, 1963). It is thought that JEV 
also replicates in the periphery in humans before crossing the BBB as in humans, JEV was* 
isolated from the liver of one fatal case, and the damage in the lungs, myocardium, liver, 
kidney, and reticuloendothelial system has been demonstrated histologically (Haymaker and 
Sabin, 1947; Miyake, 1964; Mukherhi and Bisws, 1976; Zimmerman, 1946).
The actual means mechanism by which JEV and WNV cross the BBB have been studied. In 
theory, virus could cross either by passive transport across the endothelium, by replication in 
the endothelial cells, or within infected inflammatory cells that enter the brain parenchyma. It 
has been shown that virus replication in endothelial cells is important for WNV but not for 
JEV. In vitro, endothelial cells are readily infected with WNV causing cytopathic effects 
(CPE), and electron microscopic examination reveals antigenic localization (Dropulie and 
Masters, 1990). In contrast, ultrastmctural examination of the mice brains injected with JEV 
shows that the virus undergoes endocytosis and transportation across endothelial cells and 
pericytes without replication (Liou and Hsu, 1998).
In some trials for understanding how WNV as one of the encephalitic viruses crosses the 
BBB. Experimental inoculation of WNV in mice showed that toll-like receptor 3 (TLR3) 
binding to the viral double-stranded RNA results in the generation of antiviral and 
immunomodulatory cytokines. A reasonable prediction is that targeted deletion of TLR3 
would lead to increased peripheral viral infection with enhanced viremia. The higher level of
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virus in the blood would lead to greater spread across the BBB (Diamond and Klein, 2004; 
Wang et ah, 2004). Figure 1-8 illustrates a model of how WNV may cross the BBB.
Blood Perivascular Brain 
vessel space
Figure 1-8. WNV crossing the BBB. (a) Infection of macrophages or dendritic cells by WNV 
in peripheral lymphoid tissue induces TLR-3-dependent secretion of antiviral and 
immunomodulatory cytokines which inhibit WNV infection in peripheral tissues. TLR-3- 
dependent induction of TNF-ot, however, also facilitates WNV penetration across the BBB. 
(b) TNF-x may alter endothelial cells or endothelial cell tight junctions so that WNV or 
WNV-infected leukocytes traffic across the perivascular space and glial cell foot processes 
to infect neurons. Taken from (Diamond and Klein, 2004).
It has been shown that concomitant conditions that result in a disruption of the BBB, 
allowing JEV to cross into and replicate in the CNS may play a role in the pathogenesis of JE 
encephalitis. For example, cerebral cysticercosis may be a poor prognostic indicator for JE 
(Desai et al., 1997).
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Structural Abnormalities of the Brain
JEV affects both adults as well as children when it reaches a new geographic area for the first 
time. However, adults over 60 years of age appeal’ to be more likely to have severe disease 
(Kitaoka, 1972). In Japan and Korea where widespread vaccination and changed 
socioeconomic circumstances led to reduction in the number of JE cases, the disease is now 
seen mostly in the elderly (Kono and Kim, 1969).
Possible reasons for the increased attack rate and severity in the elderly include structural 
abnormalities that facilitate viral transfer across the BBB, general poor health, and impaired 
immunity (Solomon and Vaughn, 2002).
A high incidence of cysticercosis has been noted among fatal JE cases (Desai et al., 1997; Liu 
et al., 1957; Shankar et al., 1983). There was a strong association between JE and 
neurocysticercosis, and, thus, this coinfection was more than a chance occurrence (Handique 
et al., 2008).
In Saipan, three out of ten JE patients had a structural brain abnormality preceding JE (one 
with a craniotomy, one with severe trauma, and one with a cerebrovascular accident) (Paul et 
al., 1993). Even mild head trauma during the transient viremic phase could facilitate viral 
entry into the CNS (Shiraki, 1970).
Impaired Immunity with Age
Humoral and cellular immunity play an important role in protection against JEV infection. It 
has been shown experimentally in animal models that the cellular immune response may 
contribute to the prevention of disease during acute infection by restricting vims replication 
before the CNS is invaded (Solomon and Vaughn, 2002).
The susceptibility of athymic nude mice to experimental JEV infection has increased (Yu, 
1985), and transfer of spleen cells from mice immunized with live-attenuated vims conveys 
immunity to infection (Jia et al., 1992). Spider monkeys, which are normally unaffected by 
intracerebrally inoculated JEV develop rapidly progressive encephalitis when T-cell function 
has been impaired by cyclophosphamide (Nathanson and Cole, 1970).
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However, there is little direct evidence to suggest that an impaired immune response 
contributes to JE in humans. In Japan and Korea, the increased incidence of JE in elderly 
people, who presumably were previously immune because of early exposure to the virus, 
may indicate a waning of immunity. In humans infected with SLEV impairment of T-cell 
function by human immunodeficiency virus (HIV) appeal's to increase the risk of developing 
encephalitis (Solomon and Vaughn, 2002).
JE and Travellers
Overall, travellers to Asia are at extremely low risk to acquire JE. However, the risk in the 
individual traveller may be highly variable, depending on area being visited, season, duration 
of travel and activities of the person (ACIP, 1993). Although considered to be rare in short­
term tourists, JE has been reported after brief stays in Bali in at least two cases (Macdonald et 
ah, 1989; Wittesjo et ah, 1995).
Therefore, a JE vaccine should be considered for travellers visiting JE endemic or epidemic 
areas regardless of the duration of their visit (Mayer and Neilson, 2010).
1.7.3 Clinical Features of JE
Although epidemics of encephalitis occurred in Japan from the 1870s onwards, clinical 
features of JE were not described until World War I when American service personnel were 
exposed to the vims (Solomon and Vaughn, 2002).
Patients with JE present after a few days of a nonspecific febrile illness, which include 
headache, nausea, cough, vomiting, diarrhea, and rigors (Solomon et ah, 2000). In older 
children and adult patients, abnormal behaviour may be the only clinical feature, resulting in 
an initial diagnosis of mental illness. During the Korean conflict some American servicemen 
with JE were initially diagnosed as having £war neurosis’ (Lincoln and Sivertson, 1952). 
Some patients make a rapid spontaneous recovery as they have aseptic meningitis only with 
no encephalopathic features (Chan and Loh, 1966).
The classical feautures of JE include a ‘Parkinsonian’ syndrome of dull flat ‘mask-like’ faces 
with wide unblinking eyes, tremor, generalized hypertonia, cougwheel rigidity and other
movement abnormalities. In addition, there may be upper motor neuron signs (increased tone, 
brisk reflexes, extensor plantars), cerebellar signs and cranial nerve palsies. Relative 
bradycardia has been noted in some patients with JE (Sabin, 1947) and hypertension has 
occasionally been reported (Poneprasert, 1989).
Convulsions have been reported in up to 85% of JE infected children (Kumar et ah, 1990; 
Schneider et ah, 1974) and 10% of adults (Dickerson et ah, 1952; Poneprasert, 1989).
Some form of JE motor paralysis as well as the increased tone, brisk reflexes, and extensor- 
planter reflexes are suggestive of upper motor neuron paralysis, 5%-20% of comatose 
patients have flaccid weakness with reduced or absent reflexes that is characteristic of lower- 
motor neur-on lesions (Dickerson et al., 1952; Kumar* et ah, 1991; Sabin, 1947; Schneider et 
al., 1974).
As well as comatose patients with flaccid weakness, there is a subgroup of fully conscious 
JEV infected patients with a polio-like acute flaccid paralysis (Solomon et al., 1998).
Following a short febrile illness there is a rapid onset of flaccid paralysis in one or more 
limbs, despite a normal level of consciousness. Weakness occurs more frequently in the legs 
than in the arms, and is usually asymmetrical. Occasionally it affects only the respiratory 
muscles. Thirty percent of such patients subsequently develop encephalitis, with a reduced 
level of consciousness, and upper motor neuron signs, but in the majority acute flaccid 
paralysis is the only feature. At follow-up there may be persistent weakness and marked 
wasting in the affected limbs (Solomon and Vaughn, 2002).
1.7.4 Outcome in JE
JE case-fatality rates range from 0% to 55% with most reports around 30% (Benenson et al., 
1975; Burke et al., 1985a; Grossman et al, 1973; Hoke et al., 1991; Kono and Kim, 1969; 
Kumar et al., 1990; Paul et al., 1993; Sabin, 1947; Schneider et al., 1974; Sunnara and Touch, 
1995). With better hospital facilities, it has been observed that mortality rates may be lower 
with a concomitant increase in the proportion of patients with sequelae (Solomon, 1997).
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Twenty percent of patients have severe cognitive and language impairment (most with 
concurrent motor impairment), and 20% have further convulsions (Huy et ah, 1994; Kumar et 
ah, 1993).
Patients with an apparently good recovery may have more subtle sequelae such as learning 
difficulties and behavioural problems (Kumar et ah, 1993). In most patients JE is an acute 
infection, however, chronic progressive encephalitis and relapse, possibly caused by 
persistence of the virus in the CNS, have been reported in few patients (Pradhan et al., 2000; 
Ravi et ah, 1993; Sharma et ah, 1991).
1.7.5 Prognosis in JE
Increasing age is a risk factor for severe disease in many arboviral encephalitis, however, in 
JE younger children have a worse prognosis than older children and young adults. The eldery 
are also more likely to experience severe disease. The mechanism by which older children 
and adults are protected includes a degree of cross-protective immunity from prior DENY 
infection. In support of this is the observation that positive virus isolation from the CSF, and 
a failure of immunoglobulin (Ig) M and IgG production in the CSF and serum are associated 
with a fatal outcome (Burke et ah, 1985a).
A poor JE prognosis includes deep coma (Burke et ah, 1985a; Kumar et ah, 1990; Solomon 
et ah, 2000), abnormalities of respiratory pattern, increased or decreased tone, extensor or 
flexor posturing and other signs of brainstem damage (Kumar et ah, 1990; Solomon et ah, 
2002), frequency of seizures, higher admission temperature, absent abdominal reflexes, 
hyponatremia, and low serum iron (Dapeng, 1995; Kumar et al., 1990; Libraty et al., 2000; 
Misra et al., 1998; Solomon et al., 2002; Solomon et al., 1996) and signs compatible with 
brainstem herniation through the foramen magnum were also associated with a poor outcome 
(Solomon et al., 2002).
JE-specific antibody that results from infection is life-long in duration. Seroprevelance 
studies indicate that in areas where JE circulates, there is an age-dependent increase in JE 
antibody and most adults have been exposed to and infected by JEV (Solomon and Vaughn, 
2002).
1.7.6 Treatment of JEV
Despite the significant disease burden caused by JEV, no specific antiviral therapy is 
currently licensed for treatment (Ghosha et al., 2008). JEV is treated symptomatically.
However, some compounds have shown some anti viral acttivity against JEV in vitro or in 
animal models; such as isoquinolines, anti-JEV MAbs, nucleoside analogs, the lymphocyte 
modulator Concanavalin A, nitric oxide and ribavirin (Kimura-Kuroda and Yasui, 1988).
Salicylates and nonsteroidal anti-inflammatory drugs (NSAID) were shown to inhibit the in 
vitro replication of JEV, and prevent apoptosis of infected cells (Chen et al, 2002).
Corticosteroids were given for JE, however in placebo-controlled trials there were no benefit 
associated with the administration of corticosteroids or IFN-a (Hoke et al., 1992;
Solomon et al., 2003a). IFN-a, a glycoprotein cytokine that is produced naturally in response 
to viral infections, including JEV (Burke and Morrill, 1987), has been the most promising 
antiviral aganist JEV infection. In tissue culture, recombinant interferon is effective against 
JEV and other arboviruses including WNV (Anderson and Rahal, 2002).
Since several years, the use of IVIG has increased. IVIG is a blood product administered 
intravenously. It contains the pooled IgG extracted from the plasma of over one thousand 
blood donors. IVIG's effects last between 2 weeks and 3 months.
IVIG has been used recently to treat flavivirus encephalitis. There has been a case report of, 
IVIG which has been shown which appeared to be of benefit when administered with 
symptomatic treatment for JEV. In the case report, the patient’s clinical signs has improved 
rapidly with almost complete recovery (Caramello et al., 2006). It has been sugessted that 
such antibody- containing immunoglobulin may provide a specific and effective treatment for 
serious cases of flaviviruses such as WNV infections (Shimoniz et al, 2001).
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1.7.7 Diagnosis of JE
JE diagnosis is not easy, especially in areas where two or more related flaviviruses co­
circulate. For example in Southeast Asia, all four DENY serotypes circulate and in southern 
India, in addition to DENY, WNV also circulates. In northern Australia, both KUNY and 
MVEV circulate (Endy and Nisalak, 2002).
Therefore, the ideal assay for diagnosis of acute JE infection and encephalitis should be 
highly sensitive and specific. It should have the ability to distinguish JE from other 
flaviviruses.
The co-circulation of similar flaviviruses with a high-degree of cross-reactive human 
antibody creates a challenge for serologic assays to detect JE and distinguish it from other 
flaviviruses (Wisseman et al., 1966). For example, a person with previous exposure to DENY 
who becomes infected with JE will have an increase in antibody to both JE as well as the four 
serotypes of DENY as detected by antibody-based assays such as HI or plaque reduction 
neutralization titer (PRNT).
Currently the diagnosis of JE infection is based on serologic, viral isolation, molecular, and 
inununocytochemistry assays.
Serology
(A) Haemagglutination Inhibition (HI)
Although HI was the first assay to measure human antibody specific for the arthropod-bome 
viruses including JE (Clarke and Casals, 1958) it is still a fundamental tool in arboviral and 
JE diagnostics.
Hemagglutination assay (HA) is the precursor to the HI assay, which showed that 
arboviruses, in particular’ JEV, were able to agglutinate certain types of erythrocytes (Sabin, 
1951; Sabin and Buescher, 1950).
The HA assay allowed quantification and standardization of JEV antigen produced from a 
variety of sources including the most common, suckling mouse brain. The finding that
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arbovirus-specific antibody was able to inhibit HA of erythrocytes created a relatively simple 
and inexpensive HI assay which to measure JE-specific antibody (Clarke and Casals, 1958).
The main advantage of the HI assay is that it can be performed with minimal laboratory 
equipment, reagents and expense. However, it could not discriminate adequately between the 
closely related flaviviruses such as DENY and WNV. This produces results that are difficult 
to interpret in countries where these viruses co-circulate. Despite these limitations, the HI 
assay is a powerful technique that is still a standard assay for seroprevelance studies as well 
as in the diagnosis of acute primary and secondary DENY infections (Endy and Nisalak, 
2002).
(B) IgM and IgG Enzyme Immunoassay
ELISA is widely used in the diagnosis of many viruses. Detection of IgM dining acute JEV 
infection provides a highly specific antibody based assay without the problems of cross­
reactivity that IgG antibody displays for other flaviviruses. This was demonstrated for group 
B arbovirus infections. For example, in DENY vaccinated gibbons challenged with JEY and 
in patients hospitalized with JE infection (Edelman et al., 1973; Edelman and Pariyanonda, 
1973; Scott et al., 1972).
On the basis that IgM does not cross the BBB, its detection in CSF was performed using an 
antibody capture radioimmunoassay, which was modified and simplified to an ELISA format 
using an IgM isotype specific antibody capture immunoassay (Burke and Nisalak, 1982; 
Burke et al., 1986; Burke et al., 1982; Burke et al., 1985b). The IgM isotype specific 
antibody capture immunoassay demonstrated a sensitivity of 73% and a specificity of 100% 
when used during a field trial (Burke et al, 1986).
ELISA as well as a dot enzyme immunoassay has also been used to detect JE IgM in swine 
sera with high sensitivity and specificity (Burke et al, 1985c; Cardosa et al, 1993).
Antibody-capture ELISA approach yielded a sensitive and specific method to distinguish 
acute JE from acute DENY infections (Bundo and Igrashi, 1985).
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An antidengue isotype capture ELISA has been developed to characterize DENY infections 
in regions where DENY and JEV co-circulate (Innis et ah, 1989). This assay provided a 
convenient format to distinguish acute DEN from acute JEV infections. It used an anti- 
DENV isotype-capture enzyme immunoassay to measure the proportion of Ig isotype 
reactive with DENY of JE antigen.
(C) Plaque Reduction Neutralization Titer Assay (PRNT)
Arbovirus plaques were detected using an agar overlay stained with neutral red (Henderson 
and Taylor, 1959). This technique allowed an easy in vitro assay to directly detect and 
measure the infectivity of a virus preparation or stock as plaque forming units. Its application 
to JEV awaited the finding that JEV produces CPE (plaques) in certain cell lines such as in 
cultured baby hamster kidney (BHK) cells and in chick embryonic fibroblast monolayer 
cultures (Diercks and Hammon, 1958; Kissling, 1957; Porterfield, 1959).
PRNT for JEV was developed using cultured chick embryonic fibroblasts and demonstrated a 
good correlation to HI antibody titers (Yoshioka et ah, 1965). This technique was 
subsequently adapted to the green monkey kidney cell line, Vero cells, using a constant-virus 
decreasing serum technique and was more sensitive than HI titers (Yoshioka et ah, 1966).
PRNT protocols are being used to measure JE neutralizing antibody using a variety of cell 
lines, including LLC-MK2 (Kidney, Rhesus monkey, Macaca mulatto), Vero and BHK21 
cells. The endpoint is the titer of antibody that will reduce a certain percentage of viral 
plaques such as a 50%, 70%, or 90% plaque reduction (PRNTso, PRNT70, PRNT90, 
respectively) compared to control cultures. Higher PRNT values increase the specificity but 
decrease the sensitivity of the assay, therefore a PRNT50 is the most commonly used endpoint 
(Endy & Nisalak, 2002).
A JE antibody titer as measured by the PRNT assay is interpreted in a number of ways. In a 
patient with suspected acute JE infection, a titer increasing by fourfold suggests an acute 
infection. A titer of 1:10 or more suggests past exposure or vaccination, and protective 
immunity.
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(D) Western Blot
Western blot is a technique that utilizes the characteristic of proteins to travel through a 
polyacrylamide gel, and to transfer onto nitrocellulose sheets when an electrical current is 
passed through the gel (Towbin et al., 1979).
Separation of proteins occurs as they travel through a gel at different speeds depending on 
their molecular' weight and charge. The result, when applied to proteins derived from JE, is a 
spread of different structural and NS protein components across a gel, predominantly E, NS1, 
and pre-M. These proteins are then transferred onto nitrocellulose paper by an electrical 
current applied horizontally to the gel. Human sera can then be applied to the nitrocellulose 
strip and human antibody specific to JE protein will bind; an anti-human antibody conjugate 
system is then used to detect binding of the human antibody. The result is a band showing the 
presence of antibody to those proteins (Endy and Nisalak, 2002).
Western blot has limited diagnostic utility as JEV and DENY proteins are highly cross­
reactive and this assay is unable to distinguish the two viral infections.
Virus Isolation
JEV Isolation during an acute infection is extremely difficult, partly due to the high levels of 
neutralizing antibody that exist at the time that clinical symptoms occur.
Some studies illustrate the difficulties in isolating vims from nonfatal cases of JE. In one 
series of 101 patients with JE infection of the CNS, no virus was isolated when the geometric 
mean titer of neutralizing antibody exceeded 1:500 at the onset of clinical symptoms (Kimoto 
et al., 1968). In a similar' series of patients in Thailand, among 49 cases of JE infection of the 
CNS, no plasma specimens or CSF yielded virus in the nonfatal cases. Only in 5 of the 15 
fatal cases of JE was there vims isolation from the CSF and 7 of 15 had virus isolation from 
brain tissue (Leake et al., 1986).
JEV isolation from nonfatal cases can be performed using a variety of methods, the classic 
being intracranial inoculation (i.c.) of clinical specimen in suckling mice. Normally, 1- to 2- 
day-old suckling mice (Mus musculus) are inoculated i.c. with 0.02 ml of a suspension of
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clinical material. Mice are observed twice a day for the first signs of encephalitis (failure to 
eat as evidenced by lack of milk in the stomach, colour- change, wasting, runting, or tremors), 
which occur approximately 3-10 days after inoculation. Confirmation of JEV is performed by 
staining the brain with either a polyclonal or monoclonal antibody specific for JE conjugated 
with a fluorescent tag (Endy and Nisalak, 2002).
A more direct method of JEV isolation could be carried out by direct inoculation and 
isolation in a variety of mammalian and insect cell lines such as Vero and LLC-MK2 cells 
from monkey kidneys, BHK21 from hamsters, pig kidney epithelial cells, AP61 from Ae. 
pseudoscutellaris, C6/36 from Ae. Alopictus (Fu and Zhang, 1996; Igarashi et ah, 1981; 
Igarashi et ah, 1973).
Other method for JEV isolation is inoculation of patient sera into mosquitoes to amplify and 
propagate the virus. A variety of mosquito vectors has been used including Toxorhynchites 
splendens, Ae. Albopictus, or Ae. Aegypti (Rosen and Gubler, 1974). Toxorhynchites 
mosquitoes have the advantage of being larger and easier to inoculate with human.
Viral isolation in fatal human cases of JE infection is best performed on tissue or autopsy 
specimens of brain tissue (George et ah, 1987b).
Molecular: Polymerase Chain Reaction (PCR)
PCR has been used with success for diagnosis of flavivimses. It is a molecular technique 
based on the ability to amplify small amounts of RNA or DNA to detectable levels using 
molecular primers, a polymerase enzyme and a thermocycler.
The limitations of PCR are similar- to the limitations with the isolation of virus. Viremia and 
detectable viral RNA in sera or CSF is foimd infrequently at the time of clinical illness.
PCR may have higher yield when performed using brain biopsy specimens although this has 
not been demonstrated in clinical studies (Endy and Nisalak, 2002).
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Immunocytochemistry
Immunohistochemistry is the staining of the specimens for the presence of specific proteins 
and as it applies to JE. JE antigen staining is a powerful technique to diagnose fatal cases of 
JE when serology or viral isolates are not available.
A number of techniques have been used to detect arbovirus antigen in tissue specimens to 
include both direct and indirect fluorescent antibody staining, and enzyme conjugates using 
peroxidise and alkaline phosphatase conjugates (Endy and Nisalak, 2002).
Immunohistochemistry is very useful in diagnosis of JE fatal cases when sera or CSF are not 
available. In one series 62% of fatal cases of JE were diagnosed by immuohistochemical 
staining for JE antigen in brain tissue (Zhi-shang et ah, 1988).
1.8 Immune Responses to JEV
Understanding the immune responses which contribute to the prevention of and the recovery 
from JE is important to the development of new types of vaccines and specific treatment. 
Also analysis of immune responses to JEV as a model will provide information useful to the 
understanding of immune responses to other encephalitic viruses.
1.8.1 Components of Protective Immunity to JEV
It has been found that neutralizing antibodies play a key role in protection, while cytotoxic T 
lymphocytes (CTLs) play a key role in the recovery (Kurane, 2002).
Pre-existing neutralizing antibodies are important for protection from JEV infection. It was 
demonstrated that passive transfer of neutralizing antibodies before virus inoculation 
protected mice from lethal challenge (Kimura-Kuroda and Yasui, 1988b; Mason et ah, 1989; 
Oya, 1966, 1988) and also partial protection was achieved when antibody was transferred 
passively after infection.
JEV infection induces antibodies to both NS and structural proteins. Antibodies to NS1 also 
protected mice from lethal flavivirus infection when transferred passively (Henchal et al., 
1988; Schlessinger et ah, 1985).
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Antibodies to NS1 do not neutralize viruses; although complement -mediated cell lysis and 
antibody-dependent cell-mediated cytotoxicity were attributed to protective activity, the 
mechanism of protection by anti-NSl antibodies is incompletely understood. It has been 
observed that monoclonal antibody to DENY preM protein protected mice from lethal 
infection (Kaufman et ah, 1989); it is possible, therefore, that antibodies to JEV NS1 and 
preM may also have a protective effect against lethal infection.
The role of CTLs in the recovery from JEV infection has not been well established. However, 
it has been reported that passive transfer of vinis-specific CTLs also protected mice from 
lethal challenge by JEV (Murali-Krishna et al., 1996).
1.8.2 JEV Proteins that Induce Protective Immunity
It has been demonstrated that the E protein induces protective immunity; this has been 
detected by using extracellular particles, and recombinant vaccinia vims and DNA vaccines 
containing the E gene (Chen et al., 1999; Konishi et al., 1991; Konishi et al., 1998b).
Although neutralizing antibodies that recognize the E protein play a major role in protection 
from JE infection, it has been reported that a DNA vaccine containing the NS1 gene induced 
protective immunity (Lin et al., 1998); however, the levels of protection elicited by NS1 were 
very low compared to studies by other investigators (Chen et al, 1999).
Other viral proteins do not elicit protective immunity. Thus, it is likely that the neutralizing 
antibodies to the E protein, non-neutralizing antibody to NS1 protein and specific T 
lymphocytes are involved in protective immunity against JEV (Kurane, 2002).
1.8.3 Immune Responses to JEV in Humans and Mouse Models
Human immune responses to JEV have been analyzed using specimens from JE patients, and 
from those who recovered from JE. High levels of neutralizing antibodies directed to E 
protein are induced by infection with JEV (Konishi et al., 1995; Oya and Okuno, 1975). 
Antibodies to the NS proteins, including NS1, were also detected in humans who recovered 
from JE (Kurane, 2002).
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JEV-specific T lymphocytes were detected in patients in the early convalescent phase 
(Konishi et al.} 1995). JEV- specific CD8+ human CTLs were elicited by immunization with 
recombinant attenuated vaccinia virus encoding the preM, E and NS1 genes (Konishi et al., 
1998a).
Mouse models have been used to analyze the immune responses to JEV. Infection of mice 
with JEV induces antibodies to structural and NS proteins; neutralizing antibodies recognize 
the E protein (Heinz et al., 1983; Rey et al., 1995b). Furthermore, neutralizing epitopes were 
analyzed using a panel of MAbs against the E protein (Kimura-Kuroda and Yasui, 1986).
Infection by JEV induced virus-specific CTLs (Konishi et al., 1997; Murali-Krishna et al., 
1996; Takada et al., 2000). These T cells possessed the CD3+ CD4' CD8+ phenotype and an 
ability to lyse JEV infected cells in a major histocompatibility antigen complex (MHC)- 
restricted fashion. The proteins recognized by JEV-specific CTLs were different depending 
on the mouse strains used in the experiments. Vims-specific CTLs raised in B ALB/c mice 
(H-2d) recognized the E protein, whereas those in C56BL/6 mice (H-2b) and C3H mice (H- 
2k) recognized mainly the NS1 protein (Takada et al., 2000).
1.8.4 Protective Immunity Induced by JE Inactivated Vaccine
The main protection mechanism induced by the vaccine is through the production of high 
levels of neutralizing antibodies, as the inactivated vaccine does not induce high levels of 
CD8+ CTLs. Although the inactivated vaccine does not contain NS1, antibodies to NS1 were 
detected in some vaccines. The results suggest that these vaccines were infected with JEV, 
that virus propagated, and that antibody to NS1 was induced (Kurane, 2002).
It has been demonstrated that immunized mice with undetectable levels of neutralizing 
antibodies were protected from lethal challenge (Konishi et al., 1999). High levels of 
neutralizing antibody were produced rapidly in these mice after challenge. It is thus likely 
that sterile immunity is not established in some of the vaccines, rather they are infected but 
viruses are eliminated by rapidly produced antibodies before symptoms develop.
1.8.5 Neutralization Activities of Murine and Human Sera to JEV Strains
JEV strains are divided into four- genotypes according to their nucleotide sequences. The 
neutralizing activities of antisera raised by one strain of JEV to heterogeneous strains have 
been studied examining the neutralizing activities of murine and rabbit antisera against 
homologous and heterologous strains of JEV (Ali and Igarashi, 1997; Ali et al.5 1995). 
Neutralizing titers against heterologous strains were lower than those against homologous 
strains, and titers were much lower against those strains belonging to different genotypes 
(Wills et al, 1992).
Similar- observations to those in mice were found using human sera from subjects immunized 
with JE vaccine. It was demonstrated that neutralizing antibody titers induced by the 
inactivated vaccine were lower to heterologous strains compared with the homologous strain. 
The neutralizing antibody responses to the Nakayama, JaGarOl and E-50 strains of JEV were 
compared after immunization with the Nakayama strain vaccine (Juang et al., 1983; 
Susrlowati et al., 1981) and were found to be approximately ten-fold lower against JaGAr-01 
and E-50 strains than against the homologous Nakayama strain.
Similar* results were demonstrated in Taiwan (Shyu et al., 1997). The neutralizing antibody 
titers also have been examined after* two or three immunizations with Beijing-1 or Nakayama 
vaccine (Ku et al., 1994). Neutralizing antibody titers were higher against homologous strains 
than against heterologus strains, although the Beijing-1 vaccine induced higher levels of 
neutralizing antibody against the Nakayama strain than did the Nakayama vaccine against the 
Beijing-1 strain. However, the field vaccine efficacy studies in Taiwan (Hsu et al, 1971) and 
Thailand (Hoke et al, 1988) suggest that protective immunity against heterologous strains is 
established by immunization with the current inactivated vaccine (Kurane, 2002).
1.8.6 Flavivirus Cross-reactive Immunity Induced by JEV
The genus Flavivirus includes almost 70 members. These viruses are separated into eight 
groups based on their serological relatedness (Monath and Heinz, 1996). JEV belongs to the 
JE antigenic complex with SLEV, MVEV, WNV, KUNV and others.
62 | P a g e
Neutralizing antibodies induced by JEV neutralized WNV and MVEV to lower but 
significant levels (Goverdham et al., 1992; Hammon and Sather, 1956). Furthermore, 
immunized hamsters with JEV were immune not only to JEV, but also to MVEV and WNV 
(Hammon and Sather, 1956).
Immunization with JEV protected bonnet macaques against WNV, and immunization with 
WNV reduced the severity of JEV infection (Goverdham et ah, 1992). However, It is not 
known whether immunization with the current JE vaccine protects humans from infection by 
other viruses included in the JE serocomplex (Kurane, 2002).
In Thailand, immunization with JE vaccine did not significantly reduce the number of 
patients with DEN fever (Hoke et al., 1988). This may be because antibodies induced by JE 
vaccine do not neutralize DENV. However, there is a report that prior DEN viral infection 
moderately reduced the mortality and morbidity of JE patients (Edelman et ah, 1975).
1.9 JE Vaccination
1.9.1 JE Vaccination History
The Russians were the first to practice vaccination against JE in 1941 (Pond and Smadel, 
1954). In the United States (US), a formalin inactivated mouse brain vaccine was developed 
for use in the US Anny between 1945 and 1947, and children in Okayama, Japan, between 
1946 and 1949 (Pond and Smadel, 1954).
1.9.2 JE Vaccines
JE is a vaccine-preventable disease. Three JE vaccines are currently available, namely 
inactivated mouse brain derived JE vaccine from Nakayama-NIH strain and Beijing-1 strain, 
inactivated primary BHKC-derived JE vaccine from P3 strain and live attenuated JE vaccine 
from SAM strain.
Mouse Brain-derived Inactivated JE Vaccine
The only internationally accepted vaccine today is the mouse brain derived inactivated JE 
vaccine produced using the Nakayama and Beijing-1 strains. Mice are inoculated
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intracerebrally with JEV and the brains are harvested when the mice show signs typical of 
encephalitis (Kitano and Oya, 1996). The brains are triturated in buffered isotonic sodium 
chloride (Na Cl) solution and centrifuged. The supernatants are treated by alcohol 
precipitation and with protamine sulphate, and then purified by ultracentrifugation. JEV is 
inactivated by fonnalin or any other appropriate reagents of comparable effectiveness. This 
vaccine, therefore, consists of the E, M, and C proteins (Monath, 2002).
In Japan and the former Soviet Union crude mouse brain vaccines were developed and tested 
in the late 1930s and in the US during World War II. In Japan purification steps were 
introduced into the manufactming process in the 1960s. By 1966, a purified vaccine suitable 
for children had been developed from infected adult mouse brain tissue and introduced into 
routine use (Monath, 2002).
Inactivated mouse brain vaccine is prepared either from brain tissue infected with the 
prototype Nakayama strain originally isolated in 1935 or the Beijing-1 strain originally 
isolated in 1948 in China. Beijing-1 vaccine has higher potency and elicits a broader 
neutralizing antibody response across wild-type strains of JEV (Kitano et al., 1986).
The volume for subcutaneous (s.c.) inoculation depends on the vaccine formulation. The 
vaccine produced from Nakayama strain is given in a volume of 0.5 ml for 1-3 years old 
children and 1 ml for adults and children older than 3 years. Beijing-1 vaccine is given at 
one-half these volumes as it is more potent (Monath, 2002).
In JE endemic Asian countries, the primary immunization schedule involves two doses of 
vaccine administered 1-4 weeks apart, followed by booster doses at 1 year and at variable 
intervals thereafter (Monath, 2002).
The age for primary immunization varies by country, depending on the force of enzootic 
transmission and age-specific risk of natural infection. In Japan and South Korea, where JE 
incidence has declined, vaccination starts at 18 months to 3 years of age, with boosters given 
at 1 year- and subsequently at 3-5 year’ intervals through age 15 years. In Thailand, 
vaccination stalls at 18 months of age and the second dose is given at 24-36 months of age 
(Monath, 2002).
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The Advisory Committee on Immunization Practices (ACIP) recommends three doses (at 0, 7 
and 30 or 0, 7 and 14 days) for primary immunization of travellers, military personnel or 
persons residing in nonendemic areas (ACIP, 1993).
Mouse brain vaccine is well tolerated, and adverse reactions are of mild degree in more than 
90% of subjects. Serious adverse events associated with the vaccine include allergic and 
neurologic complications.
Allergic effects include hypersensitivity reactions characterized by urticaria, angioedema and 
bronchospasm are reported (Andersen and Ronne, 1991; Berg et ah, 1997; Nazareth et ah, 
1994; Plesner et ah, 2000; Plesner and Ronne, 1997; Ruff et ah, 1991). In addition to 
anaphylactic responses, generalized pruritis has been noted. Most of patients respond well to 
treatment, but anaphylaxis may be life-threatening, and three deaths have been attributed to 
the vaccine.
Neurologic effects include encephalitis, encephalopathy, convulsions, peripheral neuropathy, 
and transverse myelitis were recorded (Ohtaki et ah, 1995; Plesner et ah, 1996; Tsai et ah, 
1999).
Use of mouse brain vaccine has been severly restricted due to concern about serious adverse 
events and a safer vaccine was developed.
Immunogenicity of the mouse brain-derived inactivated vaccine in humans has been studied 
by many groups. Neutralizing antibodies at 1:10 or greater were induced by three 
immunizations with this vaccine (Kanamitsu et ah, 1970; Minamitani et ah, 1974). The levels 
of antibodies declined to between one-third and one-half of the original levels in 3 years, but 
the titers were still 1:10 or greater in most vaccines (Akiyama et ah, 1996; Takei et ah, 1982). 
Seroconversion rates were 94% after three immunizations with each of Nakayama and 
Beijing-1 JE vaccines in Thailand (Nimmannitya et ah, 1995).
JEV-specific human CTLs were induced in humans by immunization with mouse brain- 
derived inactivated JE vaccine (Aihara et ah, 1998). These CTLs had the CD3+ CD4+ CDS' 
phenotype and recognized the E protein. The established CD4+ CTLs clones had two types of
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vims specificity: some T-lymphocytes clones were specific for only JEV, and others were 
cross-reactive for JEV and WNV (Monath, 2002).
Considering the notion that the protective neutralizing antibody level is 1:10, it is expected 
that the current inactivated JE vaccine will induce protective immunity which lasts for at least 
3 years. Protective efficacy has been determined by two studies. The protective efficacy after 
one or two immunizations was estimated to be 50% and 80%, respectively, in a field study in 
Taiwan in 1965 (Hsu et ah, 1971). In a study in Thailand, Thai children were immunized 
twice with Nakayama strain vaccine, or with a bivalent vaccine consisting of Nakayama and 
Beijing-1 strains. The protective efficacy was estimated to be 91% by either protocol (Hoke 
et ah, 1988). Thus, the inactivated JE vaccine was confirmed to be efficacious in protection 
against JE in the field.
Inactivated Cell Culture Vaccines
Foimalin inactivated unpurified vaccine prepared in primary hamster kidney (PHK) cells 
infected with P3 strain has been widely used in China since the late 1960s. Two 0.5 ml s.c. 
doses are administered 1 week apart to children at 6-12 months of age, followed by boosters 
at 1 year, at school entry and at age 10 years (Monath, 2002).
The immunogenic potency of the inactivated PHK vaccine appeal’s to be modest, with 
seroconversion rates as low as 60-70% and relatively low antibody levels (Tsai et ah, 1999).
In the 1990s, several independent efforts were initiated to develop purified inactivated 
vaccines in Vero cells using both wild type virus strains and the attenuated SA14-14-2 
vaccine strain. The Vero based system has significant advantages in quality, absence of 
animal proteins and allergens, and more efficient low cost manufacture compared to mouse 
brain vaccine (Monath, 2002).
In China, a formalin inactivated vaccine has been developed by the National Vaccine and 
Serum Institute (NVSI), Beijing in Vero cells infected with P3 strain (Ding et ah, 1998).
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In the US, a formalin-inactivated vaccine has been developed by the Walter Reed Anny 
Institute of Research (WRAIR) in Vero cells infected with the attenuated SA14-14-2 strain 
and adjuvanted with alum. The main advantage of this approach is that large-scale production 
of a virulent vims requiring Biosafety level 3 (BL3) containment is avoided.
The vaccine is well tolerated, but immune responses were low with only 40%-70% 
seroconversion across treatment groups (Monath, 2002). However, after a booster dose, 
neutralizing antibodies were developed to increase the seroconverison to 80%.
Live, Attenuated Vaccines
The derivation of the live, attenuated SA14-14-2 vaccine was a significant accomplishment 
in China (Yu et ah, 1988; Yu et ah, 1981).
The SA14-14-2 vaccine was licensed in 1988, and it is replacing the older, inactivated PHK 
vaccine for routine immunization of infants in China with an excellent record of safety and 
efficacy.
The World Health Organization (WHO) has developed guidelines for live attenuated JE 
vaccines, with the objective of facilitating the international acceptance of the SAM-14-2 
vaccine and access to a low-cost vaccine in developing countries of Southeast Asia.
The biological characteristics of SA14-14-2 have been studied in animals, with particular 
attention to neurovirulence. The vaccine is attenuated in immunocompetent mice, hamsters, 
nude and cytoxan treated mice, and in monkeys inoculated by intrathalamic/ intraspinal 
routes when compared to parental SAM virus (Tsai et ah, 1999). The PrM-E genome 
sequence and attenuation for mice are stable after serial passages in PHK cells and the 
attenuated phenotype is also stable after serial passage in suckling mouse brain (Monath, 
2002).
The genetic basis for attenuation of SAM-14-2 has been studied. Comparison of the parental 
SAM virus and SAM-14-2 vaccine reveals a large number of silent mutations and amino 
acid changes spread across structural and NS genes (Aihara et ah, 1991; Ni et ah, 1994; Ni et
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al., 1995; Nitayaphan et al., 1990). However, when two other attenuated vaccine viruses 
developed at earlier stages in the SA14-14-2 lineage (SA14-2-8 and SA14-5-3) are 
considered, only eight common amino acid differences from SA14 are found. These changes 
include six in the E glycoprotein (E107, E138, E176, E279, E315 and E439), and single 
changes in NS2B, NS3 and NS4B. One or more of these mutations are likely to be 
responsible for the profound phenotypic differences between SA14 and SA14-14-2 
(Monath, 2002).
The SAM-14-2 vims is more immunogenic for mice than inactivated PHK vaccine. In 
addition, studies in mice have demonstmted that immunization with SAM-14-2 cross­
protects against JE strains from Thailand, Vietnam and Indonesia, representing diverse JE 
genotypes (Yu et al., 1989).
SAM-14-2 vaccine showed 98% efficacy across all field trials.
1.10 Scope of this Thesis
JE is a complex and fascinating disease; the virus has evolved over time into a flavivirus 
infection primarily of birds and swine with man as an incidental host. Four genotypes of JEV 
are presently recognised (representatives of genotype I to IV have been fully sequenced). In 
addition, a strain of JEV, Muar strain, isolated in Singapore in 1952 from a brain of a patient 
who originated in Muar, Malaysia may represent a fifth genotype as determined by limited 
phylogenetic analysis of E gene sequence. I, therefore, decided to detennine the complete 
nucleotide and deduced amino acid sequence of the Muar strain, compare it with other JEV 
genomes and construct different phylogenetic trees to explore whether the Muar strain is 
indeed the “missing” fifth genotype of JEV.
It has been reported that the Muar strain has not been isolated from any other area. Why the 
more ancient lineages of JEV have not spread is uncertain. JEV uses a wide range of 
mosquito species and vertebrate hosts across Asia, and geographical differences in vector and 
host availability may explain why the Muar strain has never spread. I examined the virus’ 
complete amino acid sequence to look for molecular' determinants that might relate to 
differences in host preference.
68 | P a g e
For most of the major human pathogens, we have little idea about where they originated. 
Because JEV has recently evolved and has so rapidly spread to new areas, tracing its 
geographical origin has been possible. JE emerged in Japan in 1870 and it has been foimd 
across Asia to affect most of China and the Asian subcontinent, all of Southeast Asia, and the 
Pacific Rim, reaching northern Australian in 1998 and has become the most important cause 
of epidemic encephalitis worldwide. There is a clear need for a better understanding of the 
origins and spread of JEV. I, therefore, determined the evolutionary histoiy of JEV isolates 
and their evolutionary rate per year.
In order to identify the reason for JEV genotype shift and the patterns of genetic change of 
genotypes, I analyzed the selection pressures on the complete E gene of the JEV five 
genotypes.
JE remains a major public health problem. Newer treatments for JE which are being 
considered include treatment with IVIG. There have been case reports of IVIG therapy which 
have shown it to be beneficial when administered with symptomatic treatment for this 
disease. In the case report, clinical improvement was rapid and the patient made an almost 
complete recovery. IVIG has also been assessed recently in a randomised placebo controlled 
trial for treating encephalitis caused by the flavivirus WNV. I therefore, investigated the role 
of IVIG from JE-endemic areas in neutralising representative strains of JEV. Given the 
interest in IVIG as potential treatment for JEV, and the large genetic differences between 
JEV genotypes, particularly the 5th genotype, I assessed the ability of IVIG from JE-endemic 
parts of Asia to neutralise representative stmins form the 5 genotypes.
To summarize the aims of the thesis:
1- Detennine the complete nucleotide and predicted amino acid sequence of the Muar 
strain of JEV, compare it with other JEV genomes and determine the nucleotide and 
amino acid sequence divergence among the Muar strain and other JEV strains.
2- Detennine the phylogenetic relationship among the Muar isolate and other JEV 
strains using both nucleotide and amino acid sequence.
3- Predict the secondary structure of 5' and 3' NCRs of the Muar strain.
4- Determine the evolutionary history of JEV strains.
5- Look at the pattern of the geographical distribution of JEV isolates.
6- Look at the effect of molecular evolution of JEV on the virus spread into new 
geographical areas and on the host specificity.
7- Determine the selection pressures in E genes of JEV strains belonging to different 
JEV genotypes to understand the role played by that selection on JEV evolution.
8- Predict the three dimensional structure of the Muar' strain E glycoprotein to 
understand the antigenic and serological properties of this strain.
9" Investigate the impact of the genomic variability seen between JEV genotypes on the 
neutralization effectiveness of three different IVIGs in vitro which are used as a 
supportive treatment of JEV infection in India.
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CHAPTER 2: MATERIALS AND METHODS
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General materials and methods used are described in this chapter. Further specific methods 
relevant to particular studies are described in subsequent chapters.
2.1 Buffers, Reagents and Media
TAE1X Buffer
TAB 50X Buffer (Fisher Scientific) .................................. 20 ml
Sterile D. W..........................................................................  980 ml
Agarose 1%
Agrose Multi-Purpose (BIOLINE)...................................... I g
TAB IX Buffer....................................................................... 100 ml
PBS 1%
PBS Tablets (Fisher Scientific Oxoid Limited)...............1 Tablet
Sterile D. W.......................................................................... 100 ml
Decontaminant for Rnase Away (Fischer Scientific)
Nuclease Free Water (not DEPC treated) (Applied Biosystem)
Ethanol 190 Proof for Molecular Biology (Sigma-Aldrich)
Trypan Blue Solution (0.4%) (SIGMA)
Amnicillin Sodium Salt (SIGMA®) “91.0 -100.5%”
Trypsin flOXl (BioWhittaker)
Vero Cells Growth Media (10% FBS)
DMEM (BioWhittaker).............................................................................................................  500 ml
FBS (Heat Inactivated) (BioSera)............................................................................................... 50 ml
L-Glutamine 200mM (SIGMA®)...............................................................................................  5 ml
P/S “10,000 uni ts penicillin and 10 mg streptomycin per ml” (SIGMA®)............................... 5 ml
Virus Culture Media (5% FCS)
DMEM (BioWhittaker).............................................................................................................  500 ml
FBS (Heat Inactivated) (BioSera)............................................................................................... 25 ml
L-Glutamine 200mM (SIGMA®)...................................................................................................5 ml
P/S “10,000 units penicillin and 10 mg streptomycin per ml” (SIGMA®)................................ 5 ml
Virus Diluent
MEM 5X (SIGMA life Science)..................................................................................................20 ml
BSA 5% (Fisher Scientific).........................................................................................................20 ml
Na HC03 7.5% (SIGMA®).......................................................................................................... 4 ml
P/S “10,000 units penicillin and 10 mg streptomycin per ml (SIGMA)”.................................. 1 ml
Sterile D. W....................................................................................................................................55 ml
Nutrient Media (2X)
MEM 5X (SIGMA life Science)................................................................................................ 40 ml
FBS (Heat Inactivated) (BioSera)................................................................................................ 4 ml
NaHCOS 7.5% (SIGMA®)..................................................................................................... 6 ml
Gentamycin Sulphate (BioWhittaker®)....................................................................................200 pi
Fungizone 250 pg/ml (Invitrogen)............................................................................................200 pi
Sterile D. W...........................................................................................................................49.6 ml
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Agarose Overlay (2 %)
Seaplaque Agarose (low melting temperature) (Lonza) 
Sterile D. W.......................................................................
2g
100 ml
LB Broth Lennox (FORMEDIUM ™):
Suspend 20 g in 1 L of distilled de-ionised water
LB Agar Lennox (FORMEDIUM ™):
Suspend 35 g in 1 L of distilled de-ionised water
2. 2 Primer Design
Primers were designed to amplify overlapping fragments of the genome on the basis of a 
consensus aligmnent of complete JEV genomes available through Genbank and on the 
sequence of the Muar genome already derived. The length of PCR primers ranged from 18 to 
22 base pairs (bp). The GC content of the primer ranged between 40-60%. Primer melting 
temperature (Tm) was calculated using this formula; 2 (A+T) + 4 (C+G). Primer annealing 
temperature (Ta) is usually 5-10 °C below Tm. 
http://www,premierbiosoftcoro/tech notes/PCR Primer Design.html
Primers designed for the complete genome sequencing of the Muar strain of JEV are outlined 
in Table 2-1. Detalis of JEV isolates used for primer design and phylogenetic analysis are listed in 
Table 2-2.
Table 2-1: Designed primers for sequencing of the complete genome of the Muar strain of JEV.
Oligo Name Sequence (5' - 3') Product size
JEV (4 S)
JEV (1265 A)
AGTTTATCTGTGTGAACTTCTTGG
AARCCTTGYTTGCACACRTA
1261 bp
Muar (785 S)
Muar (2641 A)
GGATGCTTGGCAGTAACAAC
CTCTGTGCACATGCCATAGG
1856 bp
JEV (1202 S)
JEV (3518 A)
CCACGACTGGAGAAGCYCACAA
CCACACCTCATCTCTTTTCTTG
2316 bp
Muar (3125 S)
Muar (5051 A)
CATCACGTCGACTCGAGTGTGG
CCGATCCTGGATGCAGGTCCAA
1926 bp
Muar (3829 S)
Muar (4383 A)
GGACTAACCAGGAGAACATTGCTT
CTTCCCAACTAATGTCGGCTGC
554 bp
JEV (4421 S)
JEV (5122 A)
GGGAAGCAGCCGGAGGCTAGATGTTAA
TCTTGACGGTCACCTTGCACAATAGCG
701 bp
JEV (5005 S)
JEV (6378 A)
GGAACATCCGGCTCACCCAT
cttyctctcacccatycggg
1373 bp
Muar (6167 S)
Muar (6641 A)
GGATGGTGAGTATCGATTGAGG
CCACCTGTCATCACGGCTATC
474 bp
JEV (6331 S)
JEV (7653 A)
GARG A Y AACAC Y GAGGTRGA 
GTTCTTRATGAGAGTCCAGG
1322 bp
JEV (6652 S)
JEV (7376 A)
TGACAGGAGGATTCTTCCTGCTCATGATG
AACCATTCCGTCTACGACGGCATTCTT
724 bp
Muar (7520 S)
Muar (10,711 A)
ATGGTGGCCACTGACGTGCCAG
GATCAAGCTGCCACACCAGATGT
3191 bp
JEV (7601 S)
JEV (8842 A)
TGCGAGGYAGCTACCTRGCT
GTGACAAGTGGGCCCACAGC
1241 bp
Muar (8177 S)
Muar (9455 A)
GGCATCAGAGTGGTTGCACCG
GGTCTTCTCTGGAGATCACATCC
1278 bp
EMF1 (10,098 S)
VD8 (10,828 A)
TGGATGACGACGGAAGACATG
GGGTCTCCTCTAACCTCTAG
730 bp
Muar (10,220 S)
JEV (10,944 A)
GAAGACATCTGGTGTGGCAG
CCACCAGCTACATGTTTCGGCGCTC
724 bp
*JEV primers were designed by Professor Tom Solomon.
* Muar primers were designed from derived Muar sequence by Manal Mohammed.
* EMF1 and VD8 primers are universal primers for mosquito-bome flavivimses (Pierre et al, 1994).
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Table 2-2. Details of isolates used in this study for primer design and phylogenetic analysis. All 
strains are JEV, except for MVE, SEE and WN. GenBank accession numbers refer to the whole 
genome or the genes indicated in parenthses. (E, envelope gene). IU, information unavailable.
Strain Year Location Source GenBank accession no.
014178 2001 India Human EF623987
04940-4 2002 India Mosquito EF623989
057434 2005 India Human EF623988
2372 1979 Thailand Human U70401(E)
691004 1969 Sri Lanka Human Z34097 (E)
B58 1986 China Bat FJ185036
Beijing-1 1949 China Human L48961
Bennett Before 1951 Korea Human FJ872376 (E)
CH1392 1990 Taiwan Mosquito AF254452
CH2195LA 1994 Taiwan Mosquito AF221499
CNS138-11 1999 Malaysia Human AY184213 (E)
FU 1995 Australia Human AF217620
GB30 1997 China Bat FJ185037
GP05 2005 India Human FJ979830 (E)
GP78 1978 India Human AF075723
HEN070I 2007 China Swine FJ495189
HVI 1958 Taiwan Human AF098735
Ishikawa 1998 Japan Mosquito AB051292
JaGArOl 1959 Japan Mosquito AF069076
JaNAr0102 2002 Japan Mosquito AY3 77577 (E)
JaOArS982 1982 Japan Mosquito NC_001437
JaOH0566 1966 Japan Human AY508813
JEV/sw/Mie/40/2004 2004 Japan Swine AB241118
JEV/sw/Mie/41/2002 2002 Japan Swine AB241119
JKT1724 1979 Indonesia Mosquito U70404 (E)
JKT5441 1981 Indonesia Mosquito U70406 (E)
JKT6468 1981 Indonesia Mosquito AY184212
JX61 2008 China Pig GU556217
K87P39 1987 Korea Mosquito AY585242
K94P05 1994 Korea Mosquito AF045551
KPP034-35CT 1982 Thailand Mosquito U03693(E)
Ling 1965 Taiwan Human L78128
M15 1995 Australia Mosquito L47349 (E)
M40 1995 Australia Mosquito L47350 (E)
M859 1967 Cambodia Mosquito U70410(E)
Muar 1952 Malaysia Human HM596272
MVE 1-51 1951 Australia Human AF161266
Nakayama 1935 Japan Human EF571853
Nakayaina- RFVL 1U Japan IU S75726 (E)
NJ 2008 2008 IU IU GQ918133
NO 1995 Australia Human L43566(E)
P20778 1958 India Human AF080251
P3 1950 China Mosquito U47032
PhAnl242 1984 Philippines Pig U70417(E)
RP-9 1985 Taiwan Mosquito AF014161
SAM 1954 China Mosquito U14163
SC04-17 2009 China Mosquito GUI 87972
SH17M07 2007 China IU EU429297
SLE MSI.7 1975 United States Bird NCJ)07580
TIPI 1997 Taiwan Mosquito AF254453
TC IU Taiwan IU AF098736
TS00 2000 Australia Pig EF434785(E)
VN118 1979 Vietnam Mosquito U70420(E)
WNEglOl 1950 Egypt Human AF260968
WTP-70-22 1970 Malaysia Mosquito U70421 (E)
XJ69 2007 China Mosquito EU880214
XJP613 2007 China Mosquito EU693899
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CHAPTER 3: SEQUENCING & PHYLOGENETIC ANALYSIS 
OF THE COMPLETE GENOME OF 
THE MUAR STRAIN OF JEV
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3.1 INTRODUCTION
JEV consists of four genotypes; I, II, III and IV as determined by genetic studies using the 
nucleotide sequence of C/prM and E genes (Chen et al., 1992; Chen et al., 1990). 
Representatives of each of these four genotypes have been fully sequenced (Solomon et al., 
2003b). In addition, a strain of JEV, Muar strain, isolated in Singapore in 1952 from a brain 
of a patient who originated in Muar, Malaysia (Hale et al., 1952) may represent a fifth 
genotype as determined by MAbs reactivities and (Hasegawa et al., 1995; Kobayashi et al., 
1984) and limited phylogenetic analysis based on E gene sequence (Hasegawa et al., 1994; 
Solomon et al., 2003b; Uchil and Satchidanandam, 2001). Figure 3-1 illustrates the 
geographical distribution of JEV’s genotypes.
Figure 3-1. The geographical distribution of JEV genotypes and their spread from the 
Indonesia Malaysia region. Adapted from (Solomon et al, 2003b).
The unavailability of the Muar sequence in computer databases makes the genetic 
examination of the Muar virus somewhat complicated as we could not determine the relation 
between Muar and other JEV isolates. It was therefore, decided to determine the complete 
nucleotide and deduced amino acid sequence of the Muar strain, compare it with other JEV 
genomes and determine the nucleotide and amino acid sequence divergence among the Muar 
strain and representative strain of the four JEV genotypes. Also, the phylogenetic relationship 
among the Muar isolate and other JEV strains was examined using both nucleotide and amino 
acid sequence.
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3.2 MATERIALS & METHODS
3.2.1 Sequencing of the Muar Isolate Complete Genome
3.2.1.1 Sequencing of the Muar ORF
The Muar strain of JEV, isolated in Singapore in 1952 from a patient brain who originated in 
Muar, Malaysia, was obtained from Dr Ichiro Kurane, National Institute of Infectious 
Diseases, Tokyo, Japan but with unknown passage history.
The Muar vims was inoculated onto confluent monolayers of Vero cells in 5 % PCS. Culture 
supernatant containing the virus was harvested at 5 to 6 days postinfection, when CPE were 
observed. Vims was passaged four times and stored at -70 °C.
RNA was extracted by using the QIAamp Viral RNA Mini Kit (Qiagen) following the 
manufacturer’s instructions. The extracted RNA was used as a template for the amplification 
of cDNA by reverse transcriptase-PCR (RT-PCR). Muar RNA was reverse transcribed and 
was PCR amplified by using Titan One Tube RT-PCR System (Roche) according to 
manufacturer’s instructions. The RT-PCR conditions used are as follows:
Reverse transcriptase
ooo
30 min
Denaturing 94 °C 2 min xl
Annealing 55 °C 30 sec
Extension 68 °C 2 min
Denaturing 94 °C 15 sec -'i
Annealing 55 °C 15 sec x9
Extension 68 °C 2 min
Denaturing 94 °C 15 sec
*>
Annealing 55 °C 15 sec x25
Extension 68 °C 2 min A 5 sec*
Hold 4 °C
*A 5 sec means cycle elongation of 5 sec for each cycle (e.g., cycle no. 10 has additional 5 sec, cycle 
no. 11 has additional 10 sec, cycle no. 12 has additional 15 sec).
PCR products were analyzed visually by electrophoresis through ethidiuin bromide-stained 
1% agarose gels under UV light to check the template size and estimate the concentration of 
the purified cDNA to be sure that it is high enough for the sequencing reaction as determined 
by the sequencing company Euroflns MWG Operon®; the concentration of template needed 
to sequence a PCR product depends on the size of the PCR fragment as follows:
Template size
200-500 bp 
500-1000 bp 
1000-2000 bp 
> 2000 bp
Concentration
5-16 ng/pl 
16-42 ng/pl 
42-83 ng/pl 
83-100 ng/p.1
The template size and concentmtion of the RT PCR products was determined by using 1 Kb 
DNA ladder (BioLabs) visualized by ethidium bromide staining on a 1% TAE agarose gel. 
RT-PCR products were purified by using the QIAquick Gel Extraction Kit (QIAGEN). 
Purified cDNA was directly sequenced in both directions by using the appropriate sense and 
antisense primers. Amplicons were sequenced on both strands via an automated ABI 3730XL 
sequencer by Euroflns MWG Operon® Company.
3.2.1.2 Sequencing of The Muar 5r NCR
Sequencing of 5r NCR was determined by using 5" RACE System for Rapid Amplification of 
cDNA Ends (Invitrogen) and amplification of target cDNA was done by using Expand High 
Fidelity plus PCR System, dNTPack (Roche).
PCR products were analyzed visually by electrophoresis through ethidium bromide-stained 
1% agarose gels under UV light to estimate their concentrations for sequencing by Eurofms 
MWG Operon® Company. RT-PCR products were purified by using the QIAquick Gel 
Extraction Kit (QIAGEN).
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Primers used for 5' NCR sequencing were:
1-
2- Primer for the PCR of cDNA:
Muar (1265 A): (5' GTGGCGTGCGCCTCTTCAAA 3'}
2- Primer for the nested amplification step:
Muar (194 A): {5' TACCCTCTTCACTCCCACTAGTG 3'}
3,2.23 Sequencing of The Muar 3r NCR
3' NCR sequence was obtained by using E. coli poly (A) polymerase (BioLabs) to add poly 
(A) tail to the Muar mRNA. Subsequently, the poly (A) mRNA was reverse transcribed using 
Transcriptor First Strand cDNA Synthesis Kit (Roche) and was PCR amplified by 
HotStarTaq Master Mix Kit (Qiagen) using a gene-specific primer.
Primers used for 3' NCR sequencing were:
1- Primer to add poly (A) tail to the mRNA:
3' RACE AUAP: {5r GGCCACGCGTCGACTAGTACTTTTTTTTTTTTTTTTT 3'}
2- Primer for the first PCR:
EMF1 (10,098 S): {5' TGGATGACGACGGAAGACATG 3'}
3- Primer for the nested amplification step:
Muar (10,220 S): {5' GAAGACATCTGGTGTGGCAG 3'}
RT-PCR products were purified and their concentrations were estimated before sequencing 
as described for 5 "NCR.
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3' UTR was sequenced as following:
In PCR tube, add: Purified RNA
3’ RACE AUAP (20 qM)
21 (il 
5 ql
Then run RT cycle (65 °C for 10 minutes) and put on ice for 5 minutes.
Then add: Transcriptor 5X Buffer 
Rnase inhibitor 
dNTP*
Transcreptor RT
8 pi 
1 pi 
4 pi 
1 pi
Then run RT cycle (55° C for 1 hour) followed by PCR purification.
*dNTP Mix, PCR Grade (200 pi) “QIAGEN”: Mix containing 10 mM each of dATP, dCTP, dGTP, 
and dTTP (1 x 200 pi)
Two PCR were done on the purified cDNA;
1st PCR:
Hotstart PCR buffer (2X) 
3' RACE AUAP (20 pM) 
EMF1 (10,098 S) (10 pM) 
cDNA
25 pi
1 pi
2 pi 
10 pi 
12 piRnase free water
Then run hot PCR cycle for 35 cycles.
2nd PCR:
Same as the 1st PCR but another specific primer was used; Muar (10,220 S) instead of EMF1 
(10,098).
RT-PCR products were analyzed visually by electrophoresis through ethidium bromide- 
stained 1% agarose gels under UV light to estimate their concentrations for sequencing by 
Eurofins MWG Operon® Company. RT-PCR products were purified by using the QIAquick 
Gel Extraction Kit (QIAGEN).
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3.2.2 Cloning of PCR products
If there were differences between sequence results, cloning of that region was done using TA 
Cloning® Kit (Invitrogen) following the manufacturer’s instructions.
Ten colonies for each reaction were picked and screened by PCR to confinn they contained 
an insert of the appropriate size using the Qiagen HotStarTaq Master Mix Kit (Qiagen) 
according to the manufacturer’s instructions.
Specific primers for these regions of the PCR products were used with the following PCR 
conditions: An initial activation of 95 °C for 15 minutes followed by 35 cycles of 
denaturation at 94 °C for 1 minute, annealing 68 °C for 1 minute, extension at 72 °C for 1 
minute and a final extension at 72 °C for 10 minutes.
Positive colonies containing inserts of the predicted size were then incubated overnight in LB 
medium containing 100 pg/ml Ampicillin for plasmid extraction. Incubation was done at 
37 °C with vigorous shaking at 250 rpm.
Plasmid was extracted using QIAprep® Miniprep Kit (QIAGEN) as described in the protocol.
Plasmids DNA were sequenced on both strands using an automated ABI 3730XL sequencer 
by the Eurofins MWG Operon® Company.
3.2.3 Muar Genomic Sequence Analysis
The Muar strain was sequenced, as described above. The complete genome of Muar strain 
was compiled by alignment with other JEV complete genome strains available at GenBank 
(Table 2-2), using the Vector NTI suite software package (version 10; Informax Inc.).
ClustalX (1.81) (Thompson et al., 2002) was used for the alignment of the Muar nucleotide 
and derived amino acid sequences with other JEV strains.
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Percentage differences between the complete genomic sequence and the derived polyprotein 
of the Muar strain and representative strain of JEV genotypes I, II, III and IV were calculated 
by using P-distance in MEGA software (version 4.0) (Tamura et ah, 2007).
The primary structure of the conserved 5' and 3' NCRs of JEV five genotypes and other three 
flaviviruses belonging to the JE serocomplex; MVEV, WNV and SLEV was compared. Also, 
the possible folding of these NCRs was predicted using mfold web server using the 
default folding conditions (http://mfold.ma.albanv.edu/?q=mfold/RNA-Folding-Fornf).
3.2.4 Selection of the Best-fit Model for JEV Genome Nucleotide 
Substitution
Selection of the best-fit model for JEV genome nucleotide substitution was carried out by 
ModelTest 3.7 (version 0.1.1).
3.2.5 Phylogenetic Analysis of the Muar Strain of JEV
Phylogenetic analysis was performed using MP, ML and NJ methods on PAUP* (version 
4.04b 10) (Wilgenbusch and Swofford, 2003) using nucleotide and derived polyprotein 
sequences of C, PrM, E, NS3, NS5 and ORE as well as the nucleotide sequences of the 5' 
UTR and 3' NCR and the complete genome.
ClustalX was used to create a multiple alignment from the sequence in FASTA format. 
Pairwise alignment parameters were identified as slow-accurate, with gap opening penalty 
(15.00) and gap extension (6.66). In multiple alignment parameters, gap opening and gap 
extension penalties were the same as for the pairwise alignment. Output format option was 
identified as nexus format which is required for the phylogenetic analysis by PAUP.
In PAUP software, the first step is to define optimality criteria either parsimony, likelihood or 
distance then heuristic search was selected to perform the search strategy. Bets trees will be 
displayed and described.
The best-fit evolutionary model used in the ML phylogentic analysis was general time 
reversible (GTR) + Gamma + invariant model.
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The robustness of phylograms was evaluated by 1,000 bootstrap replicates. All trees were 
visualised using FigTree (version 1.2.2).
3.3 RESULTS
3.3.1 Determination of the Nucleotide Sequence of the Complete Genome of 
The Muar Strain of JEV
The complete nucleotide sequence of the Muar strain of the JEV genome RNA was 
determind using RT PCR. All RT PCR products were analyzed visually by electrophoresis 
through ethidium bromide-stained 1% agarose gels under UV light and compared with a 1 Kb 
DNA ladder to determine their sizes. Figures 3-2 to 3-8 show agarose gel of different PCR 
products of the Muar strain of JEV compared to a 1 Kb DNA ladder (M).
Figure 3-2. Agarose gel electrophoresis of the RT PCR products of the Muar isolate of JEV 
compared to 1 Kb DNA ladder (M). 2316 bp produced from using primers 1202s and 3518a 
(A), which amplified part of E and NS1 genes, and 1261 bp produced from using primers 4s 
and 1265a (B), which amplified part of 5’ NCR, C and prM genes and part of the E gene.
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Figure 3-3. Agarose gel electrophrosis of the RT PCR products of the Muar isolate of JEV 
compared to 1 Kb DNA ladder (M). 554 bp produced from using primers 3829s and 4383a 
(A), which amplified part of NS2 gene, 474 bp produced from using primers 6167s and 
6641a (B), which amplified part ofNS3 and NS4 genes, and 1856 bp produced from using 
primers 785s and 2641a (C), which amplified the E gene.
Figure 3-4. Agarose gel electrophoresis of the RT PCR products of the Muar isolate of JEV 
compared to 1 Kb DNA ladder (M). 724 bp produced from using primers 6652s and 7376a 
(A), which amplified part ofNS4 gene and 1373 bp produced from using primers 5005s, and 
6378a (B), which amplified part of NS3 and NS4 genes.
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Figure 3-5. Agarose gel electrophoresis of the RT PCR products of the Muar isolate of JEV 
compared to 1 Kb DNA ladder (M). 1322 bp produced from using primers 6331s and 7653a 
(A), which amplified part of NS3 and NS4 genes and 730 bp produced from using EMF, and 
VD8 primers (B), which amplified part of NS5 gene and part of 3’ NCR.
Figure 3-6. Agarose gel electrophoresis of the RT PCR products of the Muar isolate of JEV 
compared to 1 Kb DNA ladder (M). 1241 bp produced from using primers 7601s and 8842a 
(A), which amplified part of NS4 and NS5 genes, and 724 bp produced from using primers 
10,220s and 10,944a (B), which amplified NS5 gene and part of 3’ NCR.
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Figure 3-7. Agarose gel electrophoresis of the RT PCR products of the Muar isolate of JEV 
compared to 1 Kb DNA ladder (M). 1265 bp produced from using primers AUAP and 1265a 
(A), which amplified the 5’ NCR.
Figure 3-8. Agarose gel electrophoresis of the RT PCR products of the Muar isolate of JEV 
compared to 1 Kb DNA ladder (M). 980 bp produced from using primers EMF and 3' RACE 
(A), which amplified the 3’ NCR.
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The Muar vims genome was 10,988 nucleotides long. The JEV isolate Muar was assigned 
GenBank database accession no. HM596272.
The genome organization of the Muar strain resembles that of other known JE viruses. The 
RNA genome contains a single ORE extending from nucleotide 96 to nucleotide 10,394, 
encoding 3,432 amino acids similar' in length to those reported for other JE viruses. This ORF 
is flanked by the 5' and 3' NTRs of 95 and 593 nucleotides, respectively. The length of the 5' 
NTR is identical with that reported for other JE vimses and the 5’ cap is followed by the 
conserved dinucleotide sequence AG. However, alignment of the 3' NTR sequences of the 
Muar* strain with other JEV strains revealed the presence of an extra 7 to 25 nucleotides in the 
3' NTR of the Muar- strain genome, located at the 5' side of the 3' NTR.
Like other genomic RNAs of mosquito-borne flavivirases including JEV, the Muar strain 
appeal's to lack a 3’-terminal poly (A) tract and instead to terminate with the conserved 
dinucleotide CU as shown at the end of the nucleotide sequence of 3’ NCR in appendix A.
Processing of the JEV polyprotein generates 10 membrane associated viral proteins (three 
structural and seven NS proteins), and two polypeptide cleavage fragments. The order of 
proteins encoded in the long ORE is 5’- C- prM (M)- E- NS1- NS2A- NS2B- NS3- NS4A- 
NS4B- NS5- 3’. Annotation of the Muar complete genome was determined for other JEV 
strains (Sumiyoshi et al., 1987) as following:
5’ NCR 1-95
C 96-476
prM 477-977
E 978-2477
NS1 2478-3533
NS2 3534-4607
NS3 4608-6464
NS4 6465-7679
NS5 7680-10394
3’ NCR 10395-10988
The complete nucleotide sequence of the Muar strain is given as appendix A.
3.3.2 Determination of the Amino Acid Sequence of the ORF of The Muar 
Strain of JEV
The nucleotide sequence of the Muar strain was translated to the amino acids using ExPASy 
Proteomics Server fhttp://expasy.org/too1s/dna.htrnl\
The Muar strain has a single ORF with conserved cleavage sites with other JEV strains 
available on GenBank. Like other JEV strains, Muar has three structural proteins; C, prM and 
E and seven NS proteins; NS1, NS2A and NS2B, NS3, NS4A and NS4B and NS5.
The deduced amino acid sequence of the Muar strain is given as appendix B.
3.3.3 Determination of the Nucleotide and Amino Acid Sequence 
Divergence Percentage between the Muar Strain and Representative 
Strains of the Four JEV Genotypes
Comparison of the Muar nucleotide and amino acid sequences with a fully sequenced 
representative of GI (K94P05) “GenBank accession number: AF04555r,J GII (FU) 
“GenBank accession number: AF217620,’;, GUI (Nakayama) “GenBank accession number: 
EF571853”and GIV (JKT6468) “GenBank accession number: AY184212” showed Muar to 
have the least similarity, with nucleotide divergence ranging from 20.2% to 21.2%, and 
protein divergence from 8.5% to 9.9% as shown in Table 3-1.
Analysis by individual genes showed that Muar has 4.2 - 9.5 % nucleotide difference in the 
5’
NCR from other JEV strains (Table 3-2), 19.2 - 21.5% in the C (Table 3-3), 19.8 - 23.6% in 
the prM gene (Table 3-4), 22.1 - 23.8% in the E gene (Table 3-5), 21.1 - 22.5% in the NS1 
gene (Table 3-6), 21.1 - 22.9% in the NS2 gene (Table 3-7), 19.6 - 20.8% in the NS3 gene 
(Table 3-8), 7.1 - 8.3% in the NS4 gene (Table 3-9), 19.5 - 20.9 %) in the NS5 gene (Table 
3-10) and 13.6 -15.4% nucleotide difference in the 3’ NCR (Table 3-11).
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Table 3-1. Nucleotide and amino acid sequence divergence for the complete 
genome of the Muar strain and representative strains of the four JEV genotypes.
Divergence (%) with:
Strain Genotype K94P05 FU Nakayama JKT6468 Muar
K9P05 I 10.3 10.8 16.8 21.2
FU II 2.1 10.5 16.1 21.1
Nakayama III 3.1 2.2 15.1 20.2
JKT6468 IV 6.2 5.3 4.8 21
Muar V 9.9 8.6 8.5 9.2
Nucleotide divergence is in lightface type; amino acid divergence is in bold face type.
Table 3-2. Nucleotide sequence divergence for 5’ NCR of the Muar strain and 
representative strains of the four JEV genotypes.
Divergence (%) with:
Strain Genotype K94P05 FU Nakayama JKT6468 Muar
K94P05 I 2.1 4.2 8.4 4.2
FU II 4.2 6.3 4.2
Nakayama III 8.4 5.3
JKT6468 IV 9.5
Muar V
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Table 3-3. Nucleotide and amino acid sequence divergence for the C gene of the Muar 
strain and representative strains of the four JEV genotypes.
Divergence (%) with:
Strain Genotype K94P05 FU Nakayama JKT6468 Muar
K94P05 I 9.7 7.6 16.8 19.9
FU II 4.7 7.6 15.7 19.7
Nakayama III 5.5 4.7 15 19.2
JKT6468 IV 18.9 18.9 18.1 21.5
Muar V 19.7 18.9 18.9 26
Nucleotide divergence is in lightface type; amino acid divergence is in bold face type.
Table 3-4. Nucleotide and amino acid sequence divergence for the prM gene of the 
Muar strain and representative strains of the four JEV genotypes.
Divergence (%) with:
Strain Genotype K94P05 FU Nakayama JKT6468 Muar
K94P05 I 12.2 12.6 18.4 19.8
FU II 3 13.8 20.4 23.2
Nakayama III 3.6 2.4 17.8 22
JKT6468 IV 9.6 9.6 8.4 23.6
Muar V 10.2 10.8 11.4 16.8
Nucleotide divergence is in lightface type; amino acid divergence is in bold face type.
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Table 3-5. Nucleotide and amino acid sequence divergence for the E gene of the Muar 
strain and representative strains of the four JEV genotypes.
Divergence (%) with:
Strain Genotype K94P05 FU Nakayama JKT6468 Muar
K94P05 I 11 12.2 18.4 23.8
FU II 2 11.6 18.1 22.9
Nakayama III 2.6 2.6 16.8 22.1
JKT6468 IV 5.2 5.6 5.6 22.8
Muar V 9 8.8 8.8 9.4
Nucleotide divergence is in lightface type; amino acid divergence is in bold face type.
Table 3-6. Nucleotide and amino acid sequence divergence for the NS1 gene of the Muar 
strain and representative strains of the four JEV genotypes.
Divergence (%) with:
Strain Genotype K94P05 FU Nakayama JKT6468 Muar
K94P05 I 11.4 11.8 17.8 22.5
FU II 5.4 9.9 16.7 22.4
Nakayama III 4.3 3.7 14.4 21.1
JKT6468 IV 7.4 7.7 5.1 21.8
Muar V 10.5 9.4 8.2 8.2
Nucleotide divergence is in lightface type; amino acid divergence is in bold face type.
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Table 3-7. Nucleotide and amino acid sequence divergence for the NS2 gene of the Muar
strain and representative strains of the four JEV genotypes.
Divergence (%) with:
Strain Genotype K94P05 FU Nakayama JKT6468 Muar
K94P05 I 9.8 11.5 18.3 22.9
FU II 2.8 10.6 15.5 22
Nakayama III 2.5 3.1 15.8 21.6
JKT6468 IV 5.6 5 4.7 22.1
Muar V 13.1 11.5 11.7 11.7
Nucleotide divergence is in lightface type; amino acid divergence is in bold face type.
Table 3-8. Nucleotide and amino acid sequence divergence for the NS3 gene of the Muar
strain and representative strains of the four JEV genotypes.
Divergence (%) with:
Strain Genotype K94P05 FU Nakayama JKT6468 Muar
K94P05 I 11.1 12.7 15.6 20.7
FU II 2.7 11.9 16.4 20.8
Nakayama III 3.2 1.1 15 19.6
JKT6468 IV 4.5 2.6 2.6 20.2
Muar V 7.1 5.2 5.2 5.7
Nucleotide divergence is in lightface type; amino acid divergence is in bold face type.
94 | P a g e
Table 3-9. Nucleotide and amino acid sequence divergence for the NS4 gene of the Muar 
strain and representative strains of the four JEV genotypes.
Divergence (%) with:
Strain Genotype K94P05 FU Nakayama JKT6468 Muar
K94P05 I 1.3 1.8 4.3 8.1
FU II 1.2 1.5 4.5 7,6
Nakayama III 1.7 1.5 4.3 7.1
JKT6468 IV 4.2 4.5 4.2 8.3
Muar V 7.9 7.4 6.9 8.2
Nucleotide divergence is in lightface type; amino acid divergence is in bold face type.
Table 3-10. Nucleotide and amino acid sequence divergence for the NS5 gene of the 
Muar strain and representative strains of the four JEV genotypes.
Divergence (%) with:
Strain Genotype K94P05 FU Nakayama JKT6468 Muar
K94P05 I 10.1 9.6 16.7 20.9
FU II 4.1 9.9 15.2 20.9
Nakayama III 3.3 1.7 14.3 19.5
JKT6468 IV 6.1 4 3.5 19.7
Muar V 10 8 8 7.5
Nucleotide divergence is in lightface type; amino acid divergence is in bold face type.
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Table 3-11. Nucleotide sequence for the 3’ NCR of the Muar strain and representative 
strains of the four JEV genotypes.
Divergence (%) with:
Strain Genotype K94P05 FU Nakayama JKT6468 Muar
K94P05 I 5.7 5.7 12.7 15.4
FU II 4.4 10.8 13.6
Nakayama III 8.8 14.7
JKT6468 IV 14.5
Muar V
Nucleotide divergence is in lightface type; amino acid divergence is in bold face type.
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3.3.4 Primary and Secondary structures of 5' and 3' NCR of the Muar 
strain
Alignment of the terminal nucleotide sequence of the 5' and 3' NCRs of genotype V, the 
Muar strain, with the other JEV genotypes showed very high homology as shown in Figure 3- 
9.
5' CAP.
K94P05(GI)
FU(GII)
JaOArS982(GIII)
JKT6468(GIV)
Muar(GV)
AGMGTTTATCTGTGTGMCTTCTTCG. .CT1 
AGAAGTTTATCTGTGTGAACTTCTTG G..CT1 
AGAAGTTTATCTGTGTGAACTTCTTCGGG CT1 
AGAAGTTTATCTGTGTGAACTTCTTGG..CT1 
AGAAGTTTATCTGTGTGAACTTCTTGA..CT1
GGTGGTG/GGAAGAACACAGGATCI 
GGTGGTGlGGAAGAACACAGGATCI 
GGTGGTG ? GGAAGAACACAGGATCI 
GGTGGTGlGGAAGAACACAGGATCI 
GGTGGTG G GGAAGAACACAGGATCI
-OH 3'
Figure 3-9. Nucleotide sequence homology of 5' and 3' terminal sequences among JEV 
genotypes. Identical residues among the viruses are boxed.
♦Middle residues between the 5' and 3' terminal sequences are not shown here and they are 
represented by dots.
Furthermore, alignment of the terminal nucleotide sequence of the 5' and 3' NCRs of JE 
serocomplex; JEV, MVEV, WNV and SLEV showed high homology as shown in Figure 3- 
10.
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♦Middle residues between the 5' and 3' terminal sequences are not shown here and they are 
represented by dots.
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Similarities in the secondary structures of the 31 NCR of JEV genotypes III and V were also 
noted and are shown in Figure 3-11.
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*dG means the minimal folding free energy; the lower dG means the higher possibility of this 
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Another secondary structure shown in Figure 3-12 is also postulated (Suiniyoshi et ah, 1987). 
The structure base-pairing between 5' and 3' terminal sequences, is also noted in genotypes 
III and V of JEV.
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Figure 3-12. Proposed secondary structure for sequences of 5' and 3' NCRs terminal sequences of 
JEV. The sequence used for construction of the secondary structure model is from the 
genotype III, JaOArS982 strain (A) and genotype V, Muar strain (B).
*dG means the minimal folding free energy; the lower dG means the higher possibility of this 
structure.
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3.3.5 Phylogenetic Analysis among the Muar Strain of JEV and Other JEV 
Four Genotypes Strains
NJ, MP and ML methods based on both nucleotide and amino acid sequences were used to 
determine the relation between the Muar strain and other JEV isolates. Phylogenetic analyses 
were similar and clearly revealed that the Muar isolate represents the fifth genotype of JEV 
with 100% bootstrap support. Therefore, to avoid presenting similar trees, only NJ trees of 
the nucleotide sequence of the complete genome and different genes as well as ML of the 
nucleotide sequence of the E and NS5/ 3' NCR genes will be presented in this chapter.
NJ phylogeney based on the nucleotide sequence of 5’ and 3’ NCRs as shown in Figure 3-13 
and Figure 3-14, C gene as shown in Figure 3-15, prM gene as shown in Figure 3-16, E gene 
as shown in Figure 3-17, NS1 gene as shown in Figure 3-18, NS2 gene as shown in Figure 3- 
19, NS3 gene as shown in Figure 3-20, NS4 gene as shown in Figure 3-21, NS5 gene as 
shown in Figure 3-22 and the complete genome as shown in Figure 3-23 show that Muar 
isolate represents a fifth genotype of JEV as it is always diverging at the basal node of all NJ 
trees, apart from Figure 3-13, before the other four known genotypes with 100% bootstrap 
support.
ML phylogeney also confirms that the Muar strain represents the fifth genotype of JEV as 
shown in Figure 3-24 based on the nucleotide sequence of (A) E genes and (B) NS5/ 3' NCR 
genes with 100% and 98% bootstrap support respectively.
Thus Muar isolate was placed into a new fifth JEV genotyope based on NJ, ML and MP 
phylogenetic analyses in this study and previous phylogenetic analysis by Uchil and 
Satchidanandam (Uchil and Satchidanandam, 2001) and Solomon et al. (Solomon et al., 
2003b).
100 [Page
100
SAM (China 1954) \
057434 (India 2005)
TC (Taiwan)
GP78 (India 1978)
JaOH0566 (Japan 1966)
WHe (China)
RP-9 (Taiwan 1985)
Ling (Taiwan 1965)
CH1392 (Taiwan 1990)
CC27-S6
SH0601
CH2195SA
CH2195LA (Taiwan 1994) 
014178 (India 2001)
TL (Taiwan)
98
T1P1 (Taiwan 1997)
HVI (Taiwan 1958) 
04940-4 (India 2002) 
JaOAr982 (Japan 1982) 
P3 (China 1950)
NJ2008 (2008)
G II!
100
JaGArOI (Japan 1959) 
Beijing-1 (China 1949) 
Nakayama (Japan 1935)
__  JKT6468 (Indonesia 1981)
Muar (Malaysia 1952) -------------------
. SC04-17 (China 2009)
K94P05 (Korea 1994)
7
] GIV 
-► GV
89
JEV/sw/Mie/40/2004 (Japan 2004) 
HEN0701 (China 2007) 
JEV/sw/Mie/41/2002 (Japan 2002)
Ishikawa (Japan 1998)
FU (Australia 1995) 
IXJ69 (China 2007)
■ XJP613 (China 2007) 
SH17M07 (China 2007) 
----------MVE 1-51
G I
] S'
] G'
WNEg101 
-SLE MSI.7
0.04 substitutions/site
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Figure 3-15. A neighbour-joining phylogenetic tree of the JEV C genes, rooted by using a 
representative strain from other viruses in the JEV serogroup (MVEV, SLE and WNV). The Muar 
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representative strain from other viruses in the JEV serogroup (MVEV, SLE and WNV). The Muar 
isolate is shown with an arrow as a genotype V. Genotypes are given on the right of each tree. 
Bootstrap support values, given as a percentage of 1,000 replicates, are shown. Country and year of 
isolation for each strain used are shown in brackets.
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Figure 3-17. A neighbour-joining phylogenetic tree of the JEV E genes, rooted by using a 
representative strain from other viruses in the JEV serogroup (MVEV, SLE and WNV). The Muar 
isolate is shown with an arrow as a genotype V. Genotypes are given on the right of each tree. 
Bootstrap support values, given as a percentage of 1,000 replicates, are shown. Country and year of 
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Figure 3-18. A neighbour-joining phylogenetic tree of the JEV NS1 genes, rooted by using a 
representative strain from other viruses in the JEV serogroup (MVEV, SLE and WNV). The Muar 
isolate is shown with an arrow as a genotype V. Genotypes are given on the right of each tree. 
Bootstrap support values, given as a percentage of 1,000 replicates, are shown. Country and year- of 
isolation for each strain used are shown in brackets.
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Figure 3-19. A neighbour-joining phylogenetic tree of the JEV NS2 genes, rooted by using a 
representative strain from other viruses in the JEV serogroup (MVEV, SLE and WNV). The Muar 
isolate is shown with an arrow as a genotype V. Genotypes are given on the right of each free. 
Bootstrap support values, given as a percentage of 1,000 replicates, are shown. Country and year of 
isolation for each strain used are shown in brackets.
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Figure 3-20. A neighbour-joining phylogenetic tree of the JEV NS3 genes, rooted by using a 
representative strain from other viruses in the JEV serogroup (MVEV, SLE and WNV). The Muar 
isolate is shown with an arrow as a genotype V. Genotypes are given on the right of each tree. 
Bootsfrap support values, given as a percentage of 1,000 replicates, are shown. Country and year of 
isolation for each strain used are shown in brackets.
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Figure 3-21. A neighbour-joining phylogenetic tree of the JEV NS4 genes, rooted by using a 
representative strain from other viruses in the JEV serogroup (MVEV, SEE and WNV). The Muar 
isolate is shown with an arrow as a genotype V. Genotypes are given on the right of each tree. 
Bootstrap support values, given as a percentage of 1,000 replicates, are shown. Countiy and year of 
isolation for each strain used are shown in brackets.
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Figure 3-22. A neighbour-joining phylogenetic tree of the JEV NS5 genes, rooted by using a 
representative strain from other viruses in the JEV serogroup (MVEV, SEE and WNV). The Muar 
isolate is shown with an arrow as a genotype V. Genotypes are given on the right of each tree. 
Bootstrap support values, given as a percentage of 1,000 replicates, are shown. Country and year of 
isolation for each strain used are shown in brackets.
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Figure 3-23. A neighbour-joining phylogenetic tree of the JEV complete genome, rooted by using a 
representative strain from other viruses in the JEV serogroup (MVEV, SLE and WNV). The Muar 
isolate is shown with an arrow as a genotype V. Genotypes are given on the right of each tree. 
Bootsfrap support values, given as a percentage of 1,000 replicates, are shown. Countiy and year of 
isolation for each strain used are shown in brackets.
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Figure 3-24. Maximum likelihood phylogenetic trees of the (A) envelope genes and (B) NS5/ 3' NCR 
genes, rooted by using a representative strain from other viruses in the JEV serogroup (MVE, Murray 
Valley encephalitis; SEE; St. Louis encephalitis; WN, West Nile). The Muar isolate is shown with an 
arrow as a Genotype V. Genotypes are given on the right of each tree. Bootstrap support values, given 
as a percentage of 1,000 replicates, are shown.
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3.3.6 Phylogenetic Analysis among JEV Genotypes and WNV Lineages
Based on the nucleotide and amino acid sequence of E gene of JEV genotypes strains and 
WNV lineages strains, the closely related virus to JEV within the JE serocomplex, NJ 
phylogenetic analysis revealed that the Muar isolate is the fifth genotype of JEV with 100% 
bootstrap support as shown in Figures 3-25 and 3-26.
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Figure 3-25. A neighbour-joining phylogeny of the nucleotide sequence of the JEV E genes five 
genotypes and WNV five lineages which are given on the right of each tree, with representative 
strains from other viruses in the JE serogroup (MVE and SEE) and outgrouped by using Dengue-2 
strain New Guinea C. The Muar virus is shown with an arrow. Bootstrap support values, given as a 
percentage of 1,000 replicates, are shown.
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Figure 3-26. A neighbour-joining phylogeny of the amino acid sequence of the JEV E glycoprotein 
five genotypes and WNV five lineages which are given on the right of each tree, with representative 
strains from other viruses in the JE serogroup (MVE and SEE) and outgrouped by using Dengue-2 
strain New Guinea C. The Muar virus is shown with an arrow. Bootstrap support values, given as a 
percentage of 1,000 replicates, are shown.
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3.4 DISCUSSION
Genetic data is publicly accessible for several JE strains (more than 400 entries in NCBI 
GenBank), with the notable exception of the Muar strain, with 20 complete genomes for 
viruses from China, Japan, Korea, India, Taiwan, and Australia (Holbrook and Barrett,
2002b). The automation of nucleotide sequencing and improvements in PCR technology to 
make amplification more accurate and faster (e.g. longer PCR products with high fidelity) 
facilitate the sequencing of the complete Muar genome.
The Muar strain sequencing revealed that it has the least similarity among other JEV strains, 
with only (78.8 - 79.8%) homology for the nucleotides and (90.8 - 91.5%) homology for the 
amino acids. This indicated that Muar strain is the most structurally different from other JEV 
strains, in agreement with reactivities results using anti-Muar MAbs (Hasegawa, 1982; 
Hasegawa et ah, 1995). These data are also a more direct correlate to results found in 
serological experiments as these studies are measuring viral structure directly.
Hasegawa et al. (1994) published the sequence of the three structural genes (C, prM and E) of 
the Muar isolate (sequence has not been submitted to GenBank), the number of nucleotide 
and amino acid differences between my Muar sequence and that generated by Hasegawa et 
al. (1994) varied greatly (6.7%) and (5%) respectively; the difference in the nucleotide 
sequence and amino acid sequences of the structural genes of the two Muar strains is given as 
appendix C and D repectively. Despite this great differences, phylogenetic analyses based on 
the nucleotide and amino acid sequences of the Muar strain, sequenced by Hasegawa et al. 
(1994), revealed that it is still representing the fifth genotype of JEV (dat are not presented 
here). However, the reasons for these differences are difficult to explain. Some differences 
are to be expected due to variability arising during growth of the RNA viruses in culture and 
PCR steps. Some differences may also be due to the differences in sequencing strategies; 
Hasegawa et al. (1994) used manual sequencing, whereas in this study modem automated 
sequencing protocols were used. Although the passage history of the Muar strain used in this 
study is unknown, but it is known for the Muar strain used by Hasegawa et al. (1994) as the 
virus was passged 24 times in suckling mouse brain and only one time in C6/36 cells since its 
isolation from the human brain in 1952.1 was not able to get the same Muar strain which was 
sequenced partially by Hasegawa et al. (1994).
Phylogenetic relationship among the Muar isolate and the other JEV strains based on the 
complete genome, 5’ and 3’ NCRs, C, prM, E, NS1, NS2, NS3, NS4 and NS5 genes showed 
that the Muar strain represents the missing fifth genotype of JEV using different types of 
phylogenetic analyses; MP, NJ and ML with high bootstrap values.
The 5' NCR of JEV including the Muar strain is relatively short (95 bases in length) and 
exhibits high sequence identity among JEV strains, while the 3' NCR is usually longer but 
demonstrates extensive heterogeneity in size and sequence between different JEV strains 
because of long deletions, insertions, sequence repeats within the proximal part of the 3' NCR 
(Proutski et ah, 1997). However, at the same time, there is high sequence identity at the distal 
part of the 3' NCR among different JEV strains as demonstrated in Figure 3-9.
Furthermore, alignment of the 5' and 3' NCR terminal sequence of the four flaviviruses which 
are belonging to the same serological group; JEV, MVEV, WNV and SLEV showed 
significant homology; the 5r terminal two residues and the 3' terminal ten residues (5r AG and 
CACAGGATCT 3') were identical as shown in Figure 3-10. This high identity suggests that 
the 3' NCR sequence may play an important role for viral proliferation (Sumiyoshi et al., 
1987).
In addition to the 5' and 3' terminal primary sequence homology among JEV five genotypes, 
similarities in the secondary stractures of the 3' NCR of JEV genotypes III and V were also 
observed as shown in figure 3-11. Another secondary structure of the 5' and 3' NCRs was 
also postulated, shown in Figure 3-12 as it has been suggested that JEV genome ends may 
stick to each other (Sumiyoshi et al., 1987).
WNV is a closely related flavivirus to JEV within JE serocornplex. Based on phylogenetic 
analyses using WNV E gene revealed that WNV could be classified into five distinct groups 
that differed from each other by 20-26% (Bondre et ah, 2007). Phylogenetic analysis using 
WNV strains based on the nucleotide and amino acid sequence of E gene revealed that the 
Muar strain represents the fifth genotype of JEV as it is different from other JEV strains by 
22.1-23.8% nucleotide difference.
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Of the JEV genotypes, genotype V, the Muar strain was the basal group in almost all trees, 
diverging at the deepest node with 100% bootstrap support, suggesting that it represents the 
most ancient lineage, which branched off before genotypes I, II, III and IV.
In conclusion, I sequenced the entire genome of the Muar strain of JEV. Rigrous 
phylogenetic analysis based on multiple regions of the genome and distance and ML methods 
of phylogeny all strongly suggest that JEV has five genotypes and the Muar stmin belongs to 
a separate genotype (genotype V).
CHAPTER 4: EVOLUTIONARY HISTORY OF 
THE MUAR STRAIN OF JEV
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4.1 INTRODUCTION
Encephalitis epidemics were repoted in Japan from the 1870s onwards. JEV was first isolated 
in 1935 and has subsequently been spread across Asian countries (Solomon et al. 2003).
The origins of JEV are uncertain, but phylogenetic analyses with other flavivimses suggest it 
evolved from an African ancestral virus, perhaps as recently as a few centuries ago (Gould, 
2002).
Natural selection is affecting all evolving populations. Positive selection increases the 
frequency of alleles that confer a fitness advantage relative to the rest of the population, or 
increases its genetic diversity, and negative selection removes those alleles that are 
deleterious.
An understanding of nucleotide substitution rates is very important in the field of molecular 
evolution. Partitioning the total substitution rate into synonymous (silent) and 
nonsynonymous (amino acid-altering) components is one of the primary objectives of 
evolutionary studies involving coding regions (Muse and Gaut, 1994).
Comparison of relative fixation rates of synononymous and nonsynonymous mutations 
provides a method for understanding the mechanisms of molecular sequence evolution. The 
nonsynonymous/synonymous rate ratio (co = <7NA7S) is an important indicator of selective 
pressure at the protein level, with co = 1 meaning neutral mutations, co < 1 purifying selection, 
and co > 1 diversifying positive selection. Amino acid sites in a protein are expected to be 
under different selective pressures and have different underlying co ratios (Yang et al., 2000).
Codon-based models of molecular' evolution are able to identify the signature of selection 
from alignments of homologous sequences by estimating the relative rates of synonymous 
(dS) and nonsynonymous substitutions (dN) (Pond & Frost, 2005).
Recent studies have highlighted the potential role of selection in the ongoing evolution of 
flavivimses. Flavivimses, particularly vector borne flavivimses, appear' to be predominantly 
constrained by purifying selection (Holmes, 2003; Woelk and Holmes, 2002), but evidence is 
beginning to emerge that some flavivirus proteins are subject to positive selection. The ML
approach has been used to detect adaptive evolution in the four serotypes of DENY. For 
example, positive selection appeared to be acting primarily on the E gene of DENY, on 
amino acids involved in immune recognition, cell receptor binding, and membrane fusion 
(Twiddy et ah, 2002). Recently, a single amino acid substitution in the NS3 protein has been 
identified, which confers high virulence on otherwise low virulence strains of WNV (Brault 
et ah, 2006).
To date, many phylogenetic analyses suggest the presence of strong purifying (negative) 
selection on arboviruses in nature, supporting strong selective constraints on flavivirus 
evolution (Weaver and Vasilakis, 2009). The global dN/dS of 0.05 agreed with previous 
estimates in JEV and other flaviviruses (Tang et ah, 2010b; Woelk and Holmes, 2002).
Until now, only limited data of the selection pressures acting on JEV have been 
available (Tang et al, 2010; Yang et al, 2000) but none of these have included the Muar 
strain in the analysis, which we have shown represents a fifth genotype of JEV, and may 
provide important additional information. Here, I examine the evolutionary history of JEV 
looking in particular at selection pressures.
To understand the role that selection plays in JEV evolution, and in order to identify the 
patterns of genetic change of JEV genotypes, overall and site specific selection pressures in 
the E genes of 66 JEV strains belonging to the five JEV genotypes were measured.
4.2 MATERIALS & METHODS
4.2.1 Evolutionary History of the Muar Isolate
A maximum clade credibility (MCC) tree based on 35 complete coding sequences of JEV 
was inferred using the bayesian MCMC method available in the BEAST package (version 
1.5b2) (Drummond and Rambaut, 2007), thereby incorporating information on the isolates 
time of original sampling. This analysis utilized a relaxed molecular clock (uncorrelated 
lognormal) and a GTR + Gamma + Invariant model of nucleotide substitution for each codon 
position. All chains were run for a sufficient length to ensure convergence with 10% removed 
as bum-in. This analysis also allowed estimation of coalescent (divergence) times for each 
node on the JEV phylogeny. The degree of uncertainty in each parameter estimate is
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provided by the 95% highest posterior density (HPD) values, while posterior probability 
values provide an assessment of the degree of support for each node on the tree.
The evolutionary rate of the complete genome amongst representative strains of genotypes I 
and III, and for the E gene amongst strains of genotypes I, II and III was estimated. Such 
analysis was not possible between the strains of genotypes IV and V as there is only one 
representative strain published on GenBank.
4.2.2 Selection Pressures between JEV Genotypes
Overall and site specific selection pressures in the E genes of 66 JEV strains belonging to the 
five JEV genotypes were measured as the nonsynonymous/synonymous rate ratio (o)= dN/dS) 
using a ML method implemented by Datamonkey (Pond and Frost, 2005). Tests for positive 
selection were performed using three methods; single likelihood ancestor counting (SLAG), 
fixed effects likelihood (FEE), and internal FEE (IFEL) (http://www.datamonkev.org).
4.3 RESULTS
4.3.1 Evolutionary History of the Muar
Molecular clock analysis of 35 complete coding sequences of JEV, supported by high 
posterior probability values, confirmed that Muar belongs to a fifth JEV genotype and 
represents the oldest linage of JEV, which last shared a common ancestor with other 
genotypes approximately 449.6 years ago (95% highest posterior density interval C‘HPD”= 
373.9 -499.9). Genotype IV diverged from other genotypes approximately 274 (211.6 - 
317.8) years ago, genotype II approximately 189 (116.8 - 237.6) years ago, genotype III 
approximately 158 (111.3 - 183.7) years ago, and most recently Genotype I approximately 
110 (78.5 - 167.8) years ago as shown in Figure 4-1.
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Figure 4-1. Maximum clade credibility (MCC) phylogeny for 35 complete coding sequences of JEV 
genomes. Horizontal branches are drawn to a scale of estimated year of divergence with tip times 
reflecting sampling date (year*). The tree is automatically rooted due to the assumption of a molecular 
clock. The divergence times of genotype nodes are shown. High posterior probability values are 
shown beside the nodes. The filled black circle identifies the most recent common ancestor of JEV. 
The Muar isolate, the oldest linage, is shown with arrow as a Genotype V.
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Evolutionary analysis of full-length JEV genomes revealed that the mean evolutionary rate of 
JEV isolates is 4.35 x lO"4 nucleotides substitutions per site per year'. At the genotype level, 
the mean evolutionary rate of genotypes I and III complete genomes was 3.029 * 10'4 and 
6.029 x 10"4 nucleotides substitutions per site per year respectively. Comparing the mean 
evolutionary rate of each genotype separately using E genes showed that the mean 
evolutionary rate between genotypes I, II and III was 1.14 x 10"3, 1.97 x 10“3 and 2.69 x 10"4 
nucleotides substitutions per site per year respectively. 95% lower and upper HPD values are 
shown in (Table 4-1).
Table 4-1. Rates of nucleotide substitutions per site for JEV complete genomes and E genes.
JEV genotype Mean no. of nucleotide substitutions/site/year 95% HPD*
Lower Upper
GI-V complete genomes 4.35 x KT4 3.4906 x 10A 5.303 x ur4
GI complete genomes 3.029 x 10’4 2.0884 x KT8 8.6999 x 10'4
GUI complete genomes 6.029 x KT4 7.0492 x 10'8 1.4093 x Hr4
GI envelope genes 1.14 x KT3 2.3 x nr4 2.2 x KT3
GII envelope genes 1.97 x 10’3 2.8 x KT4 3.95 x 10'3
GUI envelope genes 2.69 x IQ-4 1.09 x 10’4 4.20 x KT4
*HPD= Highest Posterior Density interval.
4.3.2 Selection Pressures between the Five JEV Genotypes
There was no evidence for positive selection between the JEV five genotypes strains and 
different selection pressures models did not have any category with oo > 1. The average oo 
ratio (dN/dS) over the entire E gene sites was estimated to be ~ 0.05, suggestive of 
predominantly purifying selection.
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Figure 4-2. Codon-based analysis of selection pressures on E gene of JEV strains using the sinlge 
likelihood ancestor counting method (SLAC, Datamonkey). The Figure shows a plot of dN/dS values 
for each predicted codon of the consensus sequences.
*dN-dS is the logarithm of the ratio of co (dN/dS).
Codon
Figure 4-3. Codon-based analysis of selection pressures on E gene of JEV strains using the fixed 
effects likelihood method (FEE, Datamonkey). The Figure shows a plot of dN/dS values for each 
predicted codon of the consensus sequences.
*dN-dS is the logarithm of the ratio of co (dN/dS).
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Figure 4-4. Codon-based analysis of selection pressures on E gene of JEV strains using the internal 
fixed effects likelihood method (IFEL, Datamonkey). The Figure shows a plot of dN/dS values for 
each predicted codon of the consensus sequences.
*dN-dS is the logarithm of the ratio of co (dN/dS).
4.3.3 Pattern of the Geographical Distribution of JEV Isolates
NJ tree was constructed based on the nucleotide sequence of the JEV E genes available at 
GenBank. JEV strains were isolated from different geographical regions and from different 
hosts (mosquito, pig or human brain), These geographical and host characteristics were 
generally not reflected in the phylogeny, rather the strains largely appear mixed up (Figures 
4-5 and 4-6). However, JEV Indian strains could be clustered as all of them are belonging to 
genotypes III and JEV strains isolated from different hosts in Taiwan are also belonging to 
genotypes III. Almost all of JEV Australian strains are belonging to genotype I, while 
Japanese and Chinese isolates are belonging to genotypes I and II.
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Figure 4-5. A neighbour-joining phylogenetic tree of JEV E genes. Genotypes are given on the right 
of each tree. Each strain has the year of isolation, the country and the host. Each colour represents 
one host. Bootstrap support values, given as a percentage of 1,000 replicates, are shown.
1^6 (Page
78
100
100
— HK8256-Mosquito-Taiwan-1972
- RP9-Mosquito-Taiwan-1985
■ JaGAr01-Mosquito-Japan-1959 
r T1P1-Mosquito-Taiwan-1997 
‘ CH1392-Mosquito-Taiwan-1990 
L- HVI-Man-Taiwan-1958 
— DH20-Man-Nepal-1985 
r— Ling-Man-Taiwan-1965 
Beijing-1-Man-China-1949 
r-]1— VN118-Mosquito-Vietnam-1999 
1— Sagiyama-Mosquito-Japan-1957 
j— G8924-Mosquito-lndia-1956 
,-f1— P20778-Man-lndia-1958
1------ 782219-Man-lndia-1978
_j— Nakayama-Man-Japan-1935 
691004-Man-Srilanka-1969
-----  P3-Mosquito-China-1950
i— CN80-Mosquito-Taiwan-1985
P-----  CH2195LA-Mosquito-Taiwan-1994
|-----  PhAn 1242-Pig-Philippines-1984
l— JaOArS982-Mosquito-Japan-1982 
r 049404-Mosquito-lndia-2002 
j1 057434-Man-lndia-2005 
J— H49778-Man-Srilanka-1987 
Ir GP05-Man-lndia-2005 
> GP78-Man-lndia-1978 
r- 733913-Man-lndia-1973 
rn- 014178-Man-lndia-2001
ChiangMai-Man-Thailand-1964 
- 826309-Man-India-1982 
KPP034-35CT-Mosquito-Thailand-1982d
^7
k;
83
SA 14-Mosquito- China-1954 
B2524-Man-Nepal-1985
JKT1724-Mosquito-lndonesia-1979 
7812474-Man-lndia-1978
------- K87P39-Mosquito-Korea-1987
- K82P01-Mosquito-Korea-1982 
JKT1749-Mosquito-lndonesia-1979 
B106563-Pig- Thai Ian d-1983 
2372-Man- Thailand-1979 
Th2372-Man-Thailand-1972 
i— JaNAr0102-Mosquito-Japan-2002 
'— K94P05-Mosquito-Korea-1994 
i— HEN0701-Pig-China-2007 
T- JEV/Sw/Mie40/2004-Pig-Japan-2004 
j— XJ69-Mosquito-China-2007 
XJP613-Mosquito-China-2007 
JEV/Sw/Mie41/2002-Pig-Japan-2002 
lshikawa-Man-Japan-1998 
ThCMAr6793-Mosquito-Thailand-1993 
ThCMAr4492-Mosquito-Thailand-1992 
B2239-Pig- Thailand-1984 
TSOO-Pig-Australia-2000
LQ
M859-Mosquito-Cambodia-1967
100
K91P55-Mosquito-Korea-1991 
— WTP7022-Moq-Malaysia-1970
------  JKT5441-Mosquito-lndonesia-1981
M 15-Mosquito-A ustralia-1995 
FU-Man-A ustralia-1995 
M40-Mosquito-Australia-1995 
NO-Man-Australia-1995 
CNS138-11-Man-Malaysia-1999 
JKT6468-Mosquito-lndonesia-1981
G I
100
MUAR-Man-Malaysia-1952
G IV 
G V
- 0.002 substitutions/site
Figure 4-6. A neighbour-joining phylogenetic tree of JEV E genes. Genotypes are given on the right 
of each tree. Each strain has the year of isolation, the country and the host. Each colour represents 
one country. Bootstrap support values, given as a percentage of 1,000 replicates, are shown.
127 (Page
4.4 DISCUSSION
We have little idea about the origin of most of the major human pathogens. However, 
because JEV has recently evolved and has so rapidly spread to new areas, it has been possible 
to trace its geographical origin.
Here I have shown that the Muar strain represents the oldest JEV lineage, and compared it 
with other frilly sequenced genomes. Previous studies suggest that JEV arose from its 
ancestral vims in the Indonesia-Malaysia region and evolved there into five genotypes; 
genotypes IV and V, the most divergent genotypes, remained confined to the Indonesia- 
Malaysia region, whereas genotypes I, II and III, the most recently evolved genotypes spread 
across Asia (Solomon et al., 2003b).
In this chapter, detailed examination of the geographical distribution of all known JEV 
isolates is consistent with the idea that JEV originated from its ancestral virus in or near 
Malaysia in the mid 1500s; 450 (374 - 500) years ago. Subsequently genotype IV diverged, 
followed next by genotype III, then genotypes I and II diverged from each other. However, 
although my analysis is supported by high posterior probability values, we still need to 
include more fully sequenced strains from each genotype, especially genotypes II, IV and V 
to give us more accurate idea about JEV origin and spread.
The Indonesia-Malaysia region is geographically close to Australia, where JEV’s closest 
fully sequenced relative, MVEV, is found (van den Hurk et al., 2010). JEV originated in the 
Indonesia-Malaysia region from an ancestral virus common to JEV and MVEV. From this 
ancestral virus JEV genotypes IV and V diverged, followed by the more recent genotypes I,
II and III. Whereas more recent genotypes have spread to other areas, the more divergent 
genotypes (IV and V) appear- geographically confined to the Indonesia-Malaysia region and 
have not been foimd in any other countries.
To determine whether genotype V circulated in Malaysia or the Muar strain represented a 
single imported case, Malaysian strains from GenBank were analysed. There were only 4 
strains from Malaysia and they belonged to genotypes II and III as showed in the previous 
phylogenetic analysis (Solomon et al., 2003b). Thus the Muar strain represents the only 
isolate of genotype V virus. However, there is no nucleotide sequence information available
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on Malaysian strains isolated between 1952 and 1965, between 1965 and 1968, between 1986 
and 1970 and between 1970 to 1999. Therefore, it remains unknown whether the Muar strain 
isolation was the result of a genotype V epidemic focus that quickly died off, or a genotype V 
strain that circulated in Malaysia for a period of time prior to extinction, or the Muar strain 
was a single imported case from another region.
The evolutionary rate of E genes for each genotype separately showed a higher evolutionary 
rate for the most recently evolved genotypes I and II than for genotype III. However, the 
number of genotypes I and II strains that have sequence data available in Genbank is less 
than for genotypes III. Further sequencing of strains belong to the genotypes I and II from 
different time intervals may affect the evolutionary rate of the E gene of genotypes I and II to 
be similar’ to genotype III.
Evolutionary analysis of full-length JEV genomes revealed that the evolutionary rate of 
isolates is 4.35 x 10"4 (3.4906 x lO-4 to 5.303 x lO"4) nucleotides substitutions per site per 
year, similar to other viruses in the family Flaviviridae. Previous studies using BEAST have 
revealed an evolutionary rate of 8.48 x 10'4 substitutions/site/year for DENY (Weaver and 
Vasilakis, 2009). Additionally, evolutionary rate calculations indicate that WNV has evolved 
at approximately 0.85 x 10'3 substitutions/site/year- (Bertolotti et al, 2007). The high 
evolution rate of JEV genomes is consistent with that of other RNA viruses, and probably 
explained due to the lack of a proofreading function and error-repairing ability of viral RNA 
polymerases (Steinhauer and Holland, 1987), the resulting accumulated mutations providing 
the genomic variability necessary to drive viral evolution in the genus Flavivirus, including 
JEV.
The evolutionary analysis presented here confirms that the Muar* strain of JEV is not only 
from the fifth genotype but represents the oldest JEV lineage and from it the other four* 
genotypes were diverged since mid 1500s.
The E protein has been demonstrated to be a reliable phylogenetic marker for JEV 
(Ali et ah, 1995; Mangada and Takegami, 1999). It plays an important role in tissue tropism, 
cell fusion and infection, vims maturation, and protection (Westaway, 1987). A more detailed 
phylogenetic analysis of E gene showed that JEV strains have not got a specific geographical 
distribution pattern. The reason for this mixing up may be because JEV is a mosquito borne
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zoonotic vims which can be widely and rapidly transmitted between different geographical 
areas.
To improve our ability to assess the roles of selection in the evolution of JEV, the codon 
dN/dS ratios in the E glycoprotein of 66 JEV strains belonging to the five JEV genotypes 
were analysed. Many sites seemed to be under negative selection pressure, and no evidence 
for positive selection was found. Indeed, the overall picture obtained was that of strong 
purifying selection, with mean dN/dS value ~ 0.05 for all JEV genotypes, and in agreement 
with previous studies (Tang et al., 2010a). This suggests that selection pressures acting on the 
E gene, which might include the immune response, are unlikely to be responsible for the 
genotypic diversification of this vims.
In conclusion, we have shown that the Muar strain represents the oldest JEV lineage and 
JEV’s origin is back to mid 1500s. Although E protein is subjected to strong negative 
pressure, but understanding the genetic changes in the E gene is an important step to study 
the evolution of JEV. More extensive surveillance might help us understand geographic 
movement and genotype shift of JEV.
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CHAPTER 5: PREDICTION OF THE THREE DIMENSIONAL
STRUCUTURE OF THE ENVELOPE GLYCOPROTEIN 
OF THE MUAR STRAIN OF JEV
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5.1 INTRODUCTION
JEV is an RNA-enveloped virus (Monath and Heinz, 1996). The E glycoprotein, the major 
antigenic determinant on flavivirus virions, mediates receptor binding and membrane fusion 
during virus entry. It is responsible for a number of important functions including cellular 
tropism, virulence, induction of neutralizing antibodies and protective immunity 
(Chambers et al., 1990).
Each E protein subunit is composed of three domains: domain I, which forms a /^-barrel; 
domain II, which projects along the virus surface between the transmembrane regions of the 
homodimer subunits; and domain III, which maintains an Ig-like fold (Allison et al., 2001; 
Rey et al., 1995a). Domain III appears to be involved in receptor binding and is a major 
target of neutralizing antibodies. Figure 5-1 illustrates the organization of the E protein dimer 
as present at the surface of mature flavivirus.
Figure 5-1. Structural organization of the flavivirus envelope protein. (A) Schematic top 
view of the organization of the E protein dimer as present at the surface of mature virions, 
color-coded according to the three domains (DI, DII, and Dill). The fusion peptide (FP) is 
indicated in orange. (B) Crystal structure (top view) of E ectodomain dimer. Taken 
from (Ren et al. 2007).
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Neutralizing antibodies against domain III can inhibit a postattachment step of viral entry, 
and a soluble form of domain III can act as a potent dominant-negative inhibitor of this 
conformational change (Liao and Kielian, 2005).
The differences in the conformations of residues in domain III may help us to understand the 
variations in antigenic and neutralizing properties of JEV strains. Most of the phenotypically 
variant properties, like serotypic differences, variants of vaccine strains, and neutralisation 
escape valiants, map with domain III (Cecilia and Gould, 1991; Gritsun et al., 1995).
The 3D structure of the E glycoprotein of the Muar strain was predicted and the difference 
and the critical changes between the Muar’ and other JEV strains were identified so this may 
help us to understand the variations in antigenic and neutralizing properties of different JEV 
strains.
5.2 MATERIALS & METHODS
5.2.1 Determining the Signature Amino Acids of the Muar Strain 
Glycoprotein
The signature amino acids of the E glycoprotein of the Muar strain were determined through 
alignment of 292 other JEV strains belonging to different genotypes.
5.2.1. Prediction of Three-dimensional Structure of the E Glycoprotein of 
the Muar Strain
The Muar-specific amino acids of the E glycoprotein, which distinguish genotype V from 
other genotypes, were mapped onto the predicted 3D structure of the Muar E protein, as 
modelled based on predicted similarities to the homologus (77% identity) glycoprotein gene 
in WNV (PDB entry 2i69) using SWISS-MODEL via the ExPASy lb server (Schwede et al., 
2003) as the X ray structure of the E protein of JEV is not available. The predicted Muar E 
structure was viewed and manipulated using PyMol (http://pvmol.sourcecforge.ne1/).
Critical changes in the E glycoprotein which are thought to be involved in receptor binding as 
described by (Ni and Barrett, 1998; Solomon et al., 2003b) were identified in genotype V, 
the Muar strain.
5.3 RESULTS
5.3.1 Structural Differences in E Glycoprotein among the Muar and Other 
JEV Strains
Examination of the E protein of the Muar strain showed it was similar to other JEV strains. It 
consists of 500 amino acid residues. All the twelve cysteines that form disulfide bonds are 
conserved between the Muar strain and other JEV strains.
Alignment of the E glycoprotein of 292 JEV strain sequences revealed that there are twenty 
two Muar signature amino acids which are identified in Figure 5-2.
The range of intergenotypic amino acid sequence divergence of E glycoprotein between 
genotype V strain, Muar, and the other JEV genotypes was 8.5 to 9.7%.
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Figure 5-2. Alignment of the E protein amino acid sequences of JEV GI - V. Dots indicate 
consensus. Underlined amino acids represent the Muar signature amino acids.
* Red colored amino acid residues are not signature amino acids for Muar strain as they are similar to 
other JEV strains which are not shown here.
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5.3.2 Variation within the E protein Tertiary Structure of the Muar strain 
of JEV
The predicted three-dimensional (3D) structure of the E protein of the Muar strain was 
modeled onto the crystal structure of WNV (Nybakken et al., 2006) as shown in Figure 5-3.
A comprehensive alignment of E genes from 292 JEV strains identified twenty two signature 
amino acid residues that distinguished genotype V from other genotypes; two signature 
amino acids for the Muar strain in domain I as shown in Figure 5-4, twelve in domain II as 
shown in Figure 5-5 and eight in domain III as shown in Figure 5-6 but the critical change is 
in E327 mapped to the exposed lateral surface of domain III in a region thought to be 
involved in receptor binding as described previously (Ni and Barrett, 1998 ; Solomon et al, 
2003b).
Interestingly, some of the Muar* signature amino acids are similar to MVEV when MYEV is 
included in the comprehensive alignment of E genes of JEV strains including the Muar strain. 
Those amino acides that are unique to Muar in comparison with other JEV stains, but some 
of them are conserved with MVEV domains II and III as shown in Figures 5-8 and 5-9 
respectively.
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Figure 5-3. Predicted three-dimensional model of the E protein of JEV GV strain Muar, 
derived from the crystal structure of WNV, Individual E monomers are colored red (domain 
I), green (domain II), and blue (domain III).
137 | P a g e
M (188)
A (149)
Figure 5-4. JEV E protein domain I. Predicted three-dimensional model of the E protein of 
JEV GV strain Muar, derived from the crystal structure of WNV, showing two Muar 
signature amino acids compared to other JEV strains.
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Figure 5-5. JEV E protein domain II. Predicted three-dimensional model of the E protein of 
JEV GV strain Muar, derived from the crystal structure of WNV? showing twelve Muar 
signature amino acids compared to other JEV strains.
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Figure 5-6. JEV E protein domain III. Predicted three-dimensional model of the E protein of 
JEV GV strain Muar, derived from the crystal structure of WNV, showing eight Muar 
signature amino acids compared to other JEV strains; the critical change at residue 327; 
circled, (in the putative receptor binding region of domain III) from the bigger size glutamine 
amino acid in genotype V strains to the aliphatic amino acid leucine in genotype IV strains 
then to serine and threonine amino acids found in newer genotypes; I, II and III.
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Figure 5-7. JEV E protein domain II. Predicted three-dimensional model of the E protein of 
JEV GV strain Muar, derived from the crystal structure of WNV, showing twelve Muar 
signature amino acids compared to other JEV strains, however, four of these amino acids are 
similar to MVEV (underlined).
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Figure 5-8. JEV E protein domain III. Predicted three-dimensional model of the E protein of 
JEV GV strain Muan derived from the crystal structure of WNV, showing eight Muar 
signature amino acids compared to other JEV strains, however, five of these amino acids are 
similar to MVEV (underlined).
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5.4 DISCUSSION
The E protein of the flaviviruses is the major antigen for theses viruses and is also believed to 
be associated with vims binding and entry to host cells. Thus, the majority of serological and 
genetic analyses of JEV have focused on the E protein.
Analysis of the Muar E glycoprotein revealed that it is similar to the E glycoprotein of other 
JEV strains. The E glycoprotein of JEV consists of 500 amino acid residues which form three 
domains (Rey et al, 1995). Domain I, which is referred to as the central domain, consists of 
128 residues from 1-51, 137-196, and 293-311. There are two disulphide bonds in this 
domain (Cys 3-Cys 30 and Cys 193-Cys 297). This domain contains the glycosylation site in 
addition to the epitopes with serological or biological activities. The second domain, domain 
II, consists of 171 residues (52-136 and 197-292) and three disulphide bonds (Cys 60-Cys 
121, Cys 74-Cys 105 and Cys 92-Cys 116). This domain is called the dimerisation domain. 
Domain II has a hydrophilic region and contains epitopes involved in neutralisation and 
hemagglutination. The region 98-111 is a highly conserved region among flaviviruses, has a 
/Miairpin motif, and has been suggested as the one involved in the Aision activities (Roehrig 
et ah, 1990). Domain III is a contiguous stretch of 100 residues (310-411) with only one 
disulphide bridge (Cys 314-Cys 346).
Site-directed mutagenesis studies of domain III proved that it is an important domain not 
only in JEV but also in other vimses such as MVEV, TBEV, and Louping ill virus 
(Cecilia and Gould, 1991; Holzmann et ah, 1990; Jiang et ah, 1993; Lobigs et ah, 1990). 
Domain III has also been suggested to be involved in the receptor binding activities. The 399- 
RGD-401 sequence motif, present in domain III, is unique to the mosquito flaviviruses and 
was proposed to form part of the receptor binding site (Lobigs et al, 1990).
The observed difference in the predicted 3D structure of E glycoprotein of JEV strains, 
particularly in domain III, could help in understanding the antigenic and serological 
properties of these strains (Cecilia and Gould, 1991; Gritsun et ah, 1995). The differences in 
the conformations of residues in domain III may help us to understand the variations in 
antigenic and neutralizing properties of JEV strains. Most of the phenotypically variant 
properties, like serotypic differences, variants of vaccine strains, and neutralisation escape 
valiants, map with domain III (Cecilia and Gould, 1991; Gritsun et ah, 1995).
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The choice of E protein for analysis also provides the best chance of finding variability 
related to serotypic groups of the virus. The bulk of the antibody response in JEV infections 
is directed against the E protein (Monath and Heinz, 1996). Variability in this region should 
therefore be directly correlated to changes in viral surface epitopes and therefore the presence 
of multiple serotypes of the vims.
Domain III of the E protein of JEV has been shown to contain important sites for antibody- 
mediated virus neutralization and motifs associated with virulence (Rey et ah, 1995;
Wu et ah, 2003). Change in E327 in domain III of JEV has been considered as critical 
change as it is located in a region thought to be involved in receptor binding as showed in 
genotype IV strain of JEV (Ni and Barrett, 1998 ; Solomon et al., 2003b). Therfore, I could 
explain why the Muar strain is unique serollogicaly, becuse it has eight signature amino acids 
differences at domain III with a critical change at residue E327 (in the putative receptor 
binding region of domain III).
Wiry the Muar strain, the most ancient lineage of JEV has not spread is uncertain. JEV uses a 
wide range of mosquito species and vertebrate hosts across Asia, and geographical 
differences in vector and host availability may explain why genotype V, the Muar strain, has 
never spread. I examined the virus’ complete amino acid sequence to look for molecular* 
determinants that might relate to differences in host preference. I found many changes in the 
E protein, and a comprehensive alignment of E proteins identified twenty two signature 
amino acids. Depending on previous studies which showed that a small number of changes in 
E protein sequence could affect mosquito oral infectivity in arthropod borne viruses (Chen 
and Beaty, 1982; Ni et ah, 1994); Tsetsarkin et al, 2007), I could explain why genotype V, is 
confined to Malaysia and has not spread elsewhere.
It has been found that few changes in the E glycoprotein amino acids could be responsible for 
the virus spread into new geographical areas, as for example, the sequence of the Australian 
FU strain (GII) predicts five amino acid changes within the E protein, four of which lie 
within predicted antigenic domains. Three of the mutations lie in close proximity (residues 
E307, E308, E311) and are in the region of an exposed loop that lies on the outside face of 
the E protein domain III (Rey et al., 1995b).
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Interestingly, for the arthropod-bome alphavirus, Chikungunya vims (CHIKV), single amino 
acid changes in the E protein have been shown to be associated with change in vector 
competence. Although the typical vector for CHIKV is Aedes aegypti, a single mutation in 
the E protein gene was directly responsiple for CHIKV adaptation to Ae. albopictns 
mosquitoes (Tsetsarkin et al, 2007).
It has been suggested that there may be a minimum amino acid difference threshold that must 
be crossed to loose cross-protection; i.e. the occurrence of a different serotype. This 
heterogeneity threshold appeal's to be about 20% (Tsarev et al., 2000). The amino acid 
differences between JEV strains including the Muar strain are consistent with one serotype 
hypothesis. The maximum obseived differences was less than 10%. Overall, the genetic 
analysis presented here suggests that only one serotype of JEV exists indicating that JEV 
vaccines are effective against different JEV genotypes.
Interestingly, I showed that some of the Muar signature amino acids in domains II and III, 
which are different from other JEV strains, are similar* to MVEV, the closest flavivirus to 
JEV, when MVEV is included in the aligmnent of E genes of JEV including the Muar strain. 
This indicates that the Muar strain, the most ancient JEV strain, could evolve from MVEV.
Analysis of the E glycoprotein of the Muar strain of JEV may help to provide pointers as to 
which critical amino acids might explain the serological differences between genotype V and 
other more recently evolved genotypes; it may also help explain why genotype V appeal's not 
to have been as successful as other, more recently evolved genotypes, in terms of circulation 
and spread. Experimental studies with an infectious JEV clone, looking at the effect of 
particular mutations on mosquito infectivity and transmissibility would help explore this 
further.
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CHAPTER 6: INVESTIGATING NEUTRALIZATION 
EFFECTIVENESS OF INTRA VENEOUS 
IMMUNOGLOBULINS FROM AN ENDEMIC PART OF ASIA 
ON FIVE DIFFERENT GENOTYPES OF JEV
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6.1 INTRODUCTION
JE is the most common cause of viral encephalitis in Asia; 30,000—50,000 human cases are 
reported annually. Clinical disease presentations range from a flulike fever to a severe and 
deadly meningoencephalitis with a parkinsonian syndrome. The mortality rate is high (range, 
25%-30%), and neuropsychiatric sequelae occur' in 50% of patients (Solomon and Winter, 
2004).
Following infection with JEV, the ratio of symptomatic to asymptomatic disease is estimated 
to be 1:50-l :300 (Libraty et al., 2002a). JEV targets the CNS causing encephalitis as well as 
meningitis (Hosokawa et al., 2007).
Therapy for JE is supportive and no clearly effective specific antiviral agents exist 
(Mishra and Basu, 2008). Complications of infection such as seizures and raised intracranial 
pressure need to be identified and treated. Careful nursing care and physiotherapy are needed 
to reduce the risk of bedsores, malnutrition and contractures. Aspiration pneumonia is 
common in patients with a reduced gag reflex.
Experimental laboratory studies showed that some compoimds have shown good efficacy 
against JEV such as isoquinolones, anti-JEV MAbs, nucleoside analogs, the lymphocyte 
modulator concanavalin A, nitric oxide and ribavirin (Harinasuta et al., 1984; 
Kimura-KurodaandYasui, 1988a).
IFN-a has been the most promising antiviral candidate for most of viral infections including 
JEV (Burke & Morill, 1987). However, a double-blind placebo-controlled trial in Vietnamese 
children with JE showed that although IFN-a may have delayed the time of death, it made no 
effect on the overall outcome (Solomon, 2003a).
IVIGs have been used recently to treat flavivims encephalitis. In a case report, IVIG was 
shown to be of benefit when administered with symptomatic treatment for JE. The patient 
improved rapidly with complete recovery (Caramello et al., 2006).
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A previously healthy 49-year-old Italian man was admitted to the hospital after a 3-week trip 
to rural Vietnam. At admission, he was stuporose, somnolent, disoriented, and febrile 
(39.5 °C) and had mild meningismus, photophobia, and conjunctival hyperemia. The 
following signs were observed: fluctuating responsiveness, mask-like facies, orofacial 
dyskinesias, slurred speech and motor aphasia, ataxia, intentional tremors, and an inability to 
perform manual procedures. Analysis of a CSF specimen revealed a white blood cell (WBC) 
count of 400 cells/mL. Serologic testing was performed by immunofluorescence, and the 
results were positive for JEV, with seroconversion in subsequent samples of serum and CSF; 
peak titers are reported. MRI (magnetic resonance imaging) revealed asymmetrical, Tl- 
lighted hypointense and T2-Iighted hyperintense lesions at the right lentiform nucleus and 
bilateral thalamus, without contrast enhancement. Electroencephalography revealed diffuse 
theta-delta activity and generalized slow waves. Supportive therapy with saline and NSAIDs 
was administered, but a worsening of confusion and agitation were observed. On day 6 of 
hospitalization, a 5-day course of IVIG were initiated. The patient started to improve after 
receiving the first perfusion, with progressive recovery. On day 23, the patient was oriented 
but still slightly slurred in mentation, motor activity, and speech. However, a month later, 
only a slight deficit in recent memory was observed. This was the first case of the use of 
IVIG to treat JE infection (Caramello et al, 2006).
Because of the interest in IVIG as potential therapy for JE, I decided to investigate 
neutralising antibody titres in commercially available IVIG from India where JE is endemic. 
This is especially timely because IVIG is now being used on a presumptive basis in some 
cases of JE. In India genotype III of JEV has been circulating since at least the 1950s; there 
are outbreaks every year, and very large outbreaks every few years. I was particulary 
interested in whether the available IVIG had neutralisation activity against the Muar strain.
6.2 MATERIALS & METHODS
6.2.1 Neutralization Assays
The neutralization effectiveness of three different human IVIGs (Table 6-1), marketed in 
India, from pooled donors who are JEV antibody-positive were investigated against a strain 
of each of five JEV genotypes. JEV strains were chosen based on the lab availability; 2372 
from genotype I, CNS138-11 from genotype II, P3 from genotype III, JKT6468 from 
genotype IV, and Muar from genotype V.
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Table 6-1. Source of the intravenous immunoglobulins used in this study
IVIG Patented in: Manfactured By:
BHARAT SERUMS AND VACCINES
Batch No.
A) India LIMITED A3306004
(B) India CLARIS LIFESCIENCES LIMITED
BHARAT SERUMS AND VACCINES
200609032
(Q India LIMITED A3307017
6.2.1.1 Passaging Virus
JEY strains were passaged four times in Vero cells in our containment level 3 (CL3) lab 
before subsequent use. Supernatant from infected cells was added to a confluent 
monolayer of Vero cells, left for 30 minutes at room temperature before adding maintenance 
media containing 5% FBS DMEM supplemented with glutamine, penicillin/streptomycin. 
Supernatant was collected two days later and frozen at -80 °C.
6.2.1.2 Plaque Titration
Infectivity of JEV strains were measured by plaque titration using 6-well tissue culture plates 
containing confluent Vero cell monolayers. The virus was added to the cells in ten-fold 
dilutions and left at room temperature for 30 minutes, rocking the plates every five minutes. 
After this time, 4 ml of 2% agarose/MEM overlay was added to the cells and the plates were 
placed at 37°C in a CO2 incubator, with 5% CO2 level, for 5-6 days before fixing with 
formalin and staining with crystal violet. Figure 6-1 shows the ten-fold virus dilutions.
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Figure 6-1. The ten-fold virus dilutions used for plaque titration.
6,2.1.3 Plaque Reduction Neutralization Test (PRNT)
Fifty % plaque reduction neutralization titers (PRNT50) were determined for each IVIG. The 
PRNT50 test was performed essentially as originally described by De Madrid and Porterfield 
(De Madrid and Porterfield, 1974).
Briefly, the IVIGs were diluted (1/5) then followed by twofold serial dilutions. Subsequently, 
each dilution was mixed with an equal volume of virus preparation 30 plaque forming unit 
(pfu) per well” and kept for half an hour at 37 °C in a CO2 incubator. Aliquots of lOOpl of the 
mixtures were inoculated in duplicate in 6 well plates of a Vero cell monolayer and kept at 
37 °C for half an hour with four occasional agitations. Agarose overlay media were then 
added, and the cells were kept at 37 °C in a CO2 incubator for 5-6 days before fixing with 
formalin and staining with crystal violet.
1$0 | £ a g e
The highest IVIG dilution with plaque reductions of 50% was defined as the titration end 
point. IVIGs that showed 50% plaque reduction at 1:10 dilution or more were considered to 
be positive (Monath et al.3 2000).
6.3 RESULTS
6.3.IPlaque Reduction Neutralization Tests (PRNT50)
The ability of IVIG to protect against strains of JEV representing the five major genotypes 
was assessed. Neutralization assays showed IVIGs appeal’ cross-reactive across the five JEV 
genotypes, with effective but lower titres for the older genotypes IV and V.
For IVIG (A), the PRNT5o ranged between 120 in genotypes IV and V to 640 in GUI as 
shown in Figure 6-2.
For IVIG (B), the PRNT5o ranged between 160 in genotypes IV and V to 640 in G III as 
shown in Figure 6-3.
For IVIG (C), the PRNT50 ranged between 80 in GV to 320 in genotypes I and III as shown in 
Figure 6-4.
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Figure 6-2. PRNT50 for a representative strain of each JEV five genotypes against 
IVIG (A).
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Figure 6-3. PRNT50 for a representative strain of each JEV five genotypes against IVIG (B).
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Figure 6-4. PRNT50 for a representative strain of each JEV five genotypes against 
IVIG (C).
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6.4 DISCUSSION
There is no known effective, specific treatment for JE. However, a case report of JEV has 
been treated with IVIG and clinical improvement was rapid and constant during the course of 
treatment and resulted in almost complete recovery (Caramello et al, 2006).
For patients with infectious diseases, IVIG is administered with two aims. The first aim to 
increase viral clearance due to antibody dependent neutralization, as is used for example in 
immunodeficient patients (e.g., in cytomegalovirus-infected bone marrow transplant 
recipients or parvovirus-infected subjects with HIV infection) or in patients with specific 
infections (e.g., SLEV or WNV infections) (Agrawal and Petersen, 2003; Bayry et al., 2003). 
The second aim for high-dose IVIG, is to benefit patients with certain acute inflammatory 
diseases that have both viral and autoimmime causes (i.e., acute disseminated 
encephalomyelitis) (Nishikawa et al., 1999). However, in the latter case, the mechanism of 
action is not completely clear'. IVIG has been found to inhibit the function of different arms 
of the immune system (i.e., maturation and function of dendritic cells, proliferation of T 
lymphocytes, and production of proinflammatory cytokines).
Passive transfer of specific antibodies or Igs has been shown to abort or modify a number of 
Flavivirus infections, including infection with JEV (Kimura-Kuroda & Yasui, 1988) or 
MVEV (Broom et al., 2000), SLEV (Mathews and Roehrig, 1984), TBEV 
(Phillpotts et al., 1987) and 17D YF (Schlesinger et al, 1985). It appears, therefore, that the 
only currently available treatment for viral infection that could provide a state of immediate 
immunity is passive transfer of specific antibodies (Casadevall and Scharff, 1994;
Rosas et ah, 2001).
Antibodies play a major role in protection and recovery of infected mice from WNV 
infection and IVIG can be used as first-line therapy; full protection was 
(Ben-Nathan et al., 2003) achieved when the infected mice were treated with pooled human 
plasma (PP) or IVIG obtained from healthy Israeli blood donors that contained WNV- 
specific antibodies. Recovery of the lethally infected mice was dependent on the dose and 
time of IVIG administration (Ben-Nathan et al, 2003).
In this chapter, the neutralization effectiveness of three different IVIGs on representatives 
from the five JEV genotypes was determined. These are currently being used as a supportive 
treatment for JEV infection in India as until now no clearly effective specific antiviral 
agents exist (Mishra and Basu, 2008). In a cell culture model, IVIGs reacted significantly 
with higher titers for genotypes III but appear' cross-reactive against the other four genotypes 
as well. Given that so far all strains of JEV isolated in India are genotypes III strains, this is 
not unexpected. The results of the study are consistent with previous studies 
(Ali and Igarashi, 1997; Wills et ah, 1993), and suggest that the virus used in neutralization 
assays affect the antibody titre obtained. PRNT5o titers vary depending on the virus strain 
used in the neutralization tests, namely higher PRNT5o titers were obtained when the 
challange virus was homologus to the vaccine strain compared to use of a heterologous virus 
(Ferguson et ah, 2008).
Cross-neutralization experiments with sera raised against JEV strains of different genotypes 
and studies using MAbs have demonstrated antigenic differences both within and between 
genotypes of JEV strains (Ali and Igarashi, 1997; Wills et ah, 1993). However, 
epidemiological evidence indicating that secondary CNS infections with JEV are not reported 
and the limited nucleotide and amino acid divergence of JEV strains suggested to some 
authors that all JEV strains including Muar comprise a single “serotype” (Markoff, 2000; 
Tsarev et ah, 2000). Hence, exposure to virus of one genotype might be expected to protect 
against all JEV strains.
The PRNT5o titers for all IVIGs against the five JEV strains ranged between 80 and 640, and 
no single IVIG neutralized all strains better than the others. In general, the highest titers for 
all three IVIGs were observed against strains of genotype III (titers of 320 and 640), while 
PRNT50 titers against strains of genotypes IV and V ranged between (80 and 160). This 
observation is consistent with previous reports describing lower levels of neutralization 
against heterologous strains of JEV. It has been suggested that neutralizing antibody titers of 
> 10 are probably protective (Monath, 2002). The protection afforded by antibodies induced 
by experimental JEV vaccines in mice against JEV strains representing the four major 
genotypes provided protection against the vims challenge in the mouse model at > 20 
(Beasley et ah, 2004).
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Our results indicate that, although neutralizing antibody titers were lower against genotypes 
IV and V vimses, IVIGs are capable of neutralizing strains of genotypes IV and V at 
protective levels.
To our knowledge, there is only one reported case of IVIG to treat JE. Additional 
investigations and clinical trials are warranted before any standardised recommendations 
should be made, but IVIG may prove to be useful when administered with symptomatic 
treatment for this deadly disease.
Investigation into new antiviral drugs against JE is proving to be one of several important 
areas of research stimulated by the growing threat of this spreading vims.
Because of the unavailability of specific treatment for JE, vaccination remains the most 
promising tool to reduce this deadly infection (Tsai, 2000).
157 | P a g e
CHAPTER 7: GENERAL DISCUSSION
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Great interest has been directed towards emergence and evolution of infectious diseases 
especially since the start of the acquired immune deficiency syndrome (AIDS) epidemic in 
early 1980s. It is clearly extremely important to know what factors allowed new infections 
like HIV to appear*, or older ones to reappear*, and then to track their spread through 
populations (Zuckerkandl, 1987).
One of the most basic questions to ask with any infectious disease is where it comes from. 
Although arthropod-bome encephalitis viruses including JEV represent a significant public 
health problem throughout most of the world, their origins and evolution remain unclear* 
(Solomon and Cardosa, 2000).
Tracing the spread of infectious diseases was traditionally approached by serology, that is by 
studying the movement of pathogens strains which differed in immunological response, 
serological tests divided Flavivirus genus of the family Flaviviridae into eight 
serocomplexes, including THE serocomplex, DEN serocomplex, and JE serocomplex.
Several mosquito-borne neurotropic viruses of the JE serocomplex, cause encephalitis 
outbreaks in humans across the world including WNV which found in Africa and north into 
Europe, and recently in North America, SLEV which circulate in the United States, MVEV 
and KUNV which both are found in Australia and Rocio virus in Brazil. In addition, JEV, the 
most important cause of epidemic encephalitis worldwide in terms of numbers; causing 
30,000 to 50,000 cases with 10,000 to 15,000 deaths every year (Tsai 2000).
JEV is endemic to Southeast Asia and surrounding Pacific Islands. However, its recent 
emergence in northern Australia (Mackenzie, Poidinger et al. 1997; Hanna, Ritchie et al. 
1999) has caused great public health concern and global alert as this virus could expand its 
geographical range, spread to naive areas and become a worldwide public health threat.
Although JEV is confined to Asia and Australia at the moment, the possibility of it spreading 
anywhere else all over the world is high. The reasons for JEV spread may include changing 
agricultural practices, such as increasing irrigation, and animal husbandry (Tsai, 1997). In 
addition, migrating birds are thought to be important in the virus’ dispersal to new 
geographic areas (Innes, 1995).
JEV continues to spread with recent outbreaks in India, Nepal, and Australia. The most 
recent large outbreak was reported in northern India in 2005 causing 5000 cases, with 1300 
deaths (Solomon 2006). It is not known what went wrong in 2005 but it could be because of 
the vaccine unavailability, a late government response, and severe lack of medical support 
including medical staff, medicines and even beds.
The occurrence of JE- cases and JE-related deaths is increasing in recent years, suggesting 
that JE may be spreading to naive areas. This could be due to the ecological changes and the 
extensive traveling of people looking for employment and for social reasons. Despite several 
outbreaks, the knowledge gained from these epidemics is negligible. Therefore, collection of 
epidemiological information from JE epidemics from different places is inevitable to frame 
JE-control strategies (Kabilan et al., 2004). Therefore, vaccination against JE ideally should 
be practiced in all areas of Asia where the virus is responsible for human disease.
JE emerged in Japan in 1870 and then spread across Asia to affect most of China and the 
Asian subcontinent, all of Southeast Asia, and the Pacific Rim, reaching northern Australian 
in 1998. It has become the most important cause of epidemic encephalitis worldwide and 
there is a clear need for a better understanding of the origins and spread of this virus.
In this study, I showed the possibility of JEV evolution from MVEV as NJ phylogenetic 
analysis in Figures 3-25 and 3-26 revealed the evolution of the oldest JEV lineage, Muar 
strain, from MVEV. Furthermore, Muar stain of JEV shared conserved amino acids residues 
in the E glycoprotein with MVEV as elucidated in Figures 5-7 and 5-8.
Epidemiological studies have demonstrated four genotypes of JEV (I - IV). Sequencing of the 
complete genome of the Muar strain showed that the Muar isolate was the most genetically 
different of the other JEV stmins, in agreement with reactivities results using anti-Muar 
MAbs (Hasegawa, 1982; Hasegawa et al., 1995) confirming that Muar is unique both 
genetically and serologically.
Hence, Domain III of the E protein of JEV has been shown to contain important sites for 
antibody-mediated virus neutralization and motifs associated with virulence (Rey et al., 
1995b; Wu et al., 2003); the eight signature amino acids differences at domain III with a 
critical change at residue 327 (in the putative receptor binding region of domain III), may
160 (Page
explain some of the serological differences with the Muar strain. However, in this study I 
showed that all JEV strains including Muar are belonging to one serotype by determing the 
amino acid divergence percentage within the E protein, suggesting that the available JEV 
vaccines are effective against different JEV strains and exposure to virus of one genotype 
might be expected to protect against all JEV strains. However, because of the high evolution 
rate of JEV associated with the lack the proof-reading ability of viral RNA polymerases, we 
could expect the appearance of newer genotypes in the future which might escape the vaccine 
protection.
The critical amino acid change at E327 is from glutamine in genotype V strain to leucine in 
genotype IV strains then to serine and threonine amino acids found in newer genotypes I, II 
and III. This amino acid change could play a role in altering vector and/or host preference 
and could have contributed to the wider dispersal of the newer JEV genotypes compared with 
those of genotype V. Previously a small number of changes in E protein sequence have been 
shown to affect mosquito oral infectivity (Chen and Beaty, 1982; Ni et ah, 1994).
There is no doubt that phylogenetic trees have become an important analytical tool and they 
have been used to study the origin and spread of viral infections. In this study, phylogenetic 
and evolutionary analyses revealed that the Muar strain represents a fifth genotype of JEV. 
Furthermore, the Muar* strain represents the oldest JEV lineage when compared with other- 
genomic sequences. I showed that JEV arose from its ancestral virus in the Indonesia- 
Malaysia region since mid 1500s and evolved into five genotypes.
The Indonesia-Malaysia region had the most divergent genotypes (IV and V) representing the 
oldest lineages and this region is geographically close to Australia, where MVEV, the closest 
relative to JEV, is found. Thus JEV originated in the Indonesia-Malaysia region from an 
ancestral virus common to JEV and MVEV. From this ancestral vims JEV genotypes IV and 
V diverged, followed by the more recent genotypes I, II and III. This is confirmed by the fact 
that the more recently divergent genotypes have spread to other areas, whereas the more 
divergent genotypes (IV and V) appear- geographically confined to the Indonesia-Malaysia 
region (Solomon et ah, 2003b).
Muar strain represents the only isolate of genotype V vims. However, we are not sure 
whether the Muar strain isolation was the results of a genotype V epidemic focus that quickly
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died off, or a genotype V strain that circulated in Malaysia for a period of time prior to 
extinction, or the Muar strain was a single imported case from another region.
We are not sure why the Muar strain, the more ancient lineage of JEV, has not spread but the 
host availability may help to explain this. For the arthropod-bome alphavirus, CHIKV, 
single amino acid changes in the E protein have been shown to be associated with a change in 
vector competence. Although the typical vector for CHIKV is Aedes aegypti, one mutation in 
the E protein gene has been shown to be responsiple for CHIKV adaptation to Ae. albopictus 
mosquitoes (Tsetsarkin et al, 2007).
JEV is a serious encephalitic disease which is caused by RNA vims that has high 
evolutionary rate which could lead to appearance of new genotypes and the more JEV 
diversity the harder it is to control. Understanding the immune responses against JEV’s 
prevention and recovery is very important to the development of new vaccines and specific 
treatment. Our present knowledge regarding JEV immune response is incomplete and some 
of the issues that remain to be addressed towards a fuller understanding of immune responses 
to JEV such as the effect of flavivims cross-reactive immunity in the protection against and 
pathogenesis of JE, the role of CTLs in infection by JEV, protective immunity against 
heterologous virus strains, protective immunity to be elicited by vaccine, protective immunity 
elicited by NS1 and roles of nonspecific immune responses.
Because of the complex life cycle of JEV, involving mosquito vectors and multiple vertebrate 
hosts, we do not expect that this virus is going to disappear altogether. However, further 
research, studying the pathogenesis of this virus, will help to the development of specific 
antiviral therapy and effective, safe and cheaper vaccine which could be administered orally 
as a single dose.
JE is the most vaccine-preventable disease, therefore vaccination against it ideally should be 
practiced in all areas of Asia where the virus is responsible for human disease and travellers 
to endemic areas should be vaccinated too. Inactivated viral vaccines prepared in mouse brain 
or cell culture have been used effectively for the last several decades to immunize travellers 
and residents of endemic countries. However, cost and safety concerns including allergic and 
neurologic complications, led to development of live attenuated vims vaccine (SAM-14-2) 
and more recently, a purified inactivated, tissue culture-based Japanese encephalitis vaccine
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(IXIARO®) has been licensed in the United states, Europe, Canada and Australia. In addition, 
IMOJEV®, a new vaccine was recently licensed in Australia and is under review in Thailand, 
which is a novel recombinant chimeric vims vaccine, developed using the yellow fever vims 
vaccine vector (YFV 17D), by replacing the cDNA encoding the envelope proteins of yellow 
fever virus with that of an attenuated Japanese encephalitis strain (SA14-14-2). IMOJEV was 
found to be safe, highly immunogenic and a single dose was sufficient to induce protective 
immunity, which was similar to that induced by three doses of a mouse brain derived 
inactivated JE vaccine. There is no doubt that these new vaccines, when appropriately 
administered, will greatly diminish the burden of disease (Bharati and Vrati, 2010).
Up to date, there is no licensed therapy available for JEV infection. Vaccination is considered 
to be the most effective control method. Thus, the WHO called for the development of novel, 
safe and more efficacious JE vaccines. Understanding JEV immunopathogenesis will not 
only help us to devolp more safe and cheap vaccine but also specific anti JEV therapy.
In summary, the complete genome sequence analysis of the Muar strain of JEV confirms that 
this strain represents a fifth genotype of JEV with approximately 20% nucleotide sequence 
divergence from other JEV strains. Evolutionary analysis suggested Muar represents the 
oldest JEV lineage and the four genotypes diverged from genotype V approximately at mid 
1500s. I showed the possibility of evolution of JEV from MVEV. I looked at the pattern of 
the geographical distribution of JEV isolates using the E gene and I showed that JEV strains 
are completely mixed up. Furthermore, intensive E gene sequence analysis of the Muar strain 
of JEV via determing its signature amino acids when compared with other JEV strains 
revealed why the Muar strain of JEV is different serologically from other JEV strains as it is 
representing the fifth antigenic group and it also explained why the Muar strain is confined to 
the Indonesia-Malaysia region and has not been found elsewhere. In addition, I found that the 
E protein of all five JEV genotypes is subjected to strong negative selection pressure, so 
selection pressure is unlikely to be the reason for the genotypic shift of this virus. 
Interestingly, I showed the high homology of the terminal nucleotide sequence of the 5' and 
3' NCRs of JE serocomplex, JEV, MVEV, WNV and SLEV, suggesting the important role 
played by these regions for viral proliferation. Prediction of the secondary structure of the 5' 
and 3' NCRs suggested that JEV genome ends could stick to each other. Finally, I showed in 
vitro that IVIGs are capable of neutralizing all five JEV genotypes at protective levels so they 
could be used for treatment of JEV but further in vivo studies are needed to know the exact
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dose and time of IVIGs administration. Understanding the immune response to JEV will help 
us to develop more specific and effective treatment therefore; vaccination remains the only 
way to protect from this disease.
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APPENDIX
APPENDIX A
Nucleotide Sequence of 5' NCR of the Muar Strain of JEV
(From 1 to 95)
5’ AGAAGTTTATCTGTGTGAACTTCTTGACTTAGTATCGTTGAGAGGAA 
TCGAGAGATTAGTGCAGTTTAAACAGTTTTTTAGAACGGAAGAAAACC 
3*
Nucleotide Sequence of C Gene of the Muar Strain of JEV
(From 96 to 476)
5’ ATGACTAAAAAACCAGGAGGGCCCGGTAGAAACCGGGCTATCAATA 
TGCTGAAACGCGGTTTACCCCGCGTATCCCCACTTGTGGGGGTGAAGA 
GGGTAATAATGAACTTGCTGGACGGCAGAGGGCCAATACGATTCGTTT 
TGGCTCTCTTGGCGTTTTTCAAGTTCACAGCATTGGCCCCAACTAAGGC 
ACTTATTAGCCGATGGAAAGCAGTAGAGAAGAGCGTCGCGATGAAAC 
ACCTCACCAGCTTCAAAAAGGAACTGGGAACGCTCATCAACGCTGTGA 
ATAAGAGGGGCAAAAAACAAAACAAAAGAGGAGGAAGTAATGGAACA 
ATTATTTGGATGATAGGTTTGGCAGTCGTGTTCGCCACTGTGAGTGCA 
3’
Nucleotide Sequence of vrM Gene of the Muar Strain of JEV
(From 477 to 977)
5’ GTCAAGCTGTCAAACTTTCAGGGCAAGGTGCTGATGACAATCAATAA 
CACCGACGTGGCTGATGTGATCACCATTCCCACCTCGAAAGGGACCAA 
TAGATGTTGGGTTCGGGCAATAGATGTGGGACACATGTGCGAGGACAC 
AATCACCTACGAAT GCCCTAAACTTGATGCTGGTAATGACCCAGAGGA 
CATTGACTGTTGGTGCGACAAACAAGCCGTGTATGTCCAGTATGGGCG 
TTGCACGAGGACCAGGCACTCCAGGAGAAGTAGAAGATCTGTGTCAGT 
GCAAACCCACGGAGAAAGCTCCCTAGTGAACAAAAAAGAAGCTTGGA 
TGGATTCGACGAAAGCCACGCGGTATCTCATGAAAACAGAAAATTGGA 
TCATACGGAATCCAGGCTATGCTCTCGTGGCAGTGGCACTCGGATGGA 
TGCTTGGCAGCAACAACGGCCAGCGTGTGGTGTTCACAATTCTCTTGTT 
GTTGGTCGCACCCGCATACAGC3’
Nucleotide Sequence of E Gene of the Muar Strain of JEV
(From 978 to 2477)
5’ TTTAACTGCCTAGGCATGGGCAACCGCGACTTCATTGAAGGAGTCAG 
CGGAGCCACGTGGGTAGACCTGGTGCTGGAAGGAGACAGTTGCCTCAC  
CATCATGGCGAACGATAAACCAACACTGGACGTGCGCATGATAAACAT
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TGAAGCCACGCAACTGGCTGAAGTACGAACCTATTGCTACCACGCTAC 
AGTGGCTGACATTTCAACAGTAGCAAGATGCCCCACGACTGGAGAAGC 
CCACAACACAAGACGAGCCGATAGCAGTTATGTTTGCAAGCAAGGCTA 
TACAGACCGTGGATGGGGAAACGGATGCGGGTTGTTTGGGAAAGGCA 
GCATTGACACATGCGCTAAATTTGTCTGCAGCCACAAGGCCATTGGGA 
AGATAATACAGCCAGAAAATATCAAATATGAAGTTGGAGTATTTGTCC 
ATGGAACCACAACAGCCGAGAACCATGGAAACTACTCCGCTC AGATT 
GGAGCTTCCCAGGCTGCCAAGTTCACCATCACGCCCAATGCTCCTTCC 
ATCACCCTGAAGCTTGGGGACTAC GGAGAAGTCACAATGGATTGCGA 
GCCTCGTAGTGGATTTAACACTGAAGCATTTTATGTGCTGACCGTTGG 
GACTAAGTCGTTTCTAGTCCATCGCGAATGGTTTAATGATTTGGCGCTT 
CCATGGCTGTCTCCATCTAGCACAAACTGGAGAAACAGAGAGATCTTG 
CTGGAATTTGAAGAAGCCCACGCGACGAAACAGTCTGTTGTTGCACTT 
GGATCACAAGAGGGAGCTCTACACCAGGCTCTGGCTGGCGCCATAGTG 
GTGGAGTATTCTAGCTCAGTGAAGTTAACTTCTGGCCACCTCAAATGT 
AGACTAAAAATGGACAAGTTGGCCTTGAAAGGAACCACCTATGGCATG 
TGCACAGAGAAGTTCTCCTTTTCGAAAAACCCAGCTGACACTGGTCAT 
GGCACGGTCGTCATAGAATTGCAGTACACTGGCACTGATGGACCGTGC 
AAGATACCCATCTCTTCAGTGGCCAGCCTGAATGATTTGACTCCAGTT 
GGCAGATTGGTGACAGTCAATCCTTTTGTTGCCACATCCACTGCCAACT 
CGAAAGTTTT GG TGGAACTTGAACCACCGTTTGGAGATTCATTCATTGT 
TGTTGGGAGAGGAGACAAGCAGATTAACCACCATTGGCACAAGGCAG 
GCAGTTCGCTGGGAAAGGCTTTTACCACTACCCTGAAAGGTGCCCAGA 
GGTTAGCTGCCCTTGGCGACACGGCCTGGGATTTTGGGTCCATTGGAG 
GAGTTT TTAATTCCATTGGCAAGGCCGTGCACCAGGTGTTTGGAG GAG 
CTTTTAGAACACTTTTTGGTGGCATGTCTTGGATAACACAAGGATTGAT 
GGGAGCACTGCTGCTGTGGATGGGTATCAATGCGCGAGACCGGTCGAT 
CGCACTGGCCTTTCTTGCTACAGGAGGCGTGCTCTTGTTTCTGGCTACC 
AATGTCCACGCT3’
Nucleotide Sequence of NS1 Gene of the Muar Strain of JEV
(From 2478 to 3533)
5’ GACACTGGCTGCGCCATTGATGTGACTAGGAAAGAAATGAGGTGCG 
GCAGTGGCATATTTGTGCACAATGATGTGGAGGCTTGGGTGGACAGAT 
ACAAGTATTTGCCTGAGACCCCCAAGTCTCTGGCCAAAATAGTTCACA 
AAGCACATAAGGA AGGCATTTGCGGAGTGAGATCAGTCACCAGGCTG 
GAACATCAAATGTGGGAAGCCGTCAGAGATGAGTTAAATGTCCTACTG 
AAGGAGAACGCAGTAGATCTTAGTGTGGTGGTGGACAAACCAGTGGG 
AAGATACCGACCAGCGCCACTGCGGCTATCCATGACCCAGGAAAAGTT 
TGAGATGGGTTGGAAAGCAT GGGGGAAGAGCATTCTCTTTGCACCAGA
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ACTAGCCAATT CAACATTTGTGATTGACGGACCCGAAACCAAAGAGTG 
TCCAGACGAGCGCAGAGCATGGAACAGCATGCAGATTGAAGACTTTGG 
GTTTGGCATCACGTCGACTCGAGTGTGGTTGAAGATCAGGGAGGAGCG 
CACGGATGAATGTGATGGCGCCATCATTGGCACGGCCGTCAAAGGAAA 
TATGGCGGTGCACAGTGACTTGTCATACTGGATTGAAAGCCATCTCAA 
TGACACCTGGAAACTTGAAAGAGCCGTGTTTGGAGAGATTAAATCGTG 
CACCTGGCCAGAAACACACACGCTTTGGGGAGATGGTGTTGAGGAAAG 
TGAGTTAATAATACCACACACGCTCGCAGGACCCAAAAGTAAGCACAA 
TAGA AG AG AGGG GTATA AAAC AC AGAA CC A AGG ACC ATGGG ATGAG AG 
TGAAATCACCCT T GACTTTGACTACTGTCCGGGGACAACAGTTACCAT 
TGC TGAAGGATGTGGAAAAAGAGGACCCTCAATCAGAACCACCACTG 
ACAGCGGGAAATTAATCACTGATTGGTGCTGTAGGAGCTGTACTTTGC 
CCCCGCTGAGATTTAGAACAGCCAGTGGCTGCTGGTATGGAATGGAAA 
TCCGGCCCATGAAGCATGACGAATCCACGCTTGTGA AG TCACAAGTCA 
A TGC A 3’
Nucleotide Sequence of NS2 Gene of the Muar strain of JEV
(From 3534 to 4607)
S’ TTCAATGGGGAGATGATTGATCCTTTTCAGTTGGGCCTTCTGGTGATC  
TTTCTGGCCACCCAGGAGGTCCTTCGCAAGAGGTGGACGGCCAGACTA 
ACGATCCCTGCGGTTTTGGGGGCCCTACTTGTTCTGATGCTTGGGGGCA 
TCACCTACACTGATCTGGTGAGATATGTGGTACTAGTGGCTGCTGCCTT 
CGCTGAAGCTAACAATGGAGGAGATGTGGTCCACTTGGCTCTGATCGC 
CGTTTTTAAGATTCAGCCGGCATTCCTAGTCATG AGCATAGCAAGTAC 
CAATTGGACTAACCAGGAGAACATTGCTTTAGTGCTAGGAGCTGCTTT 
CTTTCAGATGGCTTCAA CGGACTTGGAGTTTGGCATCCATGGGTTGCT 
GAACGCAGCGGCGACGGCCTGGATGGTGGTGCGGGCGATTACGTTCCC 
CACGACCTCCACCATCACGATGCCCATTCTAGCTTTGTTGGCACCAGG 
AATGAGAGCTCTTCATCTCGACACCTACAGAATTTTTCTGCTCATCATT 
GGAGTCTGTGCTCTGCTGCATGAAAGGAAGAAAACTATGGCAAAAAAG 
AAAGGTGCTGTCCTCTTAGGCCTGGCCCTCAGTTCTACTGGGTGGTTTT 
CACCAGCCATTATGGCTGCTGGGCTCATGGCTTGCAACCCAAACAAGA 
AAAGAGGATGGCCAGCGACAGAATTCCTGTCTGCAATTGGGCTAATGT 
TTGCCATTGTTGGGGGTCTGGCCGAGTTGGACATTGACTCCATGGCAAT 
ACCTTTTATGTTAGCTGG AC TTATGGCAGTGTCGTATGTGGTGTCAGGA 
AAAGCAACAGACATGTGGTTGGAACGCGCAGCCGACATTAGTTGGGAA 
GTGGACGCCGCGATCACAGGTAGCAGCCAGAGGTTGGATGTCAAATTG 
GATGACGATGGAGATTTCCATCTTATTGATGACCCAGGCGTCCCATGG 
AAAATTTGGGTATTGCGCATGTCTTGTATAGGATTGGCCGCCTTCACAC
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CATGGGCCATTATACCAGCAGCTTTTGGATACTGGCTGACCCTGAAAA
CCACGAAGAGG3’
Nucleotide Sequence of NS3 Gene of the Muar Strain of JEV
(From 4608 to 6464)
5’GGAGGCGTCTTCTGGGACACACCATCTCCCAAAGTCTACGCAAAAGG
AGATACAACCACAGGAGTGTACAGGATAATGGCGCGAGGGATCCTTGG
CGTCTACCAAGCAGGCGTCGGAGTGATGTATGAGAACGTGTTCCACAC
TCTCTGGCACACGACTAGAGGAGCCGCCATAATGAGTGGTGAAGGGAA
ACTAACACCGTACTGGGGAAGTGTCAAGGAAGACCGCATAACTTATGG
GGGTCCATGGAGATTCGACCGAAAATGGAATGGAGTGGATGACGTGCA
GATGATTGTCGTTGAACCAGGGAAGGCAGCCGTGAACGTCCAAACAAA
ACCAGGAGTGTTCCGGACCCCGCACGGAGAGATCGGAGCTGTCAGCTT
AGATTATCCTAGTGGGACATCAGGCTCACCCATCCTGGACGTCAACGG
TGACATTATTGGATTGTATGGAAACGGAGTTGAACTTGGAGATGGCTC
ATATGTAAGCGCCATTGTGCAGGGTGAACGTCAAGAGGAACCCGTCCC
TGATGCATACAATCCAAACATGCTCAAGAAAAGGCAGCTGACAGTGTT
GGACCTGCATCCAGGATCGGGCAAAACAAGGAAAATTTTGCCCCAAAT
CATCAGGGATGCTATTCAACAACGCCTCAGAACAGCTGTTTTGGCACC
CACTCGTGTCGTCGCGGCAGAGATGGCAGAAGCTCTGAGAGGACTCCC
CGTCAGATACCAAACTTCAGCGGTCCAGCGGGAACACCAGGGAAATGA
GATAGTTGATGTCATGTGTCATGCCACTCTAACGCATAGACTGATGTC
ACCAAACCGCGTTCCCAATTACAACTTGTTCGTTATGGATGAGGCTCA
CTTCACTGACCCAGCTAGCATTGCTGCAAGAGGATACATATCTACCAA
AGTGGAATTGGGAGAAGCTGCGGCTATTTTTATGACTGCCACTCCACC
CGGAACGACTGACCCGTTCCCGGACTCCAATGCTCCCATTCATGATTT
GCAGGACGAAATCCCTGACAGAGCATGGAGCAGTGGGTATGAATGGA
TAACTGAGTATGTGGGCAAGACAGTATGGTTTGTGGCGAGCGTAAAAA
TGGGCAATGAAATCGCAGTGTGCTTACAGAGAGCTGGGAAGAGGGTCA
TCCAGTTGAATCGGAAATCCTATGACACCGAGTACCCTAAATGTAAGA
ATGGGGATTGGGATTTTGTCATCACCACGGACATTTCTGAGATGGGGG
CCAACTTCGGAGCGAGCAGAGTGATTGATTGTAGGAAAAGTGTGAAAC
CCACCATTTTGGAGGAGGGAGAAGGAAGAGTCATTCTCAGTAATCCAT
CGCCCATCACCAGTGCGAGCGCAGCTCAGCGGAGAGGCAGAGTGGGC
AGAAATCCAAATCAGGTTGGGGATGAGTACCATTATGGAGGTACCACG
AGTGAGGATGACACCAACCTAGCCCACTGGACAGAAGCCAAGATCATG
CTTGATAACATCCACTTGCCAAATGGATTAGTAGCTCAACTTTATGGA
CCTGAAAGGGAGAAGGCCTTCACAATGGATGGTGAGTATCGATTGAGG
GGTGAGGAAAAGAAAAATTTTCTGGAGCTGATTAGAACAGCCGACCTC
CCAGTATGGCTGGCCTACAAAGTGGCGTCAAATGGAATACAATACACC
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GATCGGAGATGGTGTTTTGATGGTCCCCGGACGAATGCCATCTTAGAG
GACAGCACTGAAGTGGAGATAATCACCAGAATGGGAGAGAGAAAAAC
TCTAAAACCAAGATGGCTGGACGCACGTGTGTATGCGGATCACCAGGC
TCTGAAGTGGTTCAAGGACTTCGCGGCAGGGAAGAGA3’
Nucleotide Sequence of NS4 Gene of the Muar Strain of JEV
(From 6465 to 7679)
S’ TCAGCTGTCAGCTTTCTAGAGGTGCTTGGGCGCATGCCGGAACATTT 
CATGGGGAAAACTCGTGAAGCCCTTGACACAATGTACCTAGTTGCCAC 
AGCAGAGAAAGGGGGGAAAGCCCATCGAATGGCTCTAGAAGAATTGC 
CAGATGCACTGGAAACGGTGACACTCATTGCAGCGATAGCCGTGATGA 
CAGGTGGGTTCTTCTTGCTCATGATGCAACGAAAGGGGATAGGGAAAA 
TGGGCCTGGGCGCCCTTGTGCTCACCCTGGCCACCTTCTTCTTGTGGAT 
GGCAGAGGTATCAGGGACGAAAATAGCCGGAACCCTACTCATAGCACT 
GTTGCTCATGGTGGTACTCATTCCGGAGCCGGAGAAACAAAGATCCCA 
AACGGACAATCAGTTGGCCGTGTTCCTGATCTGCGTCCTAACTGTGGT 
AGGAATCGTGGCTGCTAATGAATATGGTATGCTTGAGAAGACAAAGGA 
AGACATAAGGAGCATCCTTGGCAACAGGGCTCAGACATCCAGCGTGCC 
TGGAAGTCTGTCAAGCCTGGCGCTCGATTTGCGACCAGCGACAGCTTG 
GGCTCTATACGGAGGCAGCACAGTGGTTTTAACTCCACTGCTGAAACA 
CTTGATCACTTCTGAGTATGTGACAACATCTCTAGCTTCAATCAACTCA 
CAGGCCGGCTCACTCTTTGTTCTACCAAGAGGCATGCCCTTCACAGATT 
TGGATCTGACGGTTGGACTCGTCTTTCTGGGCTGCTGGGGGCAAGTCA 
CTCTTACCACTTTTTTGACAGCTGGAGTGCTGGCAGTTTTGCACTACGG 
CTACATGCTCCCTGGGTGGCAAGCCGAAGCTTTGAGGGCAGCTCAAAG 
AAGAACAGCCGCGGGCATCATGAAGAACGCCGTTGTGGATGGGATGGT 
GGCCACTGACGTGCCAGAACTGGAAAG AACAACACCTCTAATGCAGA 
AAAAGGTGGGGCAAGTGTTGCTAATAGGAGTAAGCATAGCTGCTTTTC 
TCGTCAACCCTAATGTCACAACAGTACGAGAGGCCGGTGTGTTGGTGA 
CCGCCGCCACGCTCACCCTATGGGACAACGGAGCAAGTGCTGTTTGGA 
ATTCAACTACAGCCACAGGACTCTGCCACGTTATGCGAGGCAGCTACT 
TGGCTGGTGGTTCAATAGCCTGGACCCTCATTAAAAATGTTGATAAAC 
CATCTCTGAAAAGA3,
Nucleotide Sequence of NS5 Gene of the Muar Strain of JEV
(From 7680 to 10.394)
5’ GGAAGACCTGGAGGAAGAACGCTGGGTGAGCAATGGAAAGAAAGGT 
TGAACGCCATGAACAAGGAAGAGTTTTTTAAGTACAGGAAAGAAGCCA 
TAGTCGAGGTGGACCGCACAGAGGCACGCAGGGCTAGACGAGAGAAC
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AACAAAGTGGGAGGCCATCCCGTGTCACGAGGATCAGCAAAGCTCCGA 
TGGATAGTGGAGAAAGGGTTTGTCTCACCAGTTGGAAAGGTCGTAGAT 
CTTGGTTGCGGGCGGGGAGGTTGGTGCTATTATACAGCCACCCTGAAA 
AAAGTCCAGGAAGTCAAGGGTTACACAAAAGGAGGGGCTGGACATGA 
GGAACCTATGTTGATGCAAAGTTACGGCTGGAATTTGGTCACAATGAA 
GAGTGGAGTGGACGTGTTCTACAGACCTTCAGAGCCCAGTGACACCCT 
GCTCTGTGATATAGGGGAGTCTTCCCCAAGTCCTGACGTCGAAGAACA 
ACGCACTTTGCGAGTTTTGGAAATGGCATCAGAGTGGTTGCACCGAGG 
GCCCAGGGAATTTTGCATAAAAGTCCTATGTCCATACATGCCAAAGGT 
GATAGAAAAGATGGAAACACTGCAACGCCGCTTTGGAGGTGGACTGGT 
GCGTGTTCCTCTGTCACGCAATTCGAACCATGAGATGTACTGGGTCAG 
TGGAGCCGCTGGGAATGT GGTACACGCTGTAAACATGACCAGTCAAGT 
CTTGCTAGGGCGAATGGACCGAGCAGTCTGGAGAGGACCCAAATATGA 
GGAAGATGTTAACTTGGGAAGCGGGACTAGAGCTGTAGGAAAAGGTG 
AGGTTCACAGTGACCAAGGGAAAATAAAAAAGCGGATAGAGAAACTG 
AAAGATGAGTACGCAGCAACCTGGCATGAGGATCCAGAACACC CATA 
CCGCACCTGGACATACCATGGAAGTTACGAAGTGAAAGCCACCGGGTC 
AGCCAGCTCCCTTGTCAATGGAGTGGTAAAACTCATGAGCAAGCCTTG 
GGACGCCATCACCAGTGTCACCACTATGGCCATGACTGATACTACTCC 
TTTTGGTCAGCAGAGAGTTTTCAAAGAAAAGGTTGACACTAAAGCGCC 
TGAACCACCTGCAGGAGTCCGGGAAGTGCTGGACGAGACGACCAATTG 
GCTGTGGGCCTACCTATCAAGAGAGAAAAAACCTCGTTTGTGCACGAG 
AGAGGAATTTGTTCGGAAAGTCAACAGCAACGCGGCTCTTGGGGCCAT 
GTTTGCCGAGCAGAACCAATGGAGCTCAGCCAGAGAGGCTGTTAGCGA 
CCCGGCCTTCTGGGACATGGTTGACGTTGAAAGAGAGAACCACCTACG 
AGGGGAGTGCCATACTTGCATCTATAACATGATGGGGAA AAGAGAAA 
AGAAACCCGGTGAGTTTGGGAAGGCCAAGGGAAGCAGGGCCATCTGG 
TTCATGTGGCTT GGAGCTCGCTACCTGGAATTTGAGGCACTTGGGTTC 
TTGAACGAGGACCATTGGTTGAGTAGGGAGAATTCAGGAGGAGGAGT 
GGAAGGCTCAGGCATACAGAAGCTAGGGTACATCCTGCGAGACATCTC 
AATGAAAGCTGGAGGAAAAATGTATGCTGATGACACAGCTGGCTGGG 
ACACTAGGATCACAAGGGTTGATCTGGACAATGAGGCGAAGGTACTAG 
AGCTCTTGGATGGGGAACATAGGATGTTGGCCCGTGCCATAATAGAAT 
TGACCTACAAACACAAAGTTGTCAAAGTGATGAGGCCAGCAGCCGGTG 
GAAAGACTGTAATGGATGTGATCTCCAGAGAAGACCAAAGAGGGAGT 
GGACAAGTGGTTACATATGCTCTTAACACCTTCACAAACATAGCCGTC 
CAACTGGTAAGGTTAATGGAGGCAGAAGG AGTTGTTGGCCCGCAGGA 
CGTAGAACAGCTCCCAAGAAAAACCAAGTTTGCAGTCAGGACATGGCT 
TTTTGAAAATGGAGAGGAGAGAGTCACCAGAATGGCAGTAAGTGGGG 
ATGATTGTGTTGTCAAACCACTCGATGACAGATTCGCGAATGCTCTGC
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ATTTCTTGAATGCGATGTCAAAGGTGAGGAAAGACATACAGGAATGGA 
AACCATCTCAAGGCTGGCATGACTGGCAGCAAGTCCCTTTCTGCTCAA 
ATCATTTCCAGGAGATCGTGATGAAAGATGGCAGAAGCCTCGTCGTGC 
CCTGCCGGGGACAGGATGAATTAATAGGCAGAGCCCGGATTTCACCA 
GGAGCAGGATGGAACGTGAGAGACACGGCCTGCTTAGCCAAGGCATA 
CGCCCAAATGTGGCTCCTCCTCTATTTCCACCGGAGAGACCTGCGCCTC 
ATGGCCAACGCAATCTGTTCAGCTGTTCCAGTAGACTGGGTGCCCACA 
GGCCGGACTTCATGGTCGATACACTCAAAAGGAGAATGGATGACAACA 
GAAGACATGTTGCAGGTGTGGAACAGAG TATGGATTGAAGAGAATGA 
ATGGATGAGAGACAAAACTCCCGTCGCCAGTTGGACCGACGTTCCTTA 
CGTCGGGAAAAGGGAAGACATCTG GTGTGGCAGCTTGATCGGAACGC 
GAACAAGAGCTACCTGGGCAGAGAACATCTATGCAGCAATCAACCAA 
GTGAGGGCAATAATTGGAAACGAAAAGTATGTGGACTACATGACATCA 
CTCAGGAGGTATGAAGACACTTTGGTCCAGGAAGATAGAGTCATT3’
Nucleotide Sequence of 3’ NCR of the Muar Strain of JEV
(From 10.395 to 10.988)
5’TAAAGAACTCTTGAAAACAAATGTAAATAGTAGTAATTGTTTAGTGT 
AAATAGTGTAAATAAATAAATTTAGATAGGAAGTCAGGCCGACGCGAG 
TCGCCACCGGAAGCTGAGTAGACGGTGCTGCCTGCGCCTCAGCCCCAG 
GAGGACTGGGTTAACAAATCTGACAACCGAAGGTAGGAAAGCCCTCA 
GAACCGTCTCGGAAGAAGGTCCCTGCTTACTGGAGGTTGGAAGACCGT 
GTCAGGCCACGTAAGTGCCACTTCGCTGAGGAGTGCAGCCTGTACAGC 
CCCGGGAGGACCGGGTAAACAAAGCCGAAAAGGCCCCCACGGCCCAA 
ACCTCATCTAGGATGCAATAGATGAGGCGTAAGGACTAGAGGTTAGAG 
GAGACCCCGTGGAAAAGAAGATGCGGCCCAAACTCTTTCGAAGCTGTA 
GAAGGAGTGGAAGGACTAGAGGTTAGAGGAGACCCCGCATTTGCATC 
AAAACAGCATATTGACACCTGGGATTAGACTAGGAGATCTTCTGATCT 
ATCTCAACATCAGCTACA AG GCACCGAGCGCCGAAGTATGTAGCTGGT 
GGTGGGGAAGAACACAGGATCT35
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APPENDIX B
Amino Acid Sequence of C Protein of the Muar Strain of JEV
5’MTKKPGGPGRNRAINMLKRGLPRVSPLVGVKRVIMNLLDGRGPIRFVL
ALLAFFKFTALAPTKALISRWKAVEKSVAMKHLTSFKKELGTLINAVNK
RGKKQNKRGGSNGTIIWMIGLAVVFATVSA3’
Amino Acid Sequence ofvrM Protein of the Muar Strain of JEV
S’ VKLSNFQGKVLMTINNTDVADVITIPTSKGTNRCWVRAIDVGHMCEDT 
ITYECPKLDAGNDPEDIDCWCDKQAVYVQYGRCTRTRHSRRSRRSVSVQ 
THGESSLVNKKEAWMDSTKATRYLMKTENWIIRNPGYALVAVALGWML 
GSNNGQRVVFTILLLLVAPAYS3’
Amino Acid Sequence ofE Glvcovrotein of the Muar Strain of JEV
5’FNCLGMGNRDFIEGVSGATWVDLVLEGDSCLTIMANDKPTLDVRMINI 
EATQLAEVRTYCYHATVADISTVARCPTTGEAFINTRRADSSYVCKQGYT 
DRGWGNGCGLFGKGSIDTCAKFVCSHKAIGKIIQPENIKYEVGVFVHGTT 
TAENHGNYSAQIGASQAAKFTITPNAPSITLKLGDYGEVTMDCEPRSGFN 
TEAFYVLTVGTKSFLVHREWFNDLALPWLSPSSTNWRNREILLEFEEAHA 
TKQSVVALGSQEGALHQALAGAIVVEYSSSVKLTSGHLKCRLKMDKLAL 
KGTTYGMCTEKFSFSKNPADTGHGTVVIELQYTGTDGPCKIPISSVASLN 
DLTPVGRLVTVNPFVATSTANSKVLVELEPPFGDSFIVVGRGDKQINHHW 
HKAGSSLGKAFTTTLKGAQRLAALGDTAWDFGSIGGVFNSIGKAVHQVF 
GGAFRTLFGGMSWITQGLMGALLLWMGINARDRSIALAFLATGGVLLFL 
ATN VHA3’
Amino Acid Sequence of NS1 Protein of the Muar Strain of JEV
S’ DTGCAIDVTRKEMRCGSGIFVHNDVEAWVDRYKYLPETPKSLAKIVHK 
AHKEGICGVRSVTRLEHQMWEAVRDELNVLLKENAVDLSVVVDKPVGR 
YRPAPLRLSMTQEKFEMGWKAWGKSILFAPELANSTFVID GPETKECPD 
ERRAWNSMQIEDFGFGITSTRVWLKIREERTDECDGAIIGTAVKGNMAVH 
SDLSYWIESHLNDTWKLERAVFGEIKSCTWPETHTLWGDGVEESELIIPH 
TLAGPKSKHNRREGYKTQNQGPWDESEITLDFDYCPGTTVTIAEGCGKR 
GPSIRTTTDSGKLITDWCCRSCTLPPLRFRTASGCWYGMEIRPMKHDEST 
L VKSQ VNA3’
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Amino Acid Sequence of NS2 Protein of the Muar Strain of JEV
5’FNGEMIDPFQLGLLVIFLATQEVLRKRWTARLTIPAVLGALLVLMLGGI 
TYTDL VRYVVLVAAAFAEANNGGDVVHLALIAVFKIQPAFLVMSIASTN 
WTNQENIALVLGAAFFQMASTDLEFG I HGLLNAAATAWMVVRAITFPTT 
STITMPILALLAPGMRALHLDTYRIFLLIIGVCALLHERKKTMAKKKGAV 
LLGLALSSTGWFSPAIMAAGLMACNPNKKRGWPATEFLSAIGLMFAIVG 
GLAELDIDSMAIPFMLAGLMAVSYVVSGKATDMWLERAADISWEVDAAI 
TGSSQRLDVKLDDDGDFHLIDDPGVPWKIWVLRMSCIGLAAFTPWAIIPA 
AFGYWLTLKTTKR3’
Amino Acid Sequence of NS3 Protein of the Muar Strain of JEV
5’ GGVFWDTPSPKVYAKGDTTTGVYRIMARGILGVYQAGVGVMYENVFH 
TLWHTTRGAAIMSGEGKLTPYWGSVKEDRITYGGPWRFDRKWNGVDDV 
QMIVVEPGKAAVNVQTKPGVFRTPHGEIGAVSLDYPSGTSGSPILDVNGD 
IIGLYGNGVELGDGSYVSAIVQGERQEEPVPDAYNPNMLKKRQLTVLDL 
HPGSGKTRKILPQIIRDAIQQRLRTAVLAPTRVVAAEMAEALRGLPVRYQ 
TSAVQREHQGNEIVDVMCHATLTFIRLMSPNRVPNYNLFVMDEAHFTDPA 
SIAARGYISTKVELGEAAAIFMTATPPGTTDPFPDSNAPIHDLQDEIPDRA 
WSSGYEWITEYVGKTVWFVASVKMGNEIAVCLQRAGKRVIQLNRKSYD 
TEYPKCKNGDWDFVITTDISEMGANFGASRVIDCRKSVKPTILEEGEGRV 
ILSNPSPITSASAAQRRGRVGRNPNQVGDEYHYGGTTSEDDTNLAHWTE 
AKIMLDNIHLPNGLVAQLYGPEREKAFTMDGEYRLRGEEKKNFLELIRTA 
DLPVWLAYKVASNGIQYTDRRWCFDGPRTNAILEDSTEVEIITRMGERKT 
LKPRWLDARVYADHQALKWFKDFAAGKR3’
Amino Acid Sequence of NS4 Protein of the Muar Strain of JEV
5’ SAVSFLEVLGRMPEHFMGKTREALDTMYLVATAEKGGKAHRMALEEL 
PDALETVTLIAAIAVMTGGFFLLMMQRKGIGKMGL GALVLTLATFFLWM 
AEVSGTKIAGTLLIALLLMVVLIPEPEKQRSQTDNQLAVFLICVLTVVGIV 
AANEYGMLEKTKEDIRSILGNRAQTSSVPGSLSSLALDLRPATAWALYGG 
STVVLTPL LKHLITSEYVTTSLASINSQAG SLFVLPRGMPFTDLDLTVGL 
VFLGCWGQVTLTTFLTAGVLAVLFIYGYMLPGWQAEALRAAQRRTAAGI 
MKNAVVDGMVATDVPELERTTPLMQKKVGQVLLIGVSIAAFLVNPNVTT 
VREAGVLVTAATLTLWDNGASAVWNSTTATGLCHVMRGSYLAGGSIAW 
TLIKN VDKPSLKR3’
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Amino Acid Sequence of NS5 Protein of the Muar Strain of JEV
5’ GRPGGRTLGEQWKERLNAMNKEEFFKYRKEAIVEVDRTEARRARREN 
NKVGGHPVSRGSAKLRWIVEKGFVSPVGKVVDLGCGRGGWCYYTATLK 
KVQEVKGYTKGGAGHEEPMLMQSYGWNLVTMKSGVDVFYRPSEPSDTL 
LCDIGESSPSPDVEEQRTLRVLEMASEWLHRGPREFCIKVLCPYMPKVIE 
KMETLQRRFGGGLVRVPLSRNSNHEMYWVSGAAGNVVPIAVNMTSQVLL 
GRMDRAV WRGPKYEEDVNLGSGTRAVGKGEVHSDQGKIKKRIEKLKDE 
YAATWHEDPEHPYRTWTYHGSYEVKATGSASSLVNGVVKLMSKPWDAI 
TSVTTMAMTDTTPFGQQRVFKEKVDTKAPEPPAGVREVLDETTNWLWA 
YLSREKKPRLCTREEFVRKVNSNAALGAMFAEQNQWSSAREAVSDPAFW 
DMVDVERENHLRGECHTCIYNMMGKREKKPGEFGKAKGSRAIWFMWLG 
ARYLEFEALGFLNEDHWLSRENSGGGVEGSGIQKLGYILRDISMKAGGK 
MYADDTAGWDTRITRVDLDNEAKVLELLDGEHRMLARAIIELTYKHKVV 
KVMRPAAGGKTVMDVISREDQRGSGQVVTYALNTFTNIAVQLVRLMEA 
EGVVGPQDVEQLPRKTKFAVRTWLFENGEERVTRMAVSGDDCVVKPLD 
DRFANALHFLNAMSKVRKDIQEWKPSQGWHDWQQVPFCSNHFQEIVMK 
DGRSLVVPCRGQDELIGRARISPGAGWNVRDTACLAKAYAQMWLLLYF 
HRRDLRLMANAICSAVPVDWVPTGRTSWSIHSKGEWMTTEDMLQVWNR 
VWIEENEWMRDKTPVASWTDVPYVGKREDIWCGSLIGTRTRATWAENIY 
A A IN QVRAII GNEK Y VD YMTSLRRYEDTL VQEDRVI3’
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APPENDIX C
The differences in the nucleotide sequence of the three structural genes (C, prM and E) 
between Muar (A), sequenced by Hasegawa et ah (1994), and Muar (B) sequenced by me. 
(different nucleotides are underlined)
Muar (A) AT GAG T AAAA AACCAGGAGG GCCCGGTAGA AACCGGGCTA TCAATATGCT
Muar(B) ATGACTAAAA AACCAGGAGG GCCCGGTAGA AACCGGGCTA TCAATATGCT
Muar(A) GAAACGCGGT TTACCCCGCG TATTCCCACT TGTGGGGGTG AAGAGGGTAA
Muar(B) GAAACGCGGT TTACCCCGCG _ TATCCCCACT TGTGGGGGTG AAGAGGGTAA
Muar(A) TAATGAACTT GCTGGACGGC AGAGGGCCAA TACGATTCGT TTTGGCTCTC
Muar(B) TAATGAACTT GCTGGACGGC AGAGGGCCAA TACGATTCGT TTTGGCTCTC
Muar(A) TTGGCGTTTT TCAAGTTCAC AGCATTGGCC CCAACTAAGG CACTTATTAG
Muar{B) TTGGCGTTTT TCAAGTTCAC AGCATTGGCC CCAACTAAGG C AC T TAT TAG
Muar(A) CCGATGGAAA GCAGTAGAGA AGAGCGTCGC GATGAAACAC CTCACCAGCT
Muar (B) CCGATGGAAA GCAGTAGAGA AGAGCGTCGC GATGAAACAC CTCACCAGCT
Muar (A) TCAAAAGAGA ACTGGGAACG CTCATCAACG CTGTGAATAA GAGGGGCAAA
Muar(B) TCAAAAAGGA ACTGGGAACG CTCATCAACG CTGTGAATAA GAGGGGCAAA
Muar(A) AAACAAAACA AAAGAGGAGG AAATAATGGC TCAATTATTT GGATCGTAGG
Muar(B) AAACAAAACA AAAGAGGAGG AAGTAAT GGA ACAATTATTT GGATGATAGG
Muar(A) TTTGGCAGTC GTCATAGCAT GCGCAGGAGC AATGAAGCTG TCGAATTTCC
Muar(B) TTTGGCAGTC GTGTTCGCCA CTGTGAGTGC AGTCAAGCTG TCAAACTTTC
Muar(A) AGGGGCAGCT GCTGATGACC ATCAACAACA CGGACATTGC TGATGTGATC
Muar(B) AGGGCAAGGT GCTGATGACA ATCAATAACA CCGACGTGGC TGATGTGATC
Muar(A) GTGATTCCCA CCTCGAAAGG AGAGAATAGA TGTTGGGTTC GGGCAATAGA
Muar(B) ACCATTCCCA CCTCGAAAGG GACCAATAGA TGTTGGGTTC GGGCAATAGA
Muar(A) TGTCGGCAAC ATGTGTGAGG ACACAATCAC CTACGAATGC CCTAAGCTCA
Muar(B) TGTGGGACAC ATGTGCGAGG ACACAATCAC CTACGAATGC CCTAAACTTG
Muar(A) CCATGGGTAA TGACCCAGAG GACATTGACT GTTGGTGCGA CAAACAAGCC
Muar(B) ATGCTGGTAA TGACCCAGAG GACATTGACT GTTGGTGCGA CAAACAAGCC
Muar(A) GTCTATGTCC AGTATGGGCG GTGCACGAGG ACCAGGCACT CCAGGAGAAG
Muar(B) GTGTATGTCC AGTATGGGCG TTGCACGAGG ACCAGGCACT CCAGGAGAAG
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Muar(A) 
Muar(B)
TAGAAGATCT GTGTCAGTGC AAACCCACGG AGAAAGCTCC CTAGTGAACA 
TAGAAGATCT GTGTCAGTGC AAACCCACGG AGAAAGCTCC CTAGTGAACA
Muar(A) 
Muar(B)
AAAAAGAAGC TTGGATGGAT TCGACGAAAG CCACGCGGTA TCTCATGAAA 
AAAAAGAAGC TTGGATGGAT TCGACGAAAG CCACGCGGTA TCTCATGAAA
Muar(A) 
Muar(B)
ACAGAAAATT GGATCATACG GAATCCAGGC TATGCTCTCG TGGCAGTGGC 
ACAGAAAATT GGATCATACG GAATCCAGGC TATGCTCTCG TGGCAGTGGC
Muar (A) 
Muar(B)
ACTCGGATGG ATGCTTGGCA GCAACAACGG CCAGCGTGTG GTGTTCACAA 
ACTCGGATGG ATGCTTGGCA GCAACAACGG CCAGCGTGTG GTGTTCACAA
Muar(A) 
Muar(B)
TTCTCCTGTT GTTGGTCGCA CCCGCATACA GCTTTAACTG CCTAGGCATG 
TTCTCTTGTT GTTGGTCGCA CCCGCATACA GCTTTAACTG CCTAGGCATG
Muar (A) 
Muar(B)
GGCAACCGCG ACTTCATTGA AGGAGTCAGC GGAGCCACGT GGGTAGACCT 
GGCAACCGCG ACTTCATTGA AGGAGTCAGC GGAGCCACGT GGGTAGACCT
Muar(A) 
Muar(B)
GGTGCTGGAA GGAGACAGTT GCCTCACCAT CATGGCGAAC GATAAACCAA 
GGTGCTGGAA GGAGACAGTT GCCTCACCAT CATGGCGAAC GATAAACCAA
Muar(A) 
Muar(B)
CACTGGACGT GCGCATGATA AACATTGAAG CCACGCAACT GGCTGAAGTC 
CACTGGACGT GCGCATGATA AACATTGAAG CCACGCAACT GGCTGAAGTA
Muar(A) 
Muar(B)
AGAACCTATT GCTACCACGC TACAGTGGCT GACATTTCAA CAGTAGCAAG 
CGAACCTATT GCTACCACGC TACAGTGGCT GACATTTCAA CAGTAGCAAG
Muar(A) 
Muar(B)
ATGCCCCACG ACTGGAGAAG CCCACAACAC AAGACGAGCC GATAGCAGTT 
ATGCCCCACG ACTGGAGAAG CCCACAACAC AAGACGAGCC GATAGCAGTT
Muar (A) 
Muar(B)
ATGTTTGCAA GCAAGGCTAT ACAGACCGTG GATGGGGAAA CGGATGCGGG 
ATGTTTGCAA GCAAGGCTAT ACAGACCGTG GATGGGGAAA CGGATGCGGG
Muar (A) 
Muar(B)
TTGTTTGGGA AAGGCAGCAT TGACACATGC GCAAAATTGT CCTGCAGCAG 
TTGTTTGGGA AAGGCAGCAT TGACACATGC GCTAAATTTG TCTGCAGCCA
Muar (A) 
Muar(B)
CAAAGCGATT GGGAAGATAA TACAGCCAGA AAATATCAAA TATGAAGTTG 
CAAGGCCATT GGGAAGATAA TACAGCCAGA AAATATCAAA TATGAAGTTG
Muar(A) 
Muar(B)
GCATATTTGT CCATGGAACC ACAACAGCCG AGAACCATGG AAATTACTCC 
GAGTATTTGT CCATGGAACC ACAACAGCCG AGAACCATGG AAACTACTCC
Muar(A) 
Muar(B)
GCTCAAGTTG GAGCTTCCCA GGCTGCAAAG TTCACCATCA CGCCCAATGC 
GCTCAGATTG GAGCTTCCCA GGCTGCCAAG TTCACCATCA CGCCCAATGC
Muar(A) TCCTTCCATC ACCCTGAAGC TTGGGGACTA CGGAGAAGTC ACAATGGATT
Muar(B) TCCTTCCATC ACCCTGAAGC TTGGGGACTA CGGAGAAGTC ACAATGGATT
Muar(A) GCGAGCCTCG TAGTGGATTT AACACTGAAG CATTTTATGT GCTGACCGTT
Muar(B) GCGAGCCTCG TAGTGGATTT AACACTGAAG CATTTTATGT GCTGACCGTT
Muar(A) GGGACTAAGT CGTTTCTAGT CCATCGCGAA TGGTTTAATG ATTTGGCGCT
Muar(B) GGGACTAAGT CGTTTCTAGT CCATCGCGAA TGGTTTAATG ATTTGGCGCT
Muar(A) CCCCTGGCTG TCTCCATCTA GCACAAACT G GAGAAACAGA GAGATCTTGC
Muar(B) TCCATGGCTG TCTCCATCTA GCACi\AA.CTG GAGAAACAGA GAGATCTTGC
Muar(A) TGGAATTTGA AGAAGCCCAC GC GAC GAAAC AGTCTGTTGT TGCACTTGGA
Muar(B) TGGAATTTGA AGAAGCCCAC GCGACGAAAC AGTCTGTTGT TGCACTTGGA
Muar(A) TCACAAGAGG GAGCTCTACA CCAGGCTCTG GCTGGCGCCA TAGTGGTGGA
Muar(B) TCACAAGAGG GAGCTCTACA CCAGGCTCTG GCTGGCGCCA TAGTGGTGGA
Muar(A) GTATTCTAGC TCAGTGAAGT TAACTTCTGG CCACCTCAAA TGTAGACTAA
Muar(B) GTATTCTAGC TCAGTGAAGT TAACTTCTGG C CACC T CAAA TGTAGACTAA
Muar(A) AAATGGACAA GTTGGCTCTG AAAGGAACCA CCTATGGCAO? GTGCACAGAG
Muar <B) AAATGGACAA GTTGGCCTTG AAAGGAACCA CCTATGGCAT GTGCACAGAG
Muar(A) AAGTTCTCCT TTTCGAAAAA CCCAGCTGAC ACTGGTCATG GCACGGTCGT
Muar(B) AAGTTCTCCT TTTCGAAAAA CCCAGCTGAC ACTGGTCATG GCACGGTCGT
Muar (A) CATAGAATTG CAGTACACTG GCACTGATGG ACCGTGCAAG ATACCCATCT
Muar(B) CATAGAATTG CAGTACACTG GCACTGATGG ACCGTGCAAG ATACCCATCT
Muar (A) CTTCAGTGGC CAGCCTGAAT GATTTGACTC CAGTTGGCAG ATTGGTGACA
Muar(B) CTTCAGTGGC CAGCCTGAAT GATTTGACTC CAGTTGGCAG AT TGGTGACA
Muar (A) GTCAATCCTT TTGTTGCCAC ATCCACTGCC AACTCGAAAG TTTTGGTGGA
Muar(B) GTCAATCCTT TTGTTGCCAC ATCCACTGCC AACTCGAAAG TTTTGGTGGA
Muar(A) ACTTGAACCA CCGTTTGGAG ATTCATTCAT TGTTGTTGGG AGAGGAGACA
Muar(B) ACTTGAACCA CCGTTTGGAG ATTCATTCAT TGTTGTTGGG AGAGGAGACA
Muar(A) AGCAGATTAA CCACCATTTG CACAAGGTCG GAAGCACGCT GGGCAAGGCG
Muar(B) AGCAGATTAA CCACCATTGG CACAAGGCAG GCAGTTCGCT GGGAAAGGCT
Muar (A) TTCTCAACGA CGTTGAAAGG AGCTCAAAGA CTGGCTGTGT TGGGCGATAC
Muar(B) TTTACCACTA CCCTGAAAGG TGCCCAGAGG TTAGCTGCCC TTGGCGACAC
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Muar(A) GGACTGGGAC TTCGGCTCTA CTGGAGGGGT CTTCAATTCT ATAGGCAAGG
Muar(B) GGCCTGGGAT TTTGGGTCCA TTGGAGGAGT TTTTAATTCC ATTGGCAAGG
Muar(A) 
Muar(B)
CCGTTCACCA CGTGTTCGGC GGTACCTTCA GAAGCCTCTT 
CCGTGCACCA GGTGTTTGGA GGAGCTTTTA GAACACTTTT
TGGAGGAATG
TGGTGGCATG
Muar(A) 
Muar(B)
TCCTGGATAA CACAAGGACT AATGGGGGCT CTACTCCTCT GGATGGGGGT 
TCTTGGATAA CACAAGGATT GATGGGAGCA CTGCTGCTGT GGATGGGTAT
Muar(A) 
Muar(B)
CAAAGCACGA GACGGATCAA TCGCTTTAGC CTTTTTAGGC ACAGGGGGTG 
CAATGCGCGA GACCGGTCGA TCGCACTGGC CTTTCTTGCT ACAGGAGGCG
Muar (A) 
Muar(B)
TGCTTGTATT CTTGGCGACC AACGTGCATG CT 
TGCTCTTGTT TCTGGCTACC AATGTCCACG CT
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APPENDIX D
The differences in the amino acid sequence of the three structural genes (C, prM and E) 
between Muar (A), sequenced by Hasegawa et al. (1994), and Muar (B) sequenced by me. 
(different amino acids are underlined)
Muar (A) MTKKPGGPGR NRAINMLKRG LPRVFPLVGV KRVIMNLLDG RGPIRFVLALMuar (B) MTKKPGGPGR NRAINMLKRG LPRVSPLVGV KRVIMNLLDG RGPIRFVLAL
Muar (A) IiAFFKF TAIiA PTKALISRWK AVEKSVAMKH LTSFKRELGT LINAVNKRGKMuar (B) LAFFKF TALA PTKAXiISRWK AVEKSVAMKH LTSFKKELGT LINAVNKRGK
Muar (A) KQNKRGGNNG SIIWIVGLAV VIACAGAMKL SNFQGQLLMT INNTDIADVIMuar <B) KQNKRGGSNG TIIWMIGLAV VFATVSAVRL SNFQGKyiMT INNTDVADVI
Muar (A) VIPTSKGENR CWVRAIDVGN MCEDTITYEC PKLTMGNDPE DIDCWCDKQAMuar (B) TIPTSKGTNR CWVRAIDVGH MCEDTITYEC PKLDAGNDPE DIDCWCDKQA
Muar (A) VYVQYGRCTR TRHSRRSRRS VSVQTHGESS LVNKKEAWMD STKATRYLMKMuar (B) VYVQYGRCTR TRHSRRSRRS VSVQTHGESS LVNKKEAWMD STKATRYLMK
Muar (A) TENWIIRNPG YALVAVALGW MLGSNNGQRV VFTILLLLVA PAYSFNCLGMMuar (B) TENWIIRNPG YAIiVAVALGW MLGSNNGQRV VFTILLLLVA PAYSFNCLGM
Muar (A) GNRDFIEGVS GATWVDLVLE GDSCLTIMAN DKPTLDVRMI NIEATQLAEVMuar (B) GNRDFIEGVS GATWVDLVLE GDSCLTIMAN DKPTLDVRMI NIEATQLAEV
Muar (A) RTYCYHATVA DISTVARCPT TGEAHNTRRA DSSYVCKQGY TDRGWGNGCGMuar (B) RTYCYHATVA DISTVARCPT TGEAHNTRRA DSSYVCKQGY TDRGWGNGCG
Muar (A) LFGKGSXDTC AKLSCSSKAI GKIIQPENIK YEVGIFVHGT TTAENHGNYSMuar (B) LFGKGSIDTC AKFVCSHKAI GKIIQPENIK YEVGVFVHGT TTAENHGNYS
Muar (A) AQVGASQAAK FTITPNAPSI TLKLGDYGEV TMDCEPRSGF NTEAFYVLTVMuar (B) AQIGASQAAK FTITPNAPSI TLKLGDY GEV TMDCEPRSGF NTEAFYVLTV
Muar (A) GTKSFLVHRE WFNDLALPWL SPSSTNWRNR EILLEFEEAH ATKQSWALGMuar (B) GTKSFLVHRE WFNDLALPWL SPSSTNWRNR EILLEFEEAH ATKQSWALG
Muar (A) SQEGALHQAL AGAIWEYSS SVKLTSGHLK CRLKMDKLAL KGTTYGMCTEMuar (B) SQEGALHQAL AGAIWEYSS SVKLTSGHLK ORT iTCNTOTC 11 AY ^ KGTTYGMCTE
Muar (A) KFSFSKNPAD TGHGTWIEL QYTGTDGPCK IPISSVASLN DLTPVGRLVTMuar (B) KFSFSKNPAD TGHGTWIEL QYTGTDGPCK IPISSVASLN DLTPVGRLVT
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Muar {A) 
Muar <B)
VNPFVATSTA NSKVLVELEP 
VNPFVATSTA NSKVLVELEP
PFGDSFIWG RGDKQINHHL HKVGSTLGKA 
PFGDSFIWG RGDKQINHHW HKAGSSLGKA
Muar (A) 
Muar (B)
FSTTLKGAQR IAVLGDTDWD FGSTGGVFNS 
FTTTLKGAQR LAALGDTAWD FGSIGGVFNS
IGKAVHHVFG GT FRTLFGQyl 
IGKAVHQVFG GAFRTLFGGM
Muar (A) SWITQGLMGA LLL'WMGVKAR DGSIALAFLG TGGVLVFLAT NVHA
Muar (B) SWITQGLMGA LLLWMGINAR DRSIALAFLA TGGVLLFLAT NVHA
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Japanese encephalitis virus (JEV) is the most important cause of epidemic encephalitis worldwide but its 
origin is unknown. Epidemics of encephalitis suggestive of Japanese encephalitis (JE) were described in 
Japan from the 1870s onwards. Four genotypes of JEV have been characterised and representatives of 
each genotype have been fully sequenced. Based on limited information, a single isolate from Malaysia is 
thought to represent a putative fifth genotype. We have determined the complete nucleotide and amino 
acid sequence of Muar strain and compared it with other fully sequenced JEV genomes. Muar was the 
least similar, with nucleotide divergence ranging from 20.2 to 21.2% and amino acid divergence ranging 
from 8.5 to 9.9%. Phylogenetic analysis of Muar strain revealed that it does represent a distinct fifth 
genotype of JEV. We elucidated Muar signature amino acids in the envelope (E) protein, including E327 
Glu on the exposed lateral surface of the putative receptor binding domain which distinguishes Muar 
strain from the other four genotypes. Evolutionary analysis of full-length JEV genomes revealed that the 
mean evolutionary rate is 4.35 x 10 4 (3.4906 x 10 4 to 5.303 x 10 4) nucleotides substitutions per site 
per year and suggests JEV originated from its ancestral virus in the mid 1500s in the Indonesia-Malaysia 
region and evolved there into different genotypes, which then spread across Asia. No strong evidence for 
positive selection was found between JEV strains of the five genotypes and the E gene has generally been 
subjected to strong purifying selection.
© 2011 Elsevier B.V. All rights reserved.
1. Introduction
The genus Flavivirus, family Flaviviridae are important human 
pathogens that include a number of emerging and re-emerging 
pathogens such as Japanese encephalitis virus UEV), West Nile 
virus (WNV), St. Louis encephalitis virus (SLEV), Kunjin virus 
(KUNV), Murray Valley encephalitis virus (MVEV), yellow fever 
virus (YFV) and dengue viruses (DENV). They cause a variety of 
diseases ranging from mild febrile illness to severe encephalitis 
and hemorrhagic fever (Mishra and Basu, 2008). The most 
important cause of epidemic encephalitis worldwide is JEV, with 
an estimated 35,000-50,000 cases and 10,000 deaths annually 
(Tsai, 2000).
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JEV is a member of the JE serogroup of flaviviruses and is 
transmitted between vertebrate hosts by mosquitoes, principally 
by Culex species especially Cu/ex tritaeniorhynchus (Yun et al., 
2003). The virus is maintained mainly between vector mosquitoes 
and wading birds, with pigs also acting as amplifying hosts. 
Humans become infected during the bite of an infected mosquito.
JEV has a genome structure, which is similar to that of other 
flaviviruses. It is a small-enveloped virus with a single-stranded, 
positive-sense RNA genome of approximately 11 kb in length. The 
genome contains a single long open reading frame (ORE) flanked by 
5' and 3' nontranslated regions (NTRs) that are important Cis- 
acting elements for viral replication. The RNA genome has a type I 
cap structure at its 5' terminus but lacks a poly(A) tail at its 3'. The 
ORE is translated into a large polyprotein that is co- or post- 
translationally processed into three structural and seven non- 
structural proteins whose genes are arranged in the genome as 
follows: C-prM-E-NSl-NS2A-NS2B-NS3-NS4A-NS4B-NS5 (Cham­
bers et al., 1990; Lindenbach and Rice, 2001; Venugopal and Gould, 
1994).
Outbreaks of encephalitis suggestive of JE were recorded in 
Japan from the 1870s onwards and JEV was first isolated in Japan in
856 MAR Mohammed et al./Infection. Genetics and Evolution II (2011) S55-S62
1935 (Lewis et al., 1947). Subsequently, JEV has been found 
throughout most of Asia and the virus was most recently isolated 
in Papua New Guinea and the Torres Straits of Australia, indicating 
that this virus could become a worldwide public health threat 
(Hanna etal.,1996,1999; Mackenzie etal., 1994). The geographical 
expansion of JEV’s range appears to relate to irrigated rice fields 
and to a limited extent to pig farming. These environments that are 
suitable for infectious cycle of JEV exist widely in Asia (Oya and 
Kurane, 2007). The origins of the virus are uncertain, but 
phylogenetic comparisons with other flaviviruses suggest it 
evolved from an African ancestral virus, perhaps as recently as a 
few centuries ago (Gould, 2002). Two distinct epidemiological 
patterns of JEV transmission have been observed. In northern 
temperate regions of Asia JE occurs in summer epidemics, whereas 
in southern tropical areas the disease is endemic and occurs year- 
round (Vaughn and Hoke, 1992).
Based on genetic studies, JEV consists of four genotypes (1-1V) 
(Chen et al., 1990, 1992). Genotype I includes isolates from 
Northern Thailand, Cambodia, Korea, China, Japan, Vietnam, 
Taiwan, and Australia from 1967 to the present. Genotype II 
includes isolates from Southern Thailand, Malaysia, Indonesia, 
Papua New Guinea and Northern Australia from before 1951 to 
1999. Genotype III includes isolates from mostly temperate regions 
of Asia, including Japan, China, Taiwan, the Philippines, and the 
Asian subcontinent from 1935 to the present, and genotype IV 
includes isolates from Indonesia between 1980 and 1981 only 
(Schuh et al„ 2010). Representatives of each of these four 
genotypes have been fully sequenced.
The Muar strain of JEV was isolated in Singapore in 1952 from a 
brain of a patient who originated in Muar, Malaysia (Hale et al., 
1952) and this strain may represent a fifth genotype as determined 
by monoclonal antibodies reactivities (Hasegawa et al., 1995; 
Kobayashi et al., 1984) and limited phylogenetic analysis based on 
Egene sequence (Hasegawa etal., 1994; Solomon etal., 2003; Uchil 
and Satchidanandam, 2001). Here we have determined the 
complete nucleotide and deduced amino acid sequence of the 
Muar isolate and its evolutionary history. We analyzed selection 
pressures for the complete E gene of representative strains of the 
five genotypes in order to identify the patterns of genetic change of 
JEV genotypes. We predicted the three-dimensional structure of 
envelope glycoprotein of Muar strain and observed the difference 
and critical changes between Muar and other JEV strains so this 
may help us to understand the variations in antigenic and 
neutralizing properties of different JEV strains.
2. Materials and methods
2.1. Culture and sequencing of Muar isolate
The Muar strain of JEV, isolated in Singapore in 1952 from the 
brain of a patient who originated in Muar, Malaysia, was 
inoculated onto confluent monolayers of kidney epithelial cells 
extracted from an African green monkey (Vero cells) in 5% fetal calf 
serum. Culture supernatant containing the virus was harvested at 
5-6 days postinfection, when cytopathic effects were observed, 
and virus RNA was extracted by using the QIAamp Viral RNA Mini 
Kit (Qiagen). RNA was reverse transcribed and was PCR amplified 
by using Titan One Tube RT-PCR System (Roche). Primers were 
designed to amplify overlapping fragments of the genome 
(~1000bp in length) on the basis of consensus alignment of 
complete JEV nucleotide sequences, and on partial sequences of 
Muar already derived by us and others (Hasegawa et al., 1994).
RT-PCR products were purified by using the QIAquick Gel 
Extraction Kit. Purified cDNA was directly sequenced in both 
directions by using the appropriate sense and antisense primers. 
Sequencing of the 5' UTR was determined by using 5' RACE System
for Rapid Amplification of cDNA Ends (Invitrogen) and the 3' UTR 
sequence was obtained by using £ coli poly(A) polymerase 
(BioLabs) to add a poly(A) tail to Muar mRNA. Subsequently, the 
poly(A) mRNA was reverse transcribed and was PCR amplified by 
HotStarTaq Master Mix Kit (Qiagen) using a gene-specific primer. If 
there were differences between sequence results, cloning of that 
region was performed using the TA Cloning® Kit (Invitrogen) and 
ten clones of plasmids containing inserts were sequenced in both 
directions by using Muar-specific forward and reverse primers. The 
complete genome of the Muar strain was compiled by alignment 
with other JEV complete genome strains (Table 1), using the Vector 
NTI suite software package (version 10; Informax Inc.). Percentage 
differences between the complete genomic sequence and the 
derived polyprotein of the Muar strain and representative strains 
of JEV genotypes I-IV were calculated by using P-distance in MEGA 
software (version 4.0).
2.2. Phylogenetic relationships of the Muar isolate with other JEV 
strains
ClustalX (1.81) was used for the alignment of Muar nucleotide 
and derived amino acid sequences with other JEV strains available 
at GenBank. Selection of the best-fit model for JEV genome 
nucleotide substitution was carried out by ModelTest 3.7 (version 
0.1.1). Phylogenetic analysis was performed using maximum- 
parsimony and neighbour-joining methods on PAUP* (version 
4.04b 10) and maximum-likelihood method on GARLI (version 0.96 
Beta) using nucleotide and derived polyprotein sequences of C, 
PrM, E, NS3, NS5 and ORF as well as the nucleotide sequences of the 
5' UTR and 3' UTR and the complete genome. The robustness of 
phylograms was evaluated by 1000 bootstrap replicates. All trees 
were visualised using FigTree (version 1.2.2).
2.3. Evolutionary history of Muar isolate
A Maximum Glade Credibility (MCC) tree based on 3 5 complete 
coding sequences of JEV was inferred using the Bayesian Markov 
Chain Monte Carlo (MCMC) method available in the BEAST 
package (version 1.5b2) (Drummond and Rambaut, 2007), 
thereby incorporating information on the isolates time of original 
sampling. This analysis utilized a relaxed molecular clock 
(uncorrelated lognormal) and a GTR + Gamma + invariant model 
of nucleotide substitution for each codon position. All chains were 
run for a sufficient length to ensure convergence with 10% 
removed as burn-in. This analysis also allowed us to estimate 
coalescent (divergence) times for each node on the JEV phylogeny. 
The degree of uncertainty in each parameter estimate is provided 
by the 95% highest posterior density (HPD) values, while posterior 
probability values provide an assessment of the degree of support 
for each node on the tree.
The evolutionary rate of the complete genome between 
representative strains of GI and GUI, and for the envelope gene 
between the strains of GI, G1I and Gill was estimated. Such analysis 
was not possible between the strains of GIV and GV as there is only 
one representative strain published on GenBank.
2.4. Selection pressures between genotypes
Overall and site specific selection pressures in the E genes of 66 
JEV strains belonging to the five JEV genotypes were measured as 
the nonsynonymous (silent)/synonymous (amino acid-altering) 
rate ratio (co-dNldS) using a maximum likelihood method 
implemented by Datamonkey (Pond and Frost, 2005). Tests for 
positive selection were performed using three methods - single 
likelihood ancestor counting (SLAC), fixed effects likelihood (FEL), 
and internal FEL (IFEL) (http://www.datamonkey.org).
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Table 1
Details of isolates used for analysis in this study. Ml strains are JEV. except for MVE, SLE and WN.
Strain Year Location Source GenBank accession no.
014178 2001 India Human EF623987
04940-4 2002 India Mosquito EF623989
057434 2005 India Human EF623988
2372 1979 Thailand Human U70401 (E)
691004 1969 Sri Lanka Human Z34097 (E)
B58 1986 China Bat FJ185036
Beijing-1 1949 China Human L48961
Bennett Before 1951 Korea Human FJ872376 (E)
CH1392 1990 Taiwan Mosquito AF254452
CH2195LA 1994 Taiwan Mosquito AF221499
CNS138-11 1999 Malaysia Human AY184213(E)
FU 1995 Australia Human AF217620
GB30 1997 China Bat FJ185037
GP05 2005 India Human FJ979830 (E)
GP78 1978 India Human AF075723
HEN0701 2007 China Swine FJ495189
HV1 1958 Taiwan Human AF098735
Ishikawa 1998 Japan Mosquito AB051292
JaGArOl 1959 Japan Mosquito AF069076
JaNAr0102 2002 Japan Mosquito AY377577 (E)
JaOArS982 1982 Japan Mosquito NC_001437
JaOH0566 1966 Japan Human AY508813
JEV/sw/Mie/40/2004 2004 Japan Swine AB241118
JEV/sw/Mie/41/2002 2002 Japan Swine AB241119
JKT1724 1979 Indonesia Mosquito U70404 (E)
JKT5441 1981 Indonesia Mosquito U70406 (E)
JKT6468 1981 Indonesia Mosquito AY184212
JX61 2008 China Pig GU556217
K87P39 1987 Korea Mosquito AY585242
K94P05 1994 Korea Mosquito AF045551
KPP034-35CT 1982 Thailand Mosquito U03693 (E)
Ling 1965 Taiwan Human L78128
M15 1995 Australia Mosquito L47349 (E)
M40 1995 Australia Mosquito L47350 (E)
M859 1967 Cambodia Mosquito U70410 (E)
Muar 1952 Malaysia Human This paper, accession no. HM596272
MVE 1-51 1951 Australia Human AF161266
Nakayama 1935 Japan Human EF571853
Nakayama- RFVL IU Japan IU 575726 (E)
NJ 2008 2008 1U 1U GQ918133
NO 1995 Australia Human L4356G (E)
P20778 1958 India Human AF080251
P3 1950 China Mosquito U47032
PhAnl 242 1984 Philippines Pig U70417 (E)
RP-9 1985 Taiwan Mosquito AF0141G1
SA14 1954 China Mosquito U14163
SC04-17 2009 China Mosquito GUI 87972
SH17M07 2007 China IU EU429297
SLE MSI.7 1975 United States Bird NC„007580
TIPI 1997 Taiwan Mosquito AF254453
TC 1U Taiwan IU AF098736
TS00 2000 Australia Pig EF434785 (E)
VN118 1979 Vietnam Mosquito U70420 (E)
WN EglOl 1950 Egypt Human AF260968
WTP-70-22 1970 Malaysia Mosquito U70421 (E)
XJ69 2007 China Mosquito EU880214
XJP613 2007 China Mosquito EU693899
GenBank accession numbers refer to the whole genome or the genes indicated in parentheses. E, envelope gene. 1U. information unavailable.
2.5. Prediction of three-dimensional structure of envelope 
glycoprotein ofMuar strain
Muar-specific amino acids were identified by comparing the E 
glycoprotein sequence to 292 other JEV strain sequences. These 
were subsequently mapped onto the predicted 3D structure of the 
Muar envelope protein E, as modelled based on predicted 
similarities to the homologous (77% identity) glycoprotein gene 
in WNV (PDB entry 2i69) using SWISS-MODEL via the ExPASy web 
server (Schwede et al.. 2003). The predicted Muar E structure was 
viewed and manipulated using PyMol (http://pymoI.sourcecforge. 
net/). Critical changes in the E glycoprotein which are thought to be 
involved in receptor binding as described by Ni and Barrett (1998) 
and Solomon et al. (2003) were identified.
2.6. Nucleotide sequence accession number
The JEV isolate Muar was assigned GenBank database accession 
no. HM596272.
3. Results
3.L Nucleotide and amino add sequence
The Muar virus genome was 10,988 nucleotides long. 
Comparison with other fully sequenced JEV genomes showed 
Muar to have the least similarity, with nucleotide divergence 
ranging from 20.2 to 21.2%, and protein divergence from 8.5 to 
9.9% (Table 2).
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Table 2
Sequence divergence among representatives of the five genotypes ofJEV complete 
genomes.
Strain Genotype Divergence (%) with
K94P05 FU Nakayama JKT6468 Muar
K9P05 1 10.3 10.8 16.8 21.2
FU 11 2.1 10.5 16.1 21.1
Nakayama m 3.1 2.2 15.1 20.2
JKT6468 IV 6.2 5.3 4.S 21.0
Muar V 9.9 8.6 8.5 9.2
The nucleotide divergence is shown in lightface type and the amino acid divergence 
is shown in bold face type.
Although the sequence of the structural genes of the Muar 
strain was previously published by Hasegawa et al. (1994) but we 
identified a number of nucleotide differences between their 
sequence and our sequence (genetic distance 6.7%).
3.2. Phylogenetic analyses and evolutionaiy history of Muar
Maximum likelihood phylogenetic analysis of 41 E genes 
(1500 bp) and 34 NS5/3' UTR (3380 bp) sequences for ]EV and 
representative strains of other viruses in the JE serogroup shows 
that the Muar isolate is a fifth genotype of JEV (Fig. 1A and B). 
Similar trees, with 100% bootstrap support, were produced by the 
maximum-parsimony, neighbour-joining and maximum likeli­
hood methods.
Molecular clock analysis of 35 complete coding sequences of 
JEV, supported by high posterior probability values, confirmed that 
Muar belongs to a fifth JEV genotype and represents the oldest 
linage of JEV, which last shared a common ancestor from 449.6 
years ago (95% HPD = 373.9-499.9) (Fig. 2).
Evolutionary analysis of 35 full-length JEV genomes revealed 
that the mean evolutionary rate ofJEV isolates is 4.35 x 10-4 (95% 
HPD = 3.4906 x 10-4 to 5.303 x 10-4) nucleotides substitutions 
per site per year. While the mean evolutionary rate between 10 
strains of GI, and 22 strains of GUI complete genomes are 
3.029 x 10“4 (95% HPD = 2.0884 x lO"8 to 8.6999 x IQ-4) and 
6.029 x lO"4 (95% HPD = 7.0492 x lO-8 to 1.4093 x 10"4) nucleo­
tides substitutions per site per year, respectively. Comparing 
the mean evolutionaiy rate of each genotype separately using 
envelope genes showed that the mean evolutionary rate 
between 12 strains of GI, 7 strains of GII and 39 strains of GUI 
are 1.14 x 10"3 (95% HPD = 2.3 x 10"4 to 2.2 x lO"3), 1.97 x lO"3 
(95% HPD = 2.8 x 10”4 to 3.95 x 10“3) and 2.69 x 10"4 (95% 
HPD = 1.09 x 10~4 to 4.20 x 10-4) nucleotides substitutions per 
site per year, respectively (Table 3).
3.3. Selection pressures between the five JEV genotypes
There was no evidence for positive selection between the JEV 
five genotypes strains and different selection pressures models did 
not have any category with to > 1. The average to ratio (d/V/dS) over 
the entire E gene sites was estimated to be ~0.05, suggestive of 
predominantly purifying selection.
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Fig. 1. Maximum likelihood phylogenetic trees of the (A) envelope genes and (B) NS5/3' UTR genes, outgrouped by using a representative strain from other viruses in the JEV 
serogroup (MVE, Murray Valley encephalitis; SLE; St. Louis encephalitis; WN, West Nile). The Muar isolate is shown with an arrow as a genotype V. Genotypes are given on the 
right of each tree. Bootstrap support values, given as a percentage of 1000 replicates, are shown.
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Fig. 2. Maximum clade credibility (MCC) phylogeny for 35 complete coding sequences of JEV genomes. Horizontal branches are drawn to a scale of estimated year of 
divergence with tip times reflecting sampling date (year). The tree is automatically rooted due to the assumption of a molecular clock. The divergence times of genotype nodes 
are shown. High posterior probability values are shown beside the nodes. A filled black circle identifies the most recent common ancestor of JEV. Muar isolate, the oldest 
linage, is shown with an arrow as a genotype V.
3.4. Structural differences
Examination of the E protein of Muar showed it was similar to 
other flaviviruses, with 12 cysteine residues that form six disulfide 
bridges. Alignment of the Muar E protein amino acid sequence with 
representative strains from each genotype, GI (K94P05 and 
XJP613), GII (Bennett, CNS138-11 and FU), Gill (691004, 
Nakayama-RFVL and P3), GIV (JICT6468) and GV (Muar), is shown 
in Fig. 3. The alignment of E genes from 292 strains identified 22 
signature amino acid residues that distinguished genotype V from 
other genotypes. The range of intergenotypic amino acid sequence 
divergence of E protein between the genotype V strain, Muar, and 
the other four JEV genotypes is as follows: Muar versus genotype I 
(8.9-9.1%), genotype II (8.5-9.1%), genotype HI (8.7-9.7%) and 
genotype IV (9.5%).
Table 3
Rates of nucleotide substitutions per site for JEV complete genomes and envelope 
genes.
JEV genotype Mean no, of 
nucleotide 
substitutions/ 
site/year
95% HPD
Lower Upper
GI-V complete genomes 4.35 x 10“4 3.4906 xIO”4 5.303 xIO"4
GI complete genomes 3.029x 10-'5 2.0884x10-® 8.6999 x 10-4
GUI complete genomes 6.029 xIO"4 7.0492x10-® 1.4093 xIO"4
GI envelope genes 1,14 x 10-3 2.3 xIO"4 2.2 x 10“3
GII envelope genes 1.97 x 10-3 2.8 xIO"4 3.95 x 10"3
GUI envelope genes 2.69 x 10-4 1.09 xIO-4 4.20 xIO"4
The predicted three-dimensional structure of the E protein of 
Muar strain was modelled onto the ciystal structure of WNV 
(Nybakken et al., 2006) and showed two signature amino acids for 
Muar in domain I, twelve in domain II and eight in domain III. This 
included a critical change identified in the E protein at position 327 
at the exposed lateral surface of domain III in a region thought to be 
involved in receptor binding as described previously (Ni and 
Barrett, 1998; Solomon et al.. 2003) (Fig. 4). This critical change is 
from glutamine in genotype V strain to leucine in genotype IV 
strains then to serine and threonine amino acids found in newer 
genotypes - I, II and HI.
4. Discussion
Arthropod-borne encephalitis viruses represent a significant 
public health problem throughout most of the world but their 
origins and evolution remain unclear (Solomon and Cardosa, 
2000). JEV was first described in Japan in 1870 and subsequently 
appeared to spread across Asia to affect most of China and the 
Asian subcontinent, all of Southeast Asia, and the Pacific Rim, 
reaching northern Australia in 1998. JEV has become the most 
important cause of epidemic encephalitis worldwide and there is a 
clear need for a better understanding of the origins and spread of 
the virus. Epidemiological studies have demonstrated four 
genotypes of JEV (I-IV) and at least five antigenic subgroups of 
JEV have circulated in Asia since isolation of the original Nakayama 
virus in 1935 (Hasegawa et al., 1994; Kedarnath et al., 1986; 
Kobayashi et al., 1984, 1985). One of these antigenic subgroups 
includes only the Nakayama-derived strains, whereas the majority 
of the more recent isolates in genotype III are within a subgroup
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Dots indicate consensus. Underlined amino acids represent Muar signature amino acids.
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Fig. 3. Alignment of the E protein amino acid sequences of JEV G I-V. Dots indicate consensus. Underiined amino acids represent Muar signature amino acids.
containing the Kamiyama strain isolated in 1966 (Kobayashi et aL, 
1985). In addition, two antigenic subgroups are quite distinct, the 
691004 (isolated in Sri Lanka in 1969) and Muar (isolated in 
Singapore in 1952) subgroups, each containing only the prototype 
virus for the respective subgroup (Kobayashi et al., 1985).
Sequencing of the Muar strain complete genome showed it was 
the most genetically different from other JEV strains, in agreement 
with serological results using anti-Muar monoclonal antibodies 
(Hasegawa, 1982; Hasegawa etal., 1995), and confirming that Muar 
is unique both genetically and serologically. Using the classification 
of Chen et al. (1992), Ali and Igarashi (1997), and Uchil and 
Satchidanandam (2001), our phylogenetic analyses clearly support 
the evidence that Muar represents a fifth genotype of JEV.
Hasegawa et al. (1994) previously published a sequence for the 
structural genes of the Muar isolate, and a number of nucleotide 
differences between their sequence and our sequence were 
identified (genetic distance 6.7%). The reasons for these differences 
are difficult to explain. Some differences are to be expected due to 
variability arising during growth of the RNA viruses in culture and 
PCR steps. Some differences may also be due to the differences in 
sequencing strategies; Hasegawa et al. (1994) used manual 
sequencing, whereas we used modern sequencing protocols. 
Alternatively, it is possible that the older sequencing methods 
produced results that were less reliable, or differences in the 
passage history since original isolation of the virus explain the 
sequence differences.
79663
MA.F. Mohammed et al./Infection, Genetics and Evolution 11 (2011) 855-862 861
Fig. 4. JEV envelope protein. Predicted three-dimensional model of the E protein of 
JEV genotype V strain Muar, derived from the crystal structure of West Nile virus, 
showing 8 Muar signature amino acids in domain III with the critical change at 
residue 327; circled (in the putative receptor binding region of domain 111).
Our analyses suggest that the Muar strain represents the oldest 
JEV lineage when compared with other genomic sequences. 
Because of this we examined the geographical distribution of all 
known isolates. Evolutionary analysis suggests JEV originated from 
its ancestral virus in the mid 1500s in the Indonesia-Malaysia 
region and evolved there into different genotypes, which then 
spread across Asia. Estimates of divergence times of JEV genotypes 
suggested that the deepest divergence of known JEV strains was at 
1550s. Although our results agree with the previous studies which 
suggest that JEV arose from its ancestral virus in the Indonesia- 
Malaysia region and evolved into five genotypes; genotypes IV and 
V, the most divergent genotypes, remain confined to the Indonesia- 
Malaysia region, whereas genotypes I, II and III, the most recent 
evolved genotypes appear to have spread across Asia (Solomon 
et al., 2003), one cannot be absolutely certain that this is the case.
Evolutionary analysis of full-length JEV genomes showed high 
mean evolutionary rate (4.35 x 10“4) which is expected for JEV as 
an RNA virus which lacks a proof reading mechanism during 
replication. Evolutionary rate of envelope genes for each genotype 
separately showed a higher evolutionary rate for genotypes I and II 
than genotype III.
Understanding these genetic changes in the E gene is an 
important step to study the evolution of JEV. The extensive 
surveillance helps us understand geographic movement and 
genotype shift of the virus. We determined the selection 
pressures on the E gene sequences of the five genotypes. Many 
sites seemed to be under negative selection pressure, and no 
evidence for positive selection was found. The intensity of 
selection is reflected in the magnitude of dJV/dS ratio. Indeed, the 
overall picture obtained was that of strong purifying selection, 
with mean dN/dS value ~0.05 for all JEV genotypes, and similar 
to the previous studies by Tang et al. (2010). This suggests that 
the antigenic selection might not be the reason for genotype 
shift of JEV.
The observed difference in the predicted three dimensional 
structure of E glycoprotein of JEV strains, particularly in domain III, 
could help in understanding the antigenic and neutralizing 
properties of JEV strains (Cecilia and Gould, 1991; Gritsun et al., 
1995). Hence, Domain III of the E protein of JEV has been shown to 
contain important sites for antibody-mediated virus neutralization 
and motifs associated with virulence (Rey et al., 1995; Wu et al., 
2003); the eight signature amino acids differences at domain III 
with a critical change at residue 327 (in the putative receptor
binding region of domain III), may explain some of the serological 
differences with Muar strain.
In summary, our complete genome sequence analysis confirms 
that the Muar strain represents a fifth genotype of JEV with 
approximately 20% divergence from other JEV strains. Evolutionary 
analysis suggested Muar represents the oldest JEV lineage and the 
four genotypes diverged from genotype V approximately 450 years 
ago. Whether there are other strains from genotype V, and what 
happened to them remains unknown.
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